0001689657-23-000025.txt : 20230515 0001689657-23-000025.hdr.sgml : 20230515 20230515161353 ACCESSION NUMBER: 0001689657-23-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PhenomeX Inc. CENTRAL INDEX KEY: 0001689657 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 352415390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39388 FILM NUMBER: 23922432 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET STREET 2: SUITE 320 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-858-2855 MAIL ADDRESS: STREET 1: 5858 HORTON STREET STREET 2: SUITE 320 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Berkeley Lights, Inc. DATE OF NAME CHANGE: 20161109 10-Q 1 bli-20230331.htm 10-Q bli-20230331
000168965712/312023Q1falseP8Yhttp://berkeleylights.com/20230331#AccruedLiabilitiesAndOtherLiabilitiesCurrenthttp://berkeleylights.com/20230331#AccruedLiabilitiesAndOtherLiabilitiesCurrent00016896572023-01-012023-03-3100016896572023-04-30xbrli:shares00016896572023-03-31iso4217:USD00016896572022-12-31iso4217:USDxbrli:shares0001689657us-gaap:ProductMember2023-01-012023-03-310001689657us-gaap:ProductMember2022-01-012022-03-310001689657bli:ServiceAndOtherMember2023-01-012023-03-310001689657bli:ServiceAndOtherMember2022-01-012022-03-3100016896572022-01-012022-03-310001689657us-gaap:CommonStockMember2022-12-310001689657us-gaap:AdditionalPaidInCapitalMember2022-12-310001689657us-gaap:RetainedEarningsMember2022-12-310001689657us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001689657us-gaap:CommonStockMember2023-01-012023-03-310001689657us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001689657us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001689657us-gaap:RetainedEarningsMember2023-01-012023-03-310001689657us-gaap:CommonStockMember2023-03-310001689657us-gaap:AdditionalPaidInCapitalMember2023-03-310001689657us-gaap:RetainedEarningsMember2023-03-310001689657us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001689657us-gaap:CommonStockMember2021-12-310001689657us-gaap:AdditionalPaidInCapitalMember2021-12-310001689657us-gaap:RetainedEarningsMember2021-12-310001689657us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100016896572021-12-310001689657us-gaap:CommonStockMember2022-01-012022-03-310001689657us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001689657us-gaap:RetainedEarningsMember2022-01-012022-03-310001689657us-gaap:CommonStockMember2022-03-310001689657us-gaap:AdditionalPaidInCapitalMember2022-03-310001689657us-gaap:RetainedEarningsMember2022-03-310001689657us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100016896572022-03-3100016896572023-03-032023-03-030001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2023-03-200001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2023-03-210001689657bli:PerceptiveCreditAgreementMemberus-gaap:LineOfCreditMember2023-03-212023-03-210001689657bli:EWBTermLoanMember2023-03-310001689657us-gaap:LetterOfCreditMember2023-03-310001689657us-gaap:ResearchMember2023-03-310001689657us-gaap:MoneyMarketFundsMember2023-03-310001689657us-gaap:MoneyMarketFundsMember2022-12-310001689657us-gaap:CommercialPaperMember2022-12-310001689657us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMember2022-12-310001689657us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001689657us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMember2022-12-310001689657us-gaap:RevenueFromContractWithCustomerMemberbli:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-31xbrli:pure0001689657bli:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001689657us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberbli:CustomerThreeMember2023-01-012023-03-310001689657us-gaap:RevenueFromContractWithCustomerMemberbli:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001689657bli:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001689657us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberbli:CustomerThreeMember2022-01-012022-03-310001689657bli:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-03-310001689657bli:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-03-310001689657us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberbli:CustomerThreeMember2023-01-012023-03-310001689657bli:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001689657bli:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001689657bli:IsoPlexisMember2023-03-210001689657bli:IsoPlexisMember2023-03-212023-03-2100016896572023-03-210001689657us-gaap:PatentedTechnologyMemberbli:IsoPlexisMember2023-03-210001689657us-gaap:CustomerRelationshipsMemberbli:IsoPlexisMember2023-03-210001689657us-gaap:TrademarksAndTradeNamesMemberbli:IsoPlexisMember2023-03-210001689657srt:MinimumMemberbli:IsoPlexisMember2023-03-212023-03-210001689657srt:MaximumMemberbli:IsoPlexisMember2023-03-212023-03-210001689657bli:IsoPlexisMember2023-01-012023-03-310001689657bli:IsoPlexisMember2022-10-012022-12-310001689657bli:IsoPlexisMember2022-01-012022-03-310001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMemberbli:IsoPlexisMember2023-03-212023-03-210001689657us-gaap:AcquisitionRelatedCostsMember2023-03-310001689657bli:IsoPlexisMemberbli:ServiceAndOtherMemberbli:PartnershipLicenseAndOtherMember2023-01-012023-03-310001689657bli:PlatformMemberus-gaap:ProductMember2023-01-012023-03-310001689657bli:PlatformMemberbli:ServiceAndOtherMember2023-01-012023-03-310001689657bli:PlatformMember2023-01-012023-03-310001689657bli:RecurringMemberus-gaap:ProductMember2023-01-012023-03-310001689657bli:RecurringMemberbli:ServiceAndOtherMember2023-01-012023-03-310001689657bli:RecurringMember2023-01-012023-03-310001689657us-gaap:ProductMemberbli:PartnershipLicenseAndOtherMember2023-01-012023-03-310001689657bli:ServiceAndOtherMemberbli:PartnershipLicenseAndOtherMember2023-01-012023-03-310001689657bli:PartnershipLicenseAndOtherMember2023-01-012023-03-310001689657bli:PlatformMemberus-gaap:ProductMember2022-01-012022-03-310001689657bli:PlatformMemberbli:ServiceAndOtherMember2022-01-012022-03-310001689657bli:PlatformMember2022-01-012022-03-310001689657bli:RecurringMemberus-gaap:ProductMember2022-01-012022-03-310001689657bli:RecurringMemberbli:ServiceAndOtherMember2022-01-012022-03-310001689657bli:RecurringMember2022-01-012022-03-310001689657us-gaap:ProductMemberbli:PartnershipLicenseAndOtherMember2022-01-012022-03-310001689657bli:ServiceAndOtherMemberbli:PartnershipLicenseAndOtherMember2022-01-012022-03-310001689657bli:PartnershipLicenseAndOtherMember2022-01-012022-03-3100016896572023-04-012023-03-310001689657bli:AccountsReceivableAfterAllowanceForCreditLossCurrentMember2023-03-310001689657bli:EvorionBiotechnologiesMember2023-02-152023-02-150001689657bli:EvorionBiotechnologiesMemberbli:PatentsAndTechnologyMember2023-02-152023-02-150001689657us-gaap:CustomerRelationshipsMember2023-01-012023-03-310001689657us-gaap:CustomerRelationshipsMember2023-03-310001689657us-gaap:TradeNamesMember2023-01-012023-03-310001689657us-gaap:TradeNamesMember2023-03-310001689657us-gaap:PatentedTechnologyMember2023-01-012023-03-310001689657us-gaap:PatentedTechnologyMember2023-03-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001689657us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001689657us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001689657us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001689657us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001689657us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001689657us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-03-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001689657us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001689657bli:EquipmentToolingAndMoldsMember2023-03-310001689657bli:EquipmentToolingAndMoldsMember2022-12-310001689657us-gaap:ComputerEquipmentMember2023-03-310001689657us-gaap:ComputerEquipmentMember2022-12-310001689657us-gaap:FurnitureAndFixturesMember2023-03-310001689657us-gaap:FurnitureAndFixturesMember2022-12-310001689657us-gaap:LeaseholdImprovementsMember2023-03-310001689657us-gaap:LeaseholdImprovementsMember2022-12-310001689657us-gaap:ConstructionInProgressMember2023-03-310001689657us-gaap:ConstructionInProgressMember2022-12-310001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2018-05-230001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2021-06-300001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2021-06-302021-06-300001689657us-gaap:NotesPayableToBanksMember2023-01-012023-03-310001689657us-gaap:NotesPayableToBanksMember2023-03-310001689657bli:EWBTermLoanMemberus-gaap:NotesPayableToBanksMember2023-03-212023-03-210001689657bli:EWBTermLoanMemberus-gaap:PrimeRateMemberus-gaap:NotesPayableToBanksMember2023-03-210001689657bli:EWBTermLoanMemberus-gaap:PrimeRateMemberus-gaap:NotesPayableToBanksMember2023-03-212023-03-210001689657us-gaap:RestrictedStockUnitsRSUMemberbli:IsoPlexisMember2023-03-210001689657us-gaap:EmployeeStockOptionMemberbli:IsoPlexisMember2023-03-210001689657us-gaap:EmployeeStockOptionMemberbli:IsoPlexisMember2023-03-212023-03-210001689657us-gaap:ShareBasedCompensationAwardTrancheOneMemberbli:IsoPlexisMember2023-03-212023-03-210001689657us-gaap:ShareBasedCompensationAwardTrancheTwoMemberbli:IsoPlexisMember2023-03-212023-03-210001689657us-gaap:RestrictedStockUnitsRSUMemberbli:IsoPlexisMember2023-03-212023-03-210001689657bli:IsoPlexisWarrantMember2023-03-210001689657bli:PhenomeXWarrantMember2023-03-210001689657bli:PhenomeXWarrantMemberus-gaap:CommonStockMember2023-03-210001689657us-gaap:CostOfSalesMember2023-01-012023-03-310001689657us-gaap:CostOfSalesMember2022-01-012022-03-310001689657us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001689657us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001689657us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001689657us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001689657bli:EmployeeSeveranceAndTerminationMember2022-12-310001689657bli:NonLaborRestructuringCostsMember2022-12-310001689657bli:EmployeeSeveranceAndTerminationMember2023-01-012023-03-310001689657bli:NonLaborRestructuringCostsMember2023-01-012023-03-310001689657bli:EmployeeSeveranceAndTerminationMember2023-03-310001689657bli:NonLaborRestructuringCostsMember2023-03-310001689657bli:AbCelleraAndUBCMember2021-07-012021-07-01bli:patentbli:claim00016896572021-12-012021-12-31bli:investedCompany0001689657us-gaap:WarrantMember2023-01-012023-03-310001689657us-gaap:WarrantMember2022-01-012022-03-310001689657us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001689657us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001689657us-gaap:RestrictedStockMember2023-01-012023-03-310001689657us-gaap:RestrictedStockMember2022-01-012022-03-310001689657us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001689657us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-31bli:segment0001689657srt:NorthAmericaMember2023-01-012023-03-310001689657srt:NorthAmericaMember2022-01-012022-03-310001689657srt:AsiaPacificMember2023-01-012023-03-310001689657srt:AsiaPacificMember2022-01-012022-03-310001689657srt:EuropeMember2023-01-012023-03-310001689657srt:EuropeMember2022-01-012022-03-310001689657srt:ScenarioForecastMember2023-04-012023-06-300001689657srt:ScenarioForecastMember2023-06-30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark one)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023

or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from___ to___
Commission file number: 001-39388
PhenomeX_Logo.jpg
PhenomeX Inc.
(Exact name of registrant as specified in its charter)
Delaware35-2415390
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5858 Horton Street, Suite 320
Emeryville, California 94608
(Address of principal executive offices) (Zip code)
(510) 858-2855
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.00005 par valueCELLThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 30, 2023, 98,795,621 shares of the registrant’s common stock, $0.00005 par value per share, were outstanding.

PHENOMEX INC.
FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023
Table of Contents
Page(s)
Item 1.
Item 3.
Item 4.

PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (Unaudited).
PhenomeX Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
March 31,
2023		December 31,
2022
(In thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents$51,606 $86,522 
Short-term marketable securities— 46,252 
Trade accounts receivable, net 25,119 18,534 
Inventory45,539 18,861 
Prepaid expenses and other current assets9,378 6,783 
Total current assets131,642 176,952 
Restricted cash70,093 — 
Property and equipment, net33,842 23,847 
Operating lease right-of-use assets27,449 23,326 
Goodwill12,246 — 
Intangible assets, net23,072 — 
Other assets2,217 1,969 
Total assets$300,561 $226,094 
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable$17,051 $10,092 
Accrued expenses and other current liabilities19,645 21,340 
Current portion of long-term debt— 4,966 
Deferred revenue10,746 9,092 
Total current liabilities47,442 45,490 
Long-term debt68,886 14,860 
Deferred revenue, net of current portion1,259 963 
Lease liability, long-term25,234 22,726 
Total liabilities142,821 84,039 
Commitments and contingencies (Note 17)
Stockholders’ equity:
Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding 98,744,915 and 72,169,052 shares at March 31, 2023 and December 31, 2022, respectively
5 4 
Additional paid-in capital542,805 503,708 
Accumulated deficit(385,067)(361,648)
Accumulated other comprehensive loss (3)(9)
Total stockholders’ equity157,740 142,055 
Total liabilities and stockholders’ equity$300,561 $226,094 
See accompanying notes to these condensed consolidated financial statements.
1
PhenomeX Inc.
Condensed Consolidated Statements of Operations (Unaudited)

Three months ended March 31,
(In thousands, except share and per share data)20232022
Revenue:
Product revenue$8,378 $9,774 
Service and other revenue10,138 10,432 
Total revenue18,516 20,206 
Cost of sales:
Product cost of sales3,912 2,695 
Service cost of sales1,176 3,684 
Total cost of sales5,088 6,379 
Gross profit13,428 13,827 
Operating expenses:
Research and development8,421 17,573 
Selling, general and administrative26,547 17,527 
Restructuring1,290 — 
Total operating expenses36,258 35,100 
Loss from operations(22,830)(21,273)
Other income (expense):
Interest expense(384)(224)
Interest income827 34 
Other income (expense), net(1,012)57 
Loss before income taxes(23,399)(21,406)
Provision for income taxes20 20 
Net loss $(23,419)$(21,426)
Net loss attributable to common stockholders per share, basic and diluted$(0.31)$(0.32)
Weighted-average shares used in calculating net loss per share, basic and diluted75,759,771 67,697,488 
See accompanying notes to these condensed consolidated financial statements.
2
PhenomeX Inc.
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)


Three months ended March 31,
(In thousands)20232022
Net loss$(23,419)$(21,426)
Other comprehensive loss:
Foreign currency translation adjustments(3)— 
Unrealized gain on marketable securities, net of tax9 — 
Other comprehensive income:6 — 
Comprehensive loss$(23,413)$(21,426)
See accompanying notes to these condensed consolidated financial statements.
3
PhenomeX Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)
Three Months Ended March 31, 2023
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated Other Comprehensive LossTotal
Stockholders'
Equity
(In thousands, except share data)SharesAmount
Balances at December 31, 202272,169,052 $4 $503,708 $(361,648)$(9)$142,055 
Common stock issued for IsoPlexis Merger24,945,611 1 31,929 — — 31,930 
Fair value of vested IsoPlexis options attributable to pre-merger service — — 306 — — 306 
Fair value of IsoPlexis warrant at Acquisition Date — — 170 — — 170 
Shares issued in connection with:
Exercise of stock options78,359 — 29 — — 29 
Vesting of restricted stock units285,129 — — — — — 
Employee stock purchase plan121,863 — 166 — 166 
RSUs issued for 2022 Bonuses (1)
1,144,901 — 2,107 — — 2,107 
Stock-based compensation— — 4,390 — — 4,390 
Unrealized gain (loss) on marketable securities— — — — 9 9 
Foreign currency translation adjustments— — — — (3)(3)
Net loss— — — (23,419)— (23,419)
Balances at March 31, 202398,744,915 $5 $542,805 $(385,067)$(3)$157,740 
Three Months Ended March 31, 2022
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated Other Comprehensive LossTotal
Stockholders'
Equity
(In thousands, except share data)SharesAmount
Balances at December 31, 202167,595,535 $4 $471,820 $(263,608)$— $208,216 
Shares issued in connection with:
Exercise of stock options81,654 — 412 — — 412 
Vesting of restricted stock units27,580 — — — — — 
Employee stock purchase plan115,346 — 610 — — 610 
Stock-based compensation— — 5,389 — — 5,389 
Net loss— — — (21,426)— (21,426)
Balances at March 31, 202267,820,115 $4 $478,231 $(285,034)$— $193,201 
See accompanying notes to these condensed consolidated financial statements.
(1) Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned.
4


PhenomeX Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)
Three months ended March 31,
(In thousands)20232022
Cash flows from operating activities:
Net loss$(23,419)$(21,426)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization2,100 1,944 
Stock-based compensation4,388 5,393 
RSUs issued for 2022 Bonuses2,107 — 
Amortization of operating lease right-of-use assets852 735 
Non-cash interest and other expense related to debt and note receivable agreements16 16 
Provision for doubtful accounts173 — 
Loss on debt extinguishment162 — 
Loss on disposal and impairment of property and equipment151 28 
Realized loss on marketable securities6 — 
Other non-cash(638)— 
Changes in operating assets and liabilities:
Trade accounts receivable(3,684)8,221 
Inventory964 (1,122)
Prepaid expenses, other current assets and other assets1,865 2,057 
Trade accounts payable5,373 298 
Deferred revenue551 (2,935)
Accrued expenses and other current liabilities(9,660)(2,552)
Operating lease liabilities(860)(726)
Net cash used in operating activities(19,553)(10,069)
Cash flows from investing activities:
Purchase of property and equipment(414)(4,375)
Purchase of marketable securities(2,451)— 
Proceeds from sales of marketable securities36,749 — 
Proceeds from maturities of marketable securities12,400 — 
Asset acquisition(264)— 
Acquisitions, net of cash acquired(40,285)— 
Net cash provided by (used in) investing activities5,735 (4,375)
Cash flows from financing activities:
Repayment of term loan(20,000)— 
Proceeds from issuance of debt70,000 — 
Payment of debt issuance costs(1,200)— 
Proceeds from issuance of common stock upon exercise of stock options29 412 
Proceeds from issuance of common stock under employee stock purchase plan166 610 
Net cash provided by financing activities48,995 1,022 
Net increase (decrease) in cash and cash equivalents and restricted cash35,177 (13,422)
Cash, cash equivalents and restricted cash at beginning of period86,522 178,366 
Cash, cash equivalents and restricted cash at end of period$121,699 $164,944 
See accompanying notes to these condensed consolidated financial statements.
5
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(1)The Company and Basis of Presentation

Description of Business
PhenomeX Inc. (the “Company” or “PhenomeX”) is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
PhenomeX and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California.

Basis of Presentation
On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights.
The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates.

Liquidity
The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2023, the Company had a consolidated net loss of $23.4 million and as of March 31, 2023 had an accumulated deficit of $385.1 million. Cash, cash equivalents and marketable securities were $51.6 million as of March 31, 2023.
On March 21, 2023, the Company acquired IsoPlexis which also had experienced losses since its inception, and entered into the second amended and restated credit agreement with East West Bank (“EWB”), which increased the Company’s term loan with EWB from $20.0 million to $70.0 million, of which $52.5 million (including prepayment premium and interest) was used to repay indebtedness of IsoPlexis. The second amended and restated credit agreement with EWB requires the Company to maintain $70.0 million of cash in a deposit account with EWB that is assigned to EWB. This deposit is recorded as restricted cash on the Company’s condensed consolidated balance sheet. See Note 12 for additional information on our second amended and restated credit agreement with EWB including the covenants contained therein.
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustment that might result if the Company is unable to continue as a going concern.
6
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Management’s intent is to implement plans that will allow the Company to continue as a going concern. The Company intends to improve operating cash flow by increasing its revenue and lowering its operational costs. New commercial leadership, geographic expansion, and a refined product roadmap are expected to drive revenue growth, and significant cost synergies as a result of the IsoPlexis Merger and are expected to lower operating expenses. Cost synergies are expected to be accomplished by eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies. In addition, the Company is evaluating financing options including the potential to raise equity and debt financing. While management is focused on these efforts, there can be no assurance that the Company will be successful in doing so.
(2)Summary of Significant Accounting Policies

Significant Accounting Policies
The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission.
Updates to those policies are below, including updates related to the IsoPlexis Merger.

Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer.
The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands):
March 31, 2023December 31, 2022
Cash
$45,015 $63,596 
Cash equivalents
6,591 22,926 
Restricted cash70,093 — 
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows
$121,699 $86,522 

Accounts Receivables and Allowance for Credit Losses
Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.

7
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)


Inventory
Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.

Stock-based compensation
The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors.
Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant.
The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.
The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.
Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.
For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.
The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.

Business Combinations
We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed
8
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.

Goodwill and Intangible Assets
Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.

Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.

Impairment of Long-Lived Assets
Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.

Foreign currency translation and transactions
The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net.
For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.

Research and development state tax credits
Research and development (“R&D”) tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits a qualified small business engaged in R&D activities within Connecticut to exchange its unused R&D tax credits for a cash amount equal to 65% of the value of exchanged credits, are
9
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
recorded as a receivable and other income in the year the R&D tax credits relate to, as it is reasonably assured that the R&D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets. The Company has recorded $0.2 million of R&D tax credits receivable as of March 31, 2023.

Warrants
On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, Distinguishing Liabilities from Equity.

(3)Marketable Securities
Short-Term Marketable Securities

The Company may invest in available-for-sale marketable debt securities generally consisting of commercial paper and U.S. government securities with contractual maturities due within one year.

The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands):

Marketable Securities reported as Cash Equivalents

March 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$6,591 $— $— $6,591 
   Total$6,591 $— $— $6,591 


December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$2,354 $— $— $2,354 
Commercial paper16,606 — (4)16,602 
U.S. agency securities3,969 1 — 3,970 
U.S. government securities— — — — 
   Total$22,929 $1 $(4)$22,926 


10
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Marketable Securities reported as Short-term Marketable Securities

As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial.

Short-term marketable securities at December 31, 2022 were as follows (in thousands):

December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Commercial paper$22,158 $1 $(11)$22,148 
U.S. agency securities4,941 1 — 4,942 
U.S. government securities19,159 5 (2)19,162 
   Total$46,258 $7 $(13)$46,252 

At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of December 31, 2022.

See Note 9 for information about the fair value of the Company’s short-term marketable securities.

(4)Significant Risks and Uncertainties Including Business and Credit Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in financial institutions may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any material realized losses on its deposits of cash, cash equivalents and marketable securities.

The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At March 31, 2023, the Company recorded an allowance for doubtful accounts of $0.9 million. At December 31, 2022 , the Company had not recorded any material allowance for doubtful accounts.

For the three months ended March 31, 2023, three customers accounted for 39%, 10% and 10% of revenue. For the three months ended March 31, 2022, three customers accounted for 18%, 13% and 10% of revenue.

11
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
As of March 31, 2023, three customers comprised 25%, 14% and 12% of accounts receivable. As of December 31, 2022, two customers accounted for 24% and 11% of accounts receivable.
(5)Business Combinations
IsoPlexis Merger
On March 21, 2023, the Company completed the IsoPlexis Merger. Under the terms of the Merger Agreement, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which was automatically converted into shares of PhenomeX common stock).
Consideration Transferred
The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands):
Fair value of PhenomeX common stock issued to IsoPlexis stockholders (1)
$31,930 
Repayment of IsoPlexis debt (2)
52,482 
Fair value of vested IsoPlexis options attributable to pre-merger service (3)
306 
Fair value of IsoPlexis warrant at Acquisition Date (4)
170 
   Total purchase consideration$84,888 
(1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.
(2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest.
(3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information).
(4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).

Fair Value of Assets Acquired and Liabilities Assumed
The Company accounted for the IsoPlexis Merger as a business combination. The identifiable assets acquired and liabilities assumed were recorded at their preliminary fair values as of the Acquisition Date and are consolidated into our financial statements. The assignment of fair market value requires significant judgments regarding the estimates and assumptions used to value the acquired assets and liabilities assumed. For the preliminary fair values of the assets acquired and liabilities assumed, we utilized the cost, income and market approaches from the perspective of a market participant.
The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed.

12
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Cash and cash equivalents$12,197 
Accounts receivable3,075 
Inventories27,287 
Prepaid expenses and other current assets4,190 
Property and equipment, net11,206 
Intangible assets22,900 
Goodwill12,246 
Operating lease right-of-use assets4,975 
Other assets526 
    Total assets acquired98,602 
Accounts payable2,367 
Accrued expenses and other current liabilities4,912 
Deferred revenue1,399 
Operating lease obligations5,036 
     Total liabilities assumed13,714 
Total consideration transferred$84,888 
Acquired Receivables
The fair value of assets acquired includes accounts receivable of $3.1 million, which is net of an associated allowance for credit losses of $0.7 million.
Inventory
The fair value of inventory acquired was $27.3 million, which included a step up of $4.9 million from the book value as a result of the valuation at the Acquisition Date. The original cost basis of the inventory acquired from IsoPlexis was $22.4 million, which was net of a reserve for excess and obsolete inventory of $15.4 million.
Intangible Assets and Goodwill
Intangible assets includes $11.7 million of patented technology, $7.7 million of customer relationships and $3.5 million of IsoPlexis trade names and trademarks. The intangible assets will be amortized over their respective useful lives which range from eight to fourteen years. Goodwill with a provisional assigned value of $12.2 million represents the excess of the consideration transferred over the estimated fair values of assets and liabilities assumed. None of the goodwill resulting from the IsoPlexis Merger is deductible for tax purposes.
Transaction Costs
The Company recognized transaction costs associated with the IsoPlexis Merger of $3.5 million for the three months ended March 31, 2023 plus $2.8 million which was recognized in the fourth quarter of 2022. These costs are primarily related to professional services and are recorded in “Selling, general, and administrative” expenses in the Company’s condensed consolidated statement of operations.




13
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Supplemental Pro Forma Information
The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition.
(in thousands)Three months ended March 31, 2023Three months ended March 31, 2022
Total revenue$20,170 $25,117 
Net loss$(66,463)$(50,419)
Pro forma adjustments consisted of:
•Amortization/Depreciation- Tangible and intangible assets are assumed to be recorded at their assigned fair values as of January 1, 2022. Historical depreciation and amortization for IsoPlexis has been removed and the new fair values of the assets are depreciated or amortized over their estimated useful lives.
•Interest Expense- Entry into the Second Amended Term Loan and repayment of the Perceptive Credit Agreement are assumed to have occurred on January 1, 2022. Historical interest expense has been removed and replaced with the applicable interest rate as of March 21, 2023 associated with the Second Amended Term Loan, which was 8.5%.
•Transaction costs- Both entities incurred transaction costs, which totaled $13.7 million. Of the $13.7 million, approximately $4.4 million was incurred in the first quarter of 2023 and has been eliminated as it is not recurring.
•Accounting policies adjustment- IsoPlexis historically classified certain operations, quality and facility related costs in selling, general and administrative expenses. To align with PhenomeX accounting policies, these costs were reclassified to costs of goods sold or research and development. However, since this is a reclassification between expense line items on the statement of operations, the adjustment does not have an impact on revenue or net loss for purposes of the pro forma financial information disclosed above.
For the period subsequent to the Acquisition Date, IsoPlexis contributed total revenues and operating loss of $1.0 million and $1.1 million, respectively, for the three months ended March 31, 2023, that were included in the Company’s Condensed Consolidated Statements of Operations. In addition, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (See Note 6 for additional information).

14
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(6)Revenue From Contracts With Customers
The Company’s revenue consists of both product revenue and service and other revenue, which is primarily generated through the following revenue streams: (i) platform, (ii) recurring and (iii) partnership, license and other.
The Company in the first quarter entered into a license arrangement whereby certain patents were licensed to a third party and for which the customer agreed to pay a non-refundable fee. For licenses of intellectual property the Company recognizes revenue from non-refundable fees when the license is transferred to the customer and the customer is able to use and benefit from the license.

The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations:
Income Statement Classification
Product or Service sold
Revenue Stream
Product revenue
Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)
Platform
Software and workflow licenses
Platform
Fixed term sales-type lease arrangements with qualified customers
Platform
Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)
Recurring
Consumables and reagent kits (e.g. OptoSelect chips)
Recurring
Service and other revenue
Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types
Partnership, License and Other
Application support, installation and training
Platform
Fixed fee extended warranty and service programs
Recurring
IP license revenue
Partnership, License and Other (1)
(1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue.





15
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following tables provide information by revenue stream for the periods presented:

Three Months Ended March 31, 2023
(in thousands)ProductService and otherTotal
Platform$5,773 $330 $6,103 
Recurring2,605 2,558 5,163 
Partnership, License and Other (1)
— 7,250 7,250 
   Total revenue$8,378 $10,138 $18,516 
(1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter.
Three Months Ended March 31, 2022
(in thousands)ProductService and otherTotal
Platform$6,747 $657 $7,404 
Recurring3,027 2,416 5,443 
Partnership, License and Other— 7,359 7,359 
   Total revenue$9,774 $10,432 $20,206 

Revenues by geographical markets are presented in Note 19.
Performance Obligations
A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.

As of March 31, 2023, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year was $12.0 million, which, to the extent invoiced, is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 50% is expected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards.




16
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Contract Balances
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable, net$25,119 $18,534 
Contract assets, which are included in “Prepaid expenses and other current assets”$367 $1,283 
Contract assets, long-term, which are included in “Other assets”$514 $549 
Deferred revenue (current)$10,746 $9,092 
Deferred revenue (non-current)$1,259 $963 

The contract liabilities of $12.0 million and $10.1 million as of March 31, 2023 and December 31, 2022, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2023 included $2.8 million of previously deferred revenue that was included in contract liabilities as of December 31, 2022.
Sales-type Lease Arrangements
The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three months ended March 31, 2023 and 2022.

The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands):
Year ending December 31,Sales-Type
Leases
Remainder of 2023(1)
$334 
2024445 
2025408 
2026— 
Total undiscounted cash flows1,187 
Less: unearned income(171)
Total amounts due from customers (2)
$1,016 
(1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.
(2) Of the $1.0 million, $0.1 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets.



17
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(7)Balance Sheet Accounts
Trade accounts receivable, net consists of the following (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable$26,013 $18,534 
Allowance for doubtful accounts(894)— 
Total$25,119 $18,534 

Changes in the allowance for doubtful accounts were as follows (in thousands):
Three months ended March 31, 2023
Allowance for doubtful accounts, beginning of year$— 
Allowance assumed in IsoPlexis Merger(721)
Write-offs of uncollectible accounts— 
Provision for doubtful accounts(173)
Allowance for doubtful accounts, end of period$(894)

Inventory
The following table shows the components of inventory (in thousands):
March 31,
2023		December 31,
2022
Raw materials$32,816 $11,946 
Work in progress1,106 — 
Finished goods11,617 6,915 
Total$45,539 $18,861 


Prepaid expenses and other current assets
The following table shows the components of prepaid expenses and other current assets (in thousands):
March 31,
2023		December 31,
2022
Contract asset$367 $1,283 
Vendor deposits421 126 
Deferred costs365 472 
Prepaid insurance3,534 2,025 
Other (1)
4,691 2,877 
Total$9,378 $6,783 
(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
18
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Accrued expenses and other current liabilities
The following table shows the components of accrued expenses and other current liabilities (in thousands):
March 31,
2023		December 31,
2022
Accrued payroll and employee related expenses$6,611 $7,410 
Lease liability – short-term4,958 3,291 
Accrued product warranty788 749 
Accrued legal expenses5,499 8,271 
Other (1)
1,789 1,619 
Total$19,645 $21,340 
(1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.
(8)Goodwill and Other Intangible Assets
Goodwill
On March 21, 2023, the Company completed the IsoPlexis Merger. Under the purchase method of accounting, the Company preliminarily recorded the $12.2 million excess of the Acquisition Date fair value of the consideration transferred over the estimated fair value of net tangible and identifiable intangible assets that it acquired as goodwill. At March 31, 2023, the carrying amount of this goodwill was $12.2 million.

During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. The Company considered such sustained decrease to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Based on the results of the quantitative goodwill impairment test, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2023. In future periods, if the Company were to experience a further decline in its market capitalization or expected results for a sustained period of time, the Company may be required to perform an additional quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material.

Acquired Intangible Assets
In connection with the IsoPlexis Merger, the Company identified certain intangible assets summarized in the table below (see Note 5 for further information). In addition, on February 15, 2023, the Company acquired certain tangible and intangible assets from Evorion Biotechnologies for a total purchase price of $0.3 million, of which $0.2 million related to intangible assets attributable to patents and technology. These intangible assets are also included in the table below.
March 31, 2023
 (in thousands):Remaining Useful Life (Years)GrossAccumulated AmortizationNet
Customer relationships8$7,700 $(5)$7,695 
Trade names103,500 (11)3,489 
Patented technology1411,911 (23)11,888 
Total intangible assets$23,111 $(39)$23,072 
19
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Amortization expense was $39,000 for the three months ended March 31, 2023. In connection with the License Agreement, the Company reviewed the patented technology intangible for indicators of impairment, noting that the patented technology was valued using the relief from royalty approach based on projected revenues from products and services of IsoPlexis, which did not contemplate the License Agreement. In addition, the Company still owns, and retains certain rights to, the intellectual property that was licensed under the License Agreement. Accordingly the Company concluded that an impairment was not necessary.

The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors.
March 31, 2023
Year Ending December 31:
Remainder of 2023$1,689 
2024$2,163 
2025$2,163 
2026$2,163 
2027$2,163 
(9)Fair Value of Financial Instruments
The following is a description of the valuation techniques the Company uses to measure the fair value of assets and reports fair value on a recurring basis:
•Cash equivalents: At March 31, 2023, the Company’s cash equivalents consisted of money market funds. Money market funds are highly liquid investments and are actively traded and pricing information is readily available. Accordingly, the Company classifies these securities as Level 1 of the fair value hierarchy.
•Short Term Marketable Securities: At March 31, 2023, the Company did not hold any short term marketable securities. Generally, the Company values short-term marketable securities using quoted prices in active markets for similar instruments. Accordingly, the Company classifies marketable securities as Level 2 of the fair value hierarchy.
The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of March 31, 2023 and December 31, 2022 approximate fair value due to their relatively short maturities.

20
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands):
March 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$6,591 $6,591 $— $— 
Total assets measured at fair value$6,591 $6,591 $— $— 
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$2,354 $2,354 $— $— 
Commercial paper16,602 — 16,602 — 
U.S. agency securities3,970 — 3,970 — 
Total cash equivalents22,926 2,354 20,572 — 
Debt securities, available for sale:
Commercial paper22,148 — 22,148 — 
U.S. agency securities4,942 — 4,942 — 
U.S. government securities19,162 — 19,162 — 
Total debt securities, available for sale46,252 — 46,252 — 
Total assets measured at fair value$69,178 $2,354 $66,824 $— 

The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):
March 31, 2023December 31, 2022
Carrying
Value		Fair ValueCarrying
Value		Fair Value
Long-term debt, including current maturities$68,886 $70,000 $19,826 $17,443 

The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.

The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.
21
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(10)Property and Equipment, net
Property and equipment, net comprised the following (in thousands):
March 31,
2023		December 31,
2022
Equipment, tooling and molds$47,577 $36,152 
Computer software and equipment8,037 2,667 
Furniture, fixtures and other2,600 2,007 
Leasehold improvements12,509 10,836 
Construction in process1,370 1,409 
Total property and equipment72,093 53,071 
Less: Accumulated depreciation(38,251)(29,224)
Property and equipment, net (1)
$33,842 $23,847 
(1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.

Depreciation expense for the three months ended March 31, 2023 and 2022 was $2.1 million and $1.9 million, respectively.

During the three months ended March 31, 2023 and 2022 losses on the impairment and disposal of property and equipment were not material.
(11)Leases
The Company leases office, manufacturing, distribution and laboratory facilities in various locations in the United States, primarily in Emeryville, California and Branford, Connecticut. The Company also leases facilities in Shanghai, China for office and laboratory facilities. On December 28, 2022, the Company entered into a sub-lease arrangement for its facility in Lexington, Massachusetts. Sub-lease income for the three months ended March 31, 2023 was $0.1 million and was recorded as an offset to rent expense.

Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands):
Operating leases
Undiscounted lease payments for the year ending December 31,
Remainder of 2023$4,691 
20246,297 
20255,952 
20265,398 
20274,759 
Thereafter7,464 
Total undiscounted lease payments34,561 
Less: implied interest(4,304)
Less: tenant improvement allowances receivable(65)
Present value of operating lease payments30,192 
Less: current portion (1)
(4,958)
Total long-term operating lease liabilities$25,234 
(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”

22
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Rent expense, net for the three months ended March 31, 2023 and 2022 was $0.9 million and $1.1 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.8 million and $0.8 million for the three months ended March 31, 2023 and 2022, respectively, including non-lease components such as common area maintenance fees.

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):
Three months ended March 31, 2023Three months ended March 31, 2022
Right-of-use assets obtained for new operating lease liabilities$— $— 
Right-of-use lease assets assumed in IsoPlexis Merger$4,975 $— 
Cash paid for amounts included in the measurement of lease liabilities$989 $1,098 
The following summarizes additional information related to operating leases:
March 31, 2023December 31, 2022
Weighted-average remaining lease term (years)5.716.48
Weighted-average discount rate4.73 %4.66 %

The Company also enters into leasing transactions in which the Company is the lessor, which to date have been classified as sales-type leases. See Note 6 for the related lease disclosures.

(12)Long-term Debt
On May 23, 2018, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with EWB to provide a $20.0 million term loan facility (“Term Loan”). The loan facility was fully drawn as of May 23, 2018.

On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (“Amended Loan Agreement”) with EWB. Pursuant to the Amended Loan Agreement, EWB provided a $20.0 million term loan (“Amended Term Loan”) which was used to refinance the Term Loan outstanding under the Loan Agreement dated May 23, 2018. The Amended Term Loan had a maturity of 48 months and a fixed interest rate of 4.17%. In addition, the Amended Term Loan had an initial interest-only period of 24 months, which could have been extended to up to 36 months based on the achievement of certain liquidity measures, and could have been pre-paid without penalty at any time.

On March 21, 2023, the Company entered into a Second Amended and Restated Loan and Security Agreement (“Second Amended Loan Agreement”) with EWB. Pursuant to the Second Amended Loan Agreement, EWB increased the existing Amended Term Loan amount of $20.0 million by $50.0 million to an aggregate outstanding principal of $70.0 million (“Second Amended Term Loan”). The Company used the proceeds from the Second Amended Term Loan to repay $52.5 million of indebtedness (including prepayment premium and interest) with Perceptive held by IsoPlexis (“Perceptive Credit Agreement”). Associated with these transactions, a $0.2 million loss on extinguishment of debt and a $0.7 million commitment fee associated with the Loan Agreement, was recorded in Other expense, net on our condensed consolidated statement of operations during the three months ended March 31, 2023.

23
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Second Amended Term Loan has a maturity of 60 months and bears interest at a variable rate per annum equal to (i) the greater of 6.25% or the variable rate of interest, per annum, most recently announced by EWB as its prime rate, plus (ii) one-half of one percent (0.5%). In addition, the Second Amended Term Loan has an initial interest-only period of 24 months, which can be extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Second Amended Loan Agreement are satisfied. The Second Amended Term loan carries a prepayment penalty equal to one percent (1%) of the amount of any prepayment of the outstanding balance, if the prepayment is made before the first anniversary of the loan closing date. The Second Amended Loan Agreement was accounted for as a debt extinguishment and the Company capitalized incremental debt issuance costs.

The Second Amended Term Loan is guaranteed by certain domestic subsidiaries of the Company (such subsidiaries, together with the Company, the “Credit Parties”). The Second Amended Loan Agreement grants EWB a security interest in and liens on substantially all assets of the Company and the other Credit Parties, excluding intellectual property, provided, that if the Company does not satisfy a liquidity test set forth in the Second Amended Loan Agreement, the Credit Parties will be required to grant a first-priority security interest in their intellectual property. In addition, certain other terms of the original agreements as previously in effect were amended by the Second Amended Loan Agreement, including certain financial covenants. For example, the Company must maintain cash and cash equivalents of no less than $70.0 million in the aggregate at all times in a deposit account with EWB that is assigned to EWB. As a result, the deposit of $70.0 million was recorded as restricted cash on the Company’s condensed consolidated balance sheet. In addition, if the Company’s cash and cash equivalents balance at EWB falls below $100.0 million, the Company is then required to maintain specific minimum EBITDA amounts at all times thereafter.

The Second Amended Loan Agreement contains customary affirmative and negative covenants, including limitations on mergers, asset sales, liens, investments and indebtedness. See Exhibit 10.1 for the Second Amended Loan Agreement. As of March 31, 2023, the Company was in compliance with the terms and covenants of the Agreement.

The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands):
March 31,
2023
Year Ending December 31:
Remainder of 2023$4,545 
20246,049 
202513,680 
202615,437 
202714,532 
202841,990 
Total payments due96,233 
Less:
Interest payments, loan discounts and financing costs(27,347)
Current portion, less loan discounts and financing costs— 
Notes payable, net of current portion$68,886 

Total interest cost incurred for the three months ended March 31, 2023 and 2022 was $0.4 million and $0.2 million, respectively.

24
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(13)Equity and Stock Compensation Plans

IsoPlexis Merger
On March 21, 2023, in connection with the completion of the IsoPlexis Merger:

•All outstanding IsoPlexis RSAs were assumed by PhenomeX and converted into PhenomeX RSAs based on the 0.612 conversion ratio (see Note 5) and on the same terms and conditions (including with respect to vesting schedules and restrictions) as applied to IsoPlexis RSAs immediately prior to the closing of the IsoPlexis Merger.

•All outstanding IsoPlexis stock options (whether vested or unvested) that had a per share exercise price of less than $1.28 and were held by continuing employees were assumed by PhenomeX and converted into PhenomeX stock options based on the 0.612 conversion ratio (and rounded down) and on the same terms and conditions (including with respect to time-based vesting) as applied to IsoPlexis stock options immediately prior to the closing of the IsoPlexis Merger, with the exercise price per share of the assumed stock options determined by dividing the per share exercise price of the IsoPlexis options by the 0.612 conversion ratio (and rounded up to the nearest whole cent). The assumed stock options expire 10 years from their original date of grant. The assumed stock options and RSAs generally vest 25% upon the one-year anniversary of the service inception date and then ratably each month over the remaining 36 months.

On March 21, 2023, PhenomeX assumed 304,619 IsoPlexis RSAs and 378,767 IsoPlexis stock options after applying the 0.612 conversion ratio. The Company accounted for the assumed equity awards as a modification under ASC 718 and recorded stock compensation expense of $0.1 million during the three months ended March 31, 2023 associated with the modification.
Future grants of equity awards will be issued under the Company’s 2020 Plan.

Warrant Certificate
On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive executed the Warrant Certificate. Under the Warrant Certificate, the outstanding warrant (“IsoPlexis Warrant”) to purchase shares of common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”), issued by IsoPlexis to Perceptive was assumed by PhenomeX and converted into a warrant (“PhenomeX Warrant”) to purchase shares of common stock, par value $0.00005, of PhenomeX (“PhenomeX Common Stock”), on the same terms and subject to the same conditions as were applicable to the IsoPlexis Warrant as of immediately prior to the Acquisition Date; provided, that the PhenomeX Warrant is exercisable for 496,560 shares of PhenomeX Common Stock (i.e., a number of shares of PhenomeX Common Stock equal to the number of shares of IsoPlexis Common Stock that were subject to the IsoPlexis Warrant multiplied by the 0.612 exchange ratio and has an exercise price of $9.80 per share of PhenomeX Common Stock (i.e., the exercise price per share of IsoPlexis Common Stock that was applicable to the IsoPlexis Warrant divided by 0.612).

Restricted stock awards
As a result of the IsoPlexis Merger and discussed above, the Company now has RSAs outstanding. RSAs are rights to receive shares of the Company’s Common Stock upon meeting specified vesting requirements. The fair value of a RSA is the market value as determined by the closing price of the Company’s stock on the original grant date.

25
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Stock-based compensation
Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):
Three months ended March 31,
20232022
Cost of sales$16 $51 
Research and development548 1,581 
Selling, general and administrative3,824 3,761 
Total stock-based compensation$4,388 $5,393 

Stock-based compensation capitalized in inventory was not material as of March 31, 2023 and December 31, 2022.

(14)Restructuring
During 2022, the Company adopted a new strategic plan with the intention of reducing costs and better aligning the organization with the Company’s long-term goals. As a result, the Company approved a set of restructuring initiatives in 2022 and continued with similar initiatives in the first quarter of 2023. During the three months ended March 31, 2023, the Company incurred restructuring charges of $1.3 million, related to severance and other employee-related restructuring costs associated with the termination of approximately 16% of total full-time employees. As of March 31, 2023, the Company has not fully completed its restructuring efforts. It is unable to currently estimate future restructuring charges, but will record any additional restructuring-related expenses as they are incurred.
Changes in the Company’s restructuring liability are set forth in the table below (in thousands):
Employee severance and termination benefitsNon labor restructuringTotal
Accrual at January 1, 2023$130 $107 $237 
Restructuring liability assumed in IsoPlexis Merger834 — 834 
Restructuring charges1,290 — 1,290 
Cash payments(1,010)(107)(1,117)
Non-cash settlements— — — 
Accrual at March 31, 2023$1,244 $— $1,244 
Restructuring liabilities are included in accrued expenses and other current liabilities in the condensed consolidated balance sheet.
(15)Income Taxes
The Company’s provision for income taxes was $20,000 for the three months ended March 31, 2023 and $20,000 and for the three months ended March 31, 2022. For the three months ended March 31, 2023 and 2022, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance.
26
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(16)Statements of Cash Flows
The supplemental cash flow information consists of the following (in thousands):
Three months ended March 31,
20232022
Cash paid for interest$439 $137 
Cash paid for income taxes$19 $— 
Non-cash investing and financing activities
Non-cash consideration for the acquisition of IsoPlexis$32,406 $— 
Property and equipment transferred to inventory$352 $— 
Customer return of Beacon transferred to property and equipment (1)
$201 $— 
Change in accounts payable and accrued liabilities related to purchases of property and equipment$684 $482 
(1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.
(17)Commitments and Contingencies
Legal Proceedings
From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred.
AbCellera Biologics Litigation
In July through September 2020, AbCellera Biologics Inc. (“AbCellera”) filed a series of complaints in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936, 10,704,018, 10,718,768, 10,738,270, 10,746,737, 10,753,933, 10,775,376, 10,775,377, and 10,775,378. The University of British Columbia (“UBC”), the owner of the patents, joined AbCellera as a named plaintiff in the lawsuits. AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees, and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents, for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct, and unfair competition under state and federal law.
The Company filed a motion to transfer the lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (“Consolidated Lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court issued a Case Management Order that, among other things, requires AbCellera and UBC to further reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial.
27
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In July 2021 and August 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent Nos. 10,421,936 and 10,739,270. In August 2021, in response to a Motion to Stay filed by the Company, the court stayed the Consolidated Lawsuit pending the outcome of the IPR proceedings.
In January 2022, the PTAB of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. And in January 2023, the PTAB issued a decision upholding the validity of the challenged claims in U.S. Patent No. 10,087,408: the Company has requested a rehearing of the PTAB’s decision. The Consolidated Lawsuit remains stayed at this time, AbCellera has filed a motion - opposed by the Company - to lift the stay. AbCellera’s motion to lift the stay is fully briefed and awaiting a decision from the court.
The Company believes that the patent assertions by AbCellera and UBC are without merit and it intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s position. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of the Company’s products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.
Securities Class Action
In December 2021, Victor J. Ng filed a securities class action complaint in the Northern District of California (“Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 Initial Public Offering (“IPO”) offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. The Company’s pending Motion to Dismiss is set for hearing on June 22, 2023. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.
Derivative Action
In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and former senior executives owe the Company contribution for violations of Sections 10(b) and 21D of the Exchange Act.
The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity.
28
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
No provision has been made for litigation because the Company believes that it is not probable that a liability has been incurred as of March 31, 2023.
Purchase commitments
The Company has entered into various purchase agreements, including inventory-related agreements with its contract manufacturers. Once these orders are placed, they are generally cancelable by providing notice prior to the expected ship date, however such cancellations could result in the Company incurring certain charges depending on the timing. The Company had non-cancellable purchase obligations to contract manufacturers and other suppliers of $29.7 million at March 31, 2023.
Product Warranty
The Company generally provides a one year assurance-type warranty on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):
Three months ended March 31,
20232022
Balance, beginning of period$749 $1,085 
Warranty accrual assumed in IsoPlexis Merger128 — 
Adjustments to existing warranties(111)(245)
Provision for new warranties133 163 
Settlement of pre-existing warranties(111)(89)
Balance, end of period$788 $914 
(18)Net Loss Attributable to Common Stockholders Per Share
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards and unvested restricted stock units.

The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):
Three months ended March 31,
20232022
Numerator
Net loss attributable to common stockholders, basic and diluted$(23,419)$(21,426)
Denominator
Weighted-average shares used to compute net income per share, basic and diluted75,759,77167,697,488
Net loss per share
Net loss per share attributable to common stockholders, basic and diluted$(0.31)$(0.32)

29
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect:

 March 31,
20232022
Warrants to purchase common stock496,560 — 
Options to purchase common stock7,685,997 7,020,591 
Restricted stock awards290,846 — 
Restricted stock units5,517,488 3,629,310 
Total13,990,891 10,649,901 

(19)Segments
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has one operating segment. The IsoPlexis Merger on March 21, 2023 did not change the Company’s assessment about operating segments. The Company’s principal operations and decision-making functions are located in the United States.
The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):
Three months ended March 31,
20232022
North America$14,055 $13,715 
Asia Pacific (1)
3,147 5,035 
Europe1,314 1,456 
$18,516 $20,206 
(1) Asia Pacific includes Australia.

As of March 31, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets were located in the United States.

(20)Subsequent Events

In April 2023, Phenomenex, Inc. (“Phenomenex”) filed a complaint against the Company in the U.S. District Court for the Central District of California, alleging trademark infringement and unfair competition in relation to the Company’s name and seeking injunctive relief and damages. As of the filing date for this Quarterly Report on Form 10-Q, the Company has not been served with the complaint from Phenomenex. The Company believes that Phenomenex’s complaint is without merit and intends to vigorously defend itself.

30
PhenomeX Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Restructuring
During the second quarter of 2023, the Company announced a reduction in force terminating approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $0.8 million related to this activity, substantially all of which the Company expects to incur in the second quarter of 2023.
31

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of forward-looking statements include, among others: our ability to continue as a going concern; our intention to improve operating cash flow by increasing our revenue and lowering our operational costs; our expectations regarding the drivers of expected revenue growth, including new commercial leadership, geographic expansion, and a refined product roadmap; our expectations regarding the timing to achieve our goal of generating positive operating cash flow in the fourth quarter of 2024; our expectations regarding anticipated returns on investment through increased focus and rigor on development initiatives; our strategy, plans and timing for acquisitions, growth, product development and expansion, the expected benefits of the IsoPlexis Merger, including the estimated cost synergies of the combined company in order to pursue profitability, lower operating expenses and advance the path to cash flow breakeven; our expectations regarding the drivers of our expected cost synergies, including eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies; and other expectations, outlooks and forecasts on our future business, operational and financial performance.

Forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2022 included in the Annual Report on Form 10-K and filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2023 (“Annual Report”). Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including
32

those discussed in Item 1A. “Risk Factors” of our Annual Report, Part II, Item 1A and elsewhere in this Quarterly Report on Form 10-Q, and our other reports filed with the SEC.

Overview
PhenomeX is the combination of two companies, Berkeley Lights and IsoPlexis. Berkeley Lights acquired IsoPlexis on March 21, 2023 (the “IsoPlexis Merger”) and the newly combined company was rebranded as PhenomeX.
PhenomeX is a life sciences tools company with a focus on functional cell biology. Our products and services provide customers with, among other offerings, Optofluidic platforms such as the Beacon and Beacon Select (developed by Berkeley Lights) as well as Proteomic Barcoding platforms, such as the IsoLight System and the IsoSpark System (developed by IsoPlexis). These platforms provide scientists with opportunities to perform cell biology research through experiments using our proprietary consumables.
The mission of PhenomeX is to empower scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health.

PhenomeX’s strategy is organized around the following five key pillars:

1.    Generate positive operating cash flow in the fourth quarter of 2024.

2.    Prioritize research and development’s return on investment through increased focus and rigor on development initiatives.

3.    Deliver consistent commercial execution through a new sales structure and enhanced product portfolio and pricing strategy.

4.    Build a world-class life sciences leadership team with a proven track record in profitably scaling life sciences tools companies.

5.    Evaluate merger and acquisition opportunities that will help us accelerate profitable growth and leverage our current cost structure.

Recent Events
As noted above, on March 21, 2023 we completed the IsoPlexis Merger. As Berkeley Lights was the acquiring company, historical financials included herein are the financials of Berkeley Lights. The results of IsoPlexis are included in the combined results of PhenomeX from the acquisition date (March 21, 2023). We believe the IsoPlexis Merger enhances our strategy by, among other things, the following:
•Offering an expanded product portfolio at different price points with a focus on recurring revenue;
•Growing the combined company’s share in a larger cell biology market through expanding its diversified customer base;
•Enhancing the combined company's commercial scale and execution;
•Delivering an expected $70 million in cost synergies to pursue profitability and advance the path to cash flow breakeven; and
• Serving as a platform for further consolidation in the high-growth, single-cell biology tools space.
33


Recent Trends
There are multiple broad based factors impacting our business:
1.Macroeconomic factors, including the war between Ukraine and Russia as well as political instability elsewhere, has resulted in unfavorable global economic conditions, including increased inflation and interest rates, and may lead to a recession.
2.Global and domestic supply chains and the timely availability of raw materials and product as a result of the COVID-19 pandemic factory slowdowns or shutdowns, border closing and other measures has previously impacted our operational and financial performance and its impact in future periods remains uncertain.
3.Adverse developments affecting financial institutions and the financial services industry, including the government closure of Silicon Valley Bank, have affected certain of our vendors, suppliers, investors and customers and may lead to market-wide liquidity problems.

Our business has been impacted and will continue to be impacted by the above factors. To date, our production, shipping and customer service functions have remained operational to maintain a continuous supply of products both to our customers and for our internal research and development activities. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future activities. We continue to closely monitor global supply issues around materials, parts and components, including plastics and integrated circuit chips, and we have not experienced any material supply issue to date.

The ultimate impact of the foregoing factors on our operations and financial performance in future periods remains uncertain and will depend on many factors outside of our control, including the timing, extent, trajectory, and duration of the pandemic as well as the magnitude of any potential recession and related government actions to prevent and manage these issues, all of which are uncertain and cannot be predicted. While the overall impact of these matters is impossible to measure, they have resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and, ultimately our business and operations. Refer to Part I, Item 1A of our Annual Report on Form 10-K and Part II, Item 1A in this Quarterly Report on Form 10-Q under the heading “Risk Factors” for more information.

Results of operations
Comparison of the three months ended March 31, 2023 and 2022
Revenue
Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Platform$6,103 $7,404 $(1,301)(18)%
Recurring5,163 5,443 (280)(5)%
Partnership, License and Other7,250 7,359 (109)(1)%
Total revenue$18,516 $20,206 $(1,690)(8)%

34

See Note 6 to our condensed consolidated financial statements for additional information regarding how our product and service revenue is generated through our Platform, Recurring and Partnership, License and Other revenue streams.

Platform revenue decreased by $1.3 million, or 18%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022, primarily due to decreased revenue from Optofluidic platform sales, partially offset by $0.5 million of Proteomic platform sales associated with the operations of IsoPlexis, which we acquired in March of 2023.

Recurring revenue decreased by $0.3 million, or 5%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The decrease was primarily driven by a decrease in Optofluidic consumables revenue, offset by $0.5 million of Proteomic consumables revenue associated with the operations of IsoPlexis.

Partnership, License and Other revenue for the three months ended March 31, 2023 was comprised entirely of license revenue related to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. Partnership, License, and Other revenue for the three months ended March 31, 2022 related to multiple strategic partnership and service engagements, all of which were completed or terminated in the second half of 2022.

See below for details of our installed base. Note that the significant majority of our installed base relates to platform sales, with a much smaller percentage being provided under leasing programs.

Optofluidic Platforms
Proteomic PlatformsTotal
Installed base at January 1, 20231350135
Acquired in IsoPlexis Merger0287287
Q1 2023 Placements448
Installed base at March 31, 2023139291430

Cost of sales, gross profit and gross margin
Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Cost of sales$5,088 $6,379 $(1,291)(20 %)
Gross profit$13,428 $13,827 $(399)(3 %)
Gross margin73 %68 %

Cost of sales for the three months ended March 31, 2023 decreased by $1.3 million compared to the three months ended March 31, 2022 and was primarily due to the declines in Platform and Recurring revenue as the License Agreement that comprises all of our Partnership, License and Other revenue in 2023 does not have associated cost of sales.

Gross margin for the three months ended March 31, 2023 increased compared to the three months ended March 31, 2022 due to the revenue recognized from the License Agreement, which does not have associated cost of sales. Without the impact of this transaction, gross margin declined due to increased costs per unit as a result of lower production volumes, increased inventory reserves, and lower margins from IsoPlexis from March 21, 2023.
35

Operating Expenses
Organizational and presentational changes
Starting in the third quarter of 2022, we made certain changes to our operating structure to align with our new business strategy. These changes included reorganizing our go-to-market efforts, employee terminations and additional organizational changes (see also Note 14 to our condensed consolidated financial statements for further information).
As part of these changes, our “service center,” a team of scientists and engineers who perform services for both our internal and external projects, is now part of our platform sales and support organization. The service center historically reported to our former Chief Product Officer.

As a result of these changes, we now classify expenses associated with our service center as “Selling, general and administrative” instead of “Research and development” expenses on our condensed consolidated statements of operations starting in the third quarter of 2022. Service center expenses recorded in “Research and development” during the three months ended March 31, 2022 were $4.6 million. Service center expenses recorded in “Selling, general and administrative” during the three months ended March 31, 2023 were $4.6 million.

Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Research and development$8,421 $17,573 $(9,152)(52 %)
Selling, general and administrative26,547 17,527 9,020 51 %
Restructuring1,290 — $1,290 100 %
Total operating expenses$36,258 $35,100 $1,158 3 %

Operating expenses increased by $1.2 million, or 3%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase is primarily due to restructuring expenses incurred in connection with the employee terminations.
Research and development expense decreased by $9.2 million, or 52%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. This decrease reflects the impact of the $4.6 million reclassification of the service center expenses discussed above. In addition, research and development expense decreased during the period due to the impact of workforce reductions and overall lowered spend due to our strategy to prioritize research and development return on investment through increased focus and rigor on development initiatives.

Selling, general and administrative expense increased by $9.0 million, or 51%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. This increase reflects the impact of the $4.6 million reclassification of the service center expenses discussed above. In addition, selling, general and administrative costs increased due to transaction costs associated with the IsoPlexis Merger of $3.5 million and $0.9 million in costs associated with the operations of IsoPlexis since March 21, 2023.

36

Interest expense
Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Interest expense$384 $224 $160 71 %

Interest expense increased by $0.2 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The increase was primarily due to the refinancing of our term loan with EWB on March 21, 2023, which increased the loan amount from $20.0 million to $70.0 million and also increased the interest rate from 4.17% to the Prime Rate plus one-half of one percent (0.5%).

Interest income
Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Interest income $827 $34 $793 2332 %

Interest income increased by $0.8 million during the three months ended March 31, 2023 as compared to the corresponding periods in 2022. These increases are primarily the result of higher yields received on our cash management program.

Other income (expense), net
Three months ended March 31,Three month change
(in thousands, except percentages)20232022Amount%
Other income (expense), net $(1,012)$57 $(1,069)(1875 %)

Other expense, net for the three months ended March 31, 2023 includes $0.9 million of debt refinancing costs. Other income, net for the three months ended March 31, 2022 was mainly comprised of foreign exchange gains and losses and other miscellaneous income and expense items.
Components of results of operations
Revenue
Our revenue consists of i) platform, ii) recurring and iii) partnership, license and other revenue. Platform revenue consists of the sale of Optofluidic and Proteomic platforms (including the Beacon, Beacon Quest, IsoSpark and IsoLight), associated software, fixed-term sales-type lease arrangements with qualified customers, as well as application support, installation and training. Recurring revenue includes, consumables and reagent kits, quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. Reagent Rental), and fixed fee extended warranty and service programs. Partnership, license and other revenue consists of strategic partnerships, as well as joint development and collaboration agreements where we provide services for the development of new workflows, cells or organism types, revenue from licenses of intellectual property, and other revenue. See Note 6 to our condensed consolidated financial statements for additional information regarding how our product and service revenue is generated through our platform, recurring and partnerships, license and other revenue streams.
37

Cost of sales, gross profit and gross margin
Cost of sales. Cost of sales includes manufacturing related costs incurred in the production process, including personnel and related costs, costs of component materials, labor and overhead, packaging and delivery costs and allocated costs, including facilities and information technology. Also included in cost of sales are the personnel and related costs associated with our services, expenses related to the development of customized platforms and workflows, feasibility studies on our platforms and service and warranty costs to support our customers. We also include the costs associated with the standard assurance-type product warranty provided on our platforms, which are recorded at the time of sale.

Gross profit and gross margin. Gross profit is calculated as revenue less cost of sales. Gross margin is gross profit expressed as a percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including: market conditions that may impact our pricing; sales mix among platform access options, including the regional mix of sales; sales mix changes among consumables, platforms and services; product mix changes between established products and new products; excess and obsolete inventories; our cost structure for manufacturing operations relative to volume; and product warranty obligations.
Operating expenses
Research and development. Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses and allocated facilities and IT costs for employees and contractors engaged in research and product development. We expense all research and development costs in the period in which they are incurred.

Selling, general and administrative. Our selling, general and administrative expenses primarily consist of costs related to the selling and marketing of our products and services and costs associated with our executive, finance, accounting, legal, human resources and administrative functions. These costs include salaries, benefits, sales commissions and stock-based compensation for our employees, as well as advertising and marketing costs and professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated overhead expenses. We expect these expenses to vary from period to period as a percentage of revenue.

Restructuring. Our restructuring expense primarily consists of one-time cash severance benefits associated with the termination of certain employees. Restructuring expense can also include infrastructure charges to vacate facilities and contract cancellation costs. (see Note 14 to our condensed consolidated financial statements for additional information).
Other income (expense)
Interest expense. Interest expense consists primarily of interest related to borrowings under our debt obligations.

Interest income. Interest income primarily consists of interest earned on our cash, cash equivalents and short-term available-for-sale debt securities. We sold our short-term available for sale debt securities during March 2023.

Other income (expense), net. Other income (expense), net consists primarily of foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and asset and liability balances denominated in currencies other than the U.S. dollar, primarily related to our operations in the United Kingdom and China. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates. During the three months ended March 31, 2023, other income (expense) also included debt refinancing costs.
38

Provision for income taxes
Our provision for income taxes consists primarily of foreign taxes and state taxes in the United States. The Company maintains a full valuation allowance on its deferred tax assets and intends to do so until there is sufficient evidence to support the reversal of all or some portion of these allowances. As we expand the scale and scope of our international business activities, any changes in taxation of such activities may increase our overall provision for income taxes in the future.
Liquidity and capital resources
As of March 31, 2023, we had approximately $51.6 million in cash, cash equivalents and marketable securities which were primarily held in U.S. short-term bank deposit accounts and money market funds. Restricted cash of $70.1 million at March 31, 2023 relates to a letter of credit with an international customer. We have generated negative cash flows from operations since inception through March 31, 2023.

We expect to incur additional operating losses in the foreseeable future as we continue to invest in the research and development of our product offerings, commercialize and launch platforms, and expand into new markets. Our future capital requirements will depend on many factors including our revenue growth rate, research and development efforts, the timing and extent of additional capital expenditures to invest in existing and new facilities as well as our manufacturing operations, the expansion of sales and marketing and the introduction of new products. Our future capital needs may also depend upon factors affecting the macroeconomic environment. We have implemented measures to reduce our costs to extend our cash runway, including conducting reductions in force.

On March 21, 2023, we completed the IsoPlexis Merger. In the future we may enter into additional arrangements to acquire or invest in businesses, services and technologies, and any such acquisitions or investments could significantly increase our capital needs.

As discussed in Note 1 to our condensed consolidated financial statements, certain factors raise substantial doubt about our ability to continue as a going concern within one year from the issuance of such financial statements. Management’s intent is to implement plans that will allow us to continue as a going concern. We intend to improve operating cash flow by increasing our revenue and lowering our operational costs. New commercial leadership, geographic expansion, and a refined product roadmap are expected to drive revenue growth, and significant cost synergies as a result of the IsoPlexis Merger and are expected to lower operating expenses. Cost synergies are expected to be accomplished by eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies. In addition, we are evaluating financing options including the potential to raise equity and debt financing. While management is focused on these efforts, there can be no assurance that we will be successful in doing so.

Sources of liquidity
Since our inception, we have financed our operations primarily from the issuance and sale of our equity securities, borrowings under long-term debt agreements, and to a lesser extent, cash generated by product and service sales. In July 2020, we completed our IPO, resulting in the receipt of aggregate proceeds of $187.9 million, net of offering costs, underwriter discounts and commissions of $17.0 million.
East West Bank Loan and Security Agreement
On May 23, 2018, we entered into a Loan and Security Agreement (“Loan Agreement”) with East West Bank (“EWB”) to provide a $20.0 million term loan facility (“Term Loan”). The loan facility was fully drawn as of May 23, 2018.
39


On June 30, 2021, we entered into an Amended and Restated Loan and Security Agreement (“Amended Loan Agreement”) with EWB. Pursuant to the Amended Loan Agreement, EWB provided a $20.0 million term loan (“Amended Term Loan”) which was used to refinance the Term Loan outstanding under the Loan Agreement dated May 23, 2018. The Amended Term Loan had a maturity of 48 months and a fixed interest rate of 4.17%. In addition, the Amended Term Loan had an initial interest-only period of 24 months, which could have been extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Amended Loan Agreement are satisfied.

On March 21, 2023, we entered into a Second Amended and Restated Loan and Security Agreement (“Second Amended Loan Agreement”) with EWB. Pursuant to the Second Amended Loan Agreement, EWB increased the existing Amended Term Loan amount of $20.0 million by $50.0 million to an aggregate outstanding principal of $70.0 million (“Second Amended Term Loan”). We used the proceeds from the Second Amended Term Loan to repay $52.5 million of indebtedness (including prepayment premium and interest) with Perceptive held by IsoPlexis (“Perceptive Credit Agreement”). Associated with these transactions, a $0.9 million loss on extinguishment of debt was recorded in Other expense, net on our condensed consolidated statement of operations during the three months ended March 31, 2023.

The Second Amended Term Loan has a maturity of 60 months and bears interest at a variable rate per annum equal to (i) the greater of 6.25% or the variable rate of interest, per annum, most recently announced by EWB as its prime rate, plus (ii) one-half of one percent (0.5%). In addition, the Second Amended Term Loan has an initial interest-only period of 24 months, which can be extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Second Amended Loan Agreement are satisfied. The Second Amended Term loan carries a prepayment penalty equal to one percent (1%) of the amount of any prepayment of the outstanding balance, if the prepayment is made before the first anniversary of the loan closing date. The Second Amended Loan Agreement was accounted for as a debt extinguishment and we capitalized incremental debt issuance costs.

The Second Amended Term Loan is guaranteed by certain of our domestic subsidiaries (such subsidiaries, together with the Company, the “Credit Parties”). The Second Amended Loan Agreement grants EWB a security interest in and liens on substantially all assets of the Company and the other Credit Parties, excluding intellectual property, provided, that if we do not satisfy a liquidity test set forth in Second Amended Loan Agreement, the Credit Parties will be required to grant a first-priority security interest in their intellectual property. In addition, certain other terms of the original agreements as previously in effect were amended by the Second Amended Loan Agreement, including certain financial covenants. For example, we must maintain cash and cash equivalents of no less than $70.0 million in the aggregate at all times in a deposit account with EWB that is assigned to EWB, which was recorded as restricted cash on the condensed consolidated balance sheets. As a result, the deposit of $70.0 million was recorded as restricted cash on our condensed consolidated balance sheet. In addition, if our cash and cash equivalents balance at EWB falls below $100.0 million, we are then required to maintain specific minimum EBITDA amounts at all times thereafter.

The Second Amended Loan Agreement contains customary affirmative and negative covenants, including limitations on mergers, asset sales, liens, investments, and indebtedness. As of March 31, 2023, we were in compliance with the Second Amended Loan Agreement.

40

Cash flows
The following table summarizes our cash flows for the periods presented:
Three months ended March 31,
(in thousands)20232022
Net cash (used in) provided by:
Operating activities$(19,553)$(10,069)
Investing activities5,735 (4,375)
Financing activities48,995 1,022 
Net increase (decrease) in cash, cash equivalents and restricted cash$35,177 $(13,422)
Operating activities

Net cash used in operating activities of $19.6 million for the three months ended March 31, 2023 was attributable to a net loss of $23.4 million and a net cash outflow of $5.5 million from changes in our operating assets and liabilities. These were partially offset by non-cash adjustments of $9.3 million, mainly consisting of stock-based compensation, equity awards issued for bonuses and depreciation and amortization expense.

Net cash used in operating activities of $10.1 million for the three months ended March 31, 2022 was primarily due to a net loss of $21.4 million, partially offset by non-cash adjustments of $8.1 million, mainly consisting of stock-based compensation and depreciation expense and a net cash inflow from changes in our operating assets and liabilities of $3.2 million, primarily due to a decrease in our accounts receivable.

Investing activities

Net cash provided by investing activities of $5.7 million during the three months ended March 31, 2023 was primarily attributable to the net sale of $46.7 million of available-for-sale marketable securities during the quarter, partially offset by $40.3 million in cash paid for the IsoPlexis Merger (net of cash acquired in the acquisition).

Net cash used in investing activities was $4.4 million during the three months ended March 31, 2022 and was entirely attributable to the purchase of property, plant and equipment. Capital expenditures for the first quarter of 2022 included the expansion of our BioFoundry operations to support current and planned programs as well as leasehold improvements related to our offices in Boston, Massachusetts.
Financing activities
Net cash provided by financing activities was $49.0 million during the three months ended March 31, 2023 and was primarily related to $48.8 million in proceeds from the issuance of long-term debt, net of issuance costs as a result of refinancing our term loan with EWB.
Net cash provided by financing activities was $1.0 million during the three months ended March 31, 2022 and primarily related to proceeds received from the issuance of common stock upon the exercise of stock options as well as proceeds received related to the issuance of common stock under our employee stock purchase plan.
Concentration of credit risk
Most of our customers are located in the United States and Asia Pacific. For the three months ended March 31, 2023 and, three customers accounted for 39%, 10% and 10% of revenue. For the three months ended March 31, 2022, three customers accounted for 18%, 13%, and 10% of revenue.
41

As of March 31, 2023, three customers comprised 25%, 14% and 12% of accounts receivable. As of December 31, 2022, two customers accounted for 24% and 11% of accounts receivable.
Contractual obligations and commitments
The following table summarizes our commitments to settle contractual obligations as of March 31, 2023:
Payments due by period
(in thousands)TotalLess than
1 year		1 - 3 years3 -5 yearsMore than
5 years
Debt obligations, including interest (1)
$96,233 $4,545 $19,729 $71,959 $— 
Lease commitments (2)
34,561 4,691 12,249 10,157 7,464 
Purchase Obligations (3)
29,736 21,660 8,076 — — 
Total$160,530 $30,896 $40,054 $82,116 $7,464 
(1)As of March 31, 2023, the outstanding balance of our term loan under the EWB Loan Agreement was $70.0 million. Borrowings under the term loan mature on June 30, 2025 and accrue interest at a variable rate per annum equal to the Prime Rate plus one-half of one percent (0.5%).
(2)Represents commitments under our non-cancelable office and facility leases.
(3)Purchase obligations relate primarily to our contract manufacturer which manufactures our Optofluidic instruments and makes advance purchases of components based on our sales forecasts and the placement of property by us, as well as the commitments made to certain providers of components of our consumable manufacturing. To the extent components are purchased by the contract manufacturer on our behalf and cannot be used by the contract manufacturer’s other customers, we are obligated to purchase such components.
Off-balance sheet arrangements
We do not have, and did not have during the periods presented, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities, that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Critical accounting policies and estimates
We have prepared our condensed consolidated financial statements in accordance with United States generally accepted accounting principles. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled “Management’s Discussion and Analysis of Financial Condition and Operations” included in our Annual Report on Form 10-K, with the exception of the following critical accounting policies and estimates related to the IsoPlexis Merger.
Goodwill and Intangible Assets
Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one
42

year from the Acquisition Date. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in our stock price or market capitalization. During the three months ended March 31, 2023, we experienced a decline in our market capitalization as a result of a sustained decrease in our stock price. Although we only recently acquired goodwill, as we operate as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.

Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.

Impairment of Long-Lived Assets
Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.


43

Item 3.    Quantitative and Qualitative Disclosures about Market Risk.
Not applicable to a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act.
Item 4.    Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of our “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based on that evaluation, our principal executive officer and principal financial officer concluded that as of March 31, 2023 our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
On March 21, 2023, we completed the IsoPlexis Merger. This resulted in us implementing new processes and internal controls to assist us in the preparation and disclosure of financial information associated with the transaction. Given the magnitude of the IsoPlexis Merger and the complexity of the applicable systems and business processes, we have excluded IsoPlexis from our assessment and report on internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), during the most recently completed fiscal quarter.
Limitations on the Effectiveness of Controls
Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any system of controls must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
44

Part II. OTHER INFORMATION.
Item 1.    Legal Proceedings.
See Note 17 to our condensed consolidated financial statements for legal proceedings and related matters.
Item 1A. Risk Factors.
Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in our Annual Report on Form 10-K filed with the SEC on February 23, 2023. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer.

Our negative cash flows and current lack of financial resources raise substantial doubt as to our ability to continue as a going concern. If we are unable to raise additional funding to meet our operational needs, we may be forced to limit or cease our operations and/or liquidate our assets.

Although our unaudited consolidated interim financial statements have been prepared assuming our company will continue as a going concern, our negative cash flows and current lack of financial resources raise substantial doubt as to our ability to satisfy our obligations as they become due within one year from the date of filing of this Quarterly Report on Form 10-Q. For the three months ended March 31, 2023, we had a consolidated net loss of $23.4 million and had an accumulated deficit of $385.1 million as of March 31, 2023. Cash, cash equivalents and marketable securities were $51.6 million as of March 31, 2023. We expect to incur additional operating losses in the foreseeable future as we continue to invest in the research and development of our product offerings, commercialize and launch platforms, and expand into new markets. Although we intend to improve operating cash flow by increasing our revenue and lowering our operational costs, we may not succeed in driving revenue growth, including through new commercial leadership, geographic expansion or a refined product roadmap, or in lowering operating expenses, including through the cost synergies expected as a result of the IsoPlexis Merger by eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies. If at any time in the future we are unable to continue as a going concern, we may be forced to seek protection from our creditors through bankruptcy proceedings, discontinue operations, and liquidate our assets, and we may receive less than the value at which those assets are carried on our unaudited interim financial statements. Any of these outcomes could cause our stockholders to lose some or all of their investment.

Even if we are able to raise significant additional capital necessary to continue our operations over the next year, if we are unable to obtain additional adequate financing on terms satisfactory to us, or at all, when we require it, our ability to continue to pursue our business objectives, develop our technology and products, and respond to business opportunities, challenges, unforeseen circumstances or developments could be significantly limited, and our business, financial condition, results of operations and prospects could be materially and adversely affected.

The failure to successfully integrate the businesses and operations of Berkeley Lights and IsoPlexis in the expected time frame may adversely affect the combined company’s future results.

On March 21, 2023, we completed the IsoPlexis Merger, and the newly combined company was renamed PhenomeX. The future success of the IsoPlexis Merger, including its anticipated benefits, depends, in part, on our ability to optimize our combined operations, which is a complex, costly and time-consuming process. There can be no assurances that the businesses can be integrated successfully. It is possible that the integration process could
45

result in the loss of key employees, the loss of customers, the disruption of ongoing businesses, inconsistencies in standards, controls, procedures and policies, unexpected integration issues, higher than expected integration costs and an overall post-completion integration process that takes longer than originally anticipated. Specifically, the following issues, among others, must be addressed in integrating the operations of Berkeley Lights and IsoPlexis in order to realize the anticipated benefits of the merger so the combined company performs as expected:
•combining the companies’ operations and corporate functions;
•combining the companies’ businesses and meeting the capital requirements of the combined company, in a manner that permits the combined company to achieve any cost savings or other synergies anticipated to result from the merger, the failure of which would result in the anticipated benefits of the merger not being realized in the time frame currently anticipated or at all;
•integrating personnel from the two companies;
•integrating the companies’ technologies;
•integrating and unifying the offerings and services available to customers;
•identifying and eliminating redundant and underperforming functions and assets;
•harmonizing the companies’ operating practices, employee development and compensation programs, internal controls and other policies, procedures and processes;
•maintaining existing agreements with customers, suppliers, distributors and vendors and avoiding delays in entering into new agreements with prospective customers, suppliers, distributors and vendors;
•addressing possible differences in business backgrounds, corporate cultures and management philosophies;
•consolidating the companies’ administrative and information technology infrastructure;
•coordinating distribution and marketing efforts;
•managing the movement of certain positions to different locations;
•coordinating geographically dispersed organizations; and
•effecting actions that may be required in connection with obtaining regulatory approvals.

In addition, at times the attention of certain members of management and resources may be focused on the integration of the businesses of the two companies and diverted from day-to-day business operations or other opportunities that may have been beneficial to us, which may disrupt the business of the combined company.

If our goodwill or intangible assets become impaired, we may be required to record a significant charges against earnings.

We have recorded goodwill related to the closing of the IsoPlexis Merger, and a significant portion of the purchase price of any companies we acquire in the future may be allocated to acquired goodwill and other intangible assets. Under accounting principles generally accepted in the United States, we review our intangible assets for impairment when events or changes in circumstances indicate the carrying value of our goodwill and other intangible assets may not be recoverable. Goodwill is required to be tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in our stock price or market capitalization. If our acquisitions do not yield expected returns, our stock price declines or any other adverse change in market conditions occurs, a change to the estimation of fair value could result.
46

For example, during the three months ended March 31, 2023, we experienced a decline in our market capitalization as a result of a sustained decrease in our stock price. Although we only recently acquired goodwill, as we operate as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. While we ultimately did not record a goodwill impairment charge during the three months ended March 31, 2023, any further adverse changes in our business environment, stock price, market capitalization and future cash flow projections could result in additional impairment charges to our intangible assets or goodwill, particularly if such change impacts any of our critical assumptions or estimates, and may have a negative impact on our financial position and operating results.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Events or factors such as a severe or prolonged economic downturn, or additional global financial crises, whether related to the ongoing COVID-19 pandemic or not, or macroeconomic issues caused by events such as the Russia-Ukraine conflict, inflation, rising interest rates, availability of capital markets, concerns about the stability and liquidity of certain financial institutions, energy availability and costs or governmental initiatives to manage economic conditions, could result in a variety of risks to our business, including weakened demand for our platforms and our workflows, systems and instruments, or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption.

Adverse developments that affect financial institutions, transactional counterparties, or other third parties, or concerns or rumors about these events, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the U.S. Federal Deposit Insurance Corporation (“FDIC”) as receiver. Similarly, other institutions have been and may continue to be swept into receivership. Given that our balance in our deposit account with SVB does not exceed the FDIC-insured limit of $250,000, we have not yet experienced an adverse impact to our liquidity or to our business operations, financial condition, or results of operations as a result of these recent events. However, there is no guarantee that the federal government would guarantee all depositors as they did with SVB depositors in the event of further bank closures. Uncertainty may remain over liquidity concerns in the broader financial services industry, and there may be unpredictable impacts to our business and our industry.

We cannot predict changes in worldwide or regional economic conditions and government policies, as such conditions are highly volatile and beyond our control. If these conditions deteriorate for extended periods, however, our business, results of operations and financial condition could be materially adversely affected.

Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay employees, key vendors and others.

Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay employees, key vendors and others. For example, on March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, which resulted in all funds held at SVB being temporarily inaccessible by SVB’s customers. If other banks and financial institutions with whom we have banking relationships enter receivership or become insolvent in the future due to financial conditions affecting the banking system and financial markets, our ability to access our cash, cash equivalents and investments, including transferring funds, making payments or receiving funds, may be threatened and could have a material adverse
47

effect on our business and financial condition. In addition, in such circumstances we might not be able to timely pay employees, key vendors and others. We regularly maintain cash balances that are not insured or are in excess of the FDIC’s current insurance limit. For example, the Second Amended Loan Agreement with EWB requires us to maintain $70.0 million of cash in a deposit account with EWB that is assigned to EWB. Any delay in our ability to access our cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay employees, key vendors and others could have a material adverse effect on our operations.





48

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
Sale of Unregistered Securities
There were no unregistered sales of the Company's equity securities during the three months ended March 31, 2023.
Item 3.    Defaults Upon Senior Securities.
Not applicable.
Item 4.    Mine Safety Disclosures.
Not applicable.
Item 5.    Other Information.
None.
49

Item 6. Exhibits.
The following exhibits are filed with this Quarterly Report on Form 10-Q:
Incorporated by Reference
Exhibit NumberExhibit TitleFormFile No.ExhibitFiling DateFiled Herewith
8-K001-393883.13/21/2023
8-K001-393883.23/21/2023
8-K001-3938810.23/21/2023
8-K001-3938810.13/21/2023
X
X
X
X
101.INSXBRL Instance Document.X
101.SCHXBRL Taxonomy Extension Schema Document.X
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.X
101.LABXBRL Taxonomy Extension Label Linkbase Document.X
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.X
104Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101X
*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the
50

Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in such filings
51

Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.

PhenomeX Inc.



Date: May 15, 2023
By:  /s/ Mehul Joshi
Mehul Joshi
Chief Financial Officer
(Principal Financial Officer)


52
 EX-31.1 2 ex-311cellx20230331x10q.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Siddhartha Kadia, certify that:
(1)I have reviewed this Quarterly Report on Form 10-Q of PhenomeX Inc.,
(2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5)The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
May 15, 2023By:/s/ SIDDHARTHA KADIA
Name:Siddhartha Kadia, Ph.D.
Title:
Chief Executive Officer
                (Principal Executive Officer)

 EX-31.2 3 ex-312cellx20230331x10q.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mehul Joshi, certify that:
(1)I have reviewed this Quarterly Report on Form 10-Q of PhenomeX Inc.,
(2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4)The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5)The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
May 15, 2023By:/s/ MEHUL JOSHI
Name:Mehul Joshi
Title:Chief Financial Officer
(Principal Financial Officer)

 EX-32.1 4 ex-321cellx20230331x10q.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of PhenomeX Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2023By:/s/ SIDDHARTHA KADIA
Name:Siddhartha Kadia, Ph.D.
Title:
Chief Executive Officer
(Principal Executive Officer)


 EX-32.2 5 ex-322cellx20230331x10q.htm EX-32.2 Document

EXHIBIT 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of PhenomeX Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2023By:/s/ MEHUL JOSHI
Name:Mehul Joshi
Title:Chief Financial Officer
(Principal Financial Officer)

 EX-101.SCH 6 bli-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Revenue From Contracts With Customers link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Balance Sheet Accounts link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Equity and Stock Compensation Plans link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Net Loss Attributable to Common Stockholders Per Share link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - The Company and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Revenue From Contracts With Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Balance Sheet Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases (Table) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Equity and Stock Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Statements of Cash Flows (Tables) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Commitment and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Net Loss Attributable to Common Stockholders Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - The Company and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Summary of Significant Accounting Policies - Research and development state tax credits (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Business Combinations - Schedule of Acquired Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Business Combinations - Schedule of Pro forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Revenue from Contracts with Customer (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Revenue from Contracts with Customer (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Balance Sheet Accounts - Trade Accounts Receivable, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Balance Sheet Accounts - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Property and Equipment, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Leases - Maturity Schedule of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Leases - Maturity Schedule of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Equity and Stock Compensation Plans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Equity and Stock Compensation Plans - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Restructuring - Changes in Restructuring Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Commitment and Contingencies - Product Warranty (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bli-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bli-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bli-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Thereafter Lessee, Operating Lease Liability, Payments Due After Year Four Lessee, Operating Lease Liability, Payments Due After Year Four Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Schedule of cash and cash equivalents and restricted cash Schedule of Cash and Cash Equivalents [Table Text Block] Foreign currency translation and transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Provision for doubtful accounts Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Total payments due Long-Term Debt, Gross Customer Three Customer Three [Member] Customer Three Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment [Abstract] 2025 Long-Term Debt, Maturity, Year Two Business Combinations Business Combinations Policy [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Total property and equipment Property, Plant and Equipment, Gross Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Restructuring liability, beginning balance Restructuring liability, ending balance Restructuring Reserve Contract liability , revenue recognized Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Additional paid-in capital Additional Paid in Capital Measurement Basis [Domain] Fair Value Measurement [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation and amortization Depreciation Proceeds from issuance of debt Proceeds from Issuance of Debt Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Customer One Customer One [Member] Customer One Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Interest rate Debt Instrument, Interest Rate, Stated Percentage Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Share-Based Payment Arrangement [Abstract] Unrealized Losses Cash Equivalents, Unrealized Loss Cash Equivalents, Unrealized Loss Schedule of fair value of consideration transferred Schedule of Business Acquisitions, by Acquisition [Table Text Block] Common stock issued for IsoPlexis Merger (in shares) Stock Issued During Period, Shares, Acquisitions Other non-cash Other Noncash Income (Expense) PhenomeX Warrant PhenomeX Warrant [Member] PhenomeX Warrant Cash paid for income taxes Income Taxes Paid Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from the calculation of net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Trade accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Prepaid insurance Prepaid Insurance Equity Component [Domain] Equity Component [Domain] Scenario [Axis] Scenario [Axis] Total assets measured at fair value Assets, Fair Value Disclosure Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Leases Lessee, Operating Leases [Text Block] Unrealized Gains Cash Equivalents, Unrealized Gain Cash Equivalents, Unrealized Gain Stock-based compensation Share-Based Payment Arrangement, Plan Modification, Incremental Cost Price per share of the common stock acquired (in dollars per share) Business Acquisition, Share Price Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Right-of-use lease assets assumed in IsoPlexis Merger Right Of Use Asset Assumed Right Of Use Asset Assumed Lease liability - short-term [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Number of operating segments Number of Operating Segments Remainder of 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Perceptive Credit Agreement Perceptive Credit Agreement [Member] Perceptive Credit Agreement Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Fair value of IsoPlexis warrant at merger date Business Acquisition, Assumed Warrant Business Acquisition, Assumed Warrant Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Lease liability – short-term Less: current portion Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of unrealized gains and losses related to our available-for-sale marketable securities Debt Securities, Available-for-Sale [Table Text Block] 2026 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Severance and employee-related restructuring costs Restructuring and Related Cost, Expected Cost Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Long-term debt Notes payable, net of current portion Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Geographical [Axis] Geographical [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Contract asset Sales-Type Lease, Net Investment In Lease, Contract Asset Sales-Type Lease, Net Investment In Lease, Contract Asset Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Document Type Document Type Realized loss on marketable securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Interest-only period Debt Instrument, Interest-Only Period Debt Instrument, Interest-Only Period Settlement of pre-existing warranties Standard Product Warranty Accrual, Decrease for Payments Restructuring Type [Axis] Restructuring Type [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Principal repayment to retire debt Debt Instrument, Principal Repaid Debt Instrument, Principal Repaid Change in accounts payable and accrued liabilities related to purchases of property and equipment Noncash Increase (Decrease) In Accounts Payable And Accrued Liabilities Related to Purchase Of Fixed Assets Noncash Increase (Decrease) In Accounts Payable And Accrued Liabilities Related to Purchase Of Fixed Assets Fair value of accounts receivable acquired Business Combination, Acquired Receivable, Fair Value Long-Term Debt Debt Disclosure [Text Block] Cost of sales: Cost of Revenue [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Recurring Recurring [Member] Recurring Concentration Risk [Table] Concentration Risk [Table] 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Fair value of common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Financial Instrument [Axis] Financial Instrument [Axis] 2026 Long-Term Debt, Maturity, Year Three Accrued expenses and other current liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses And Other Current Liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses And Other Current Liabilities Schedule of receivables, contract assets and deferred revenue from contracts with customers Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Case management order, maximum number of patents allegedly infringed Loss Contingency, Case Management Order, Maximum Patents Allegedly Infringed, Number Loss Contingency, Case Management Order, Maximum Patents Allegedly Infringed, Number Accrued product warranty Product Warranty Accrual, Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Total assets Assets Write-offs of uncollectible accounts Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Earnings Per Share [Abstract] Accounts Receivables and Allowance for Credit Losses Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Purchase obligations Recorded Unconditional Purchase Obligation Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Fair value of assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Acquisition-related Costs Acquisition-related Costs [Member] Current portion of long-term debt Current portion, less loan discounts and financing costs Long-Term Debt, Current Maturities Intangible assets acuired Finite-Lived Intangible Assets Acquired Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Long-term debt, including current maturities Long-Term Debt, Fair Value Accounting Policies [Abstract] Interest cost Interest Expense, Debt Schedule of financial instruments not measured at fair value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Accrued payroll and employee related expenses Employee-related Liabilities, Current Line of Credit Line of Credit [Member] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Total Prepaid Expense and Other Assets, Current Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Non-cash interest and other expense related to debt and note receivable agreements Amortization of Debt Issuance Costs and Discounts Net Loss Attributable to Common Stockholders Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Customer return of Beacon transferred to property and equipment Transfer To Property And Equipment Transfer To Property And Equipment Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Award Type [Domain] Award Type [Domain] Warrant exercisable shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Loss on debt extinguishment Loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Schedule of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Non-cash settlements Restructuring Reserve, Settled without Cash Computer software and equipment Computer Equipment [Member] Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Case management order, maximum asserted patent claims per patent Loss Contingency, Case Management Order, Maximum Asserted Patent Claims Per Patent, Number Loss Contingency, Case Management Order, Maximum Asserted Patent Claims Per Patent, Number Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Subsequent Events Subsequent Events [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Lease income Sales-type Lease, Lease Income Customer Relationships Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Minimum Minimum [Member] Debt instrument, covenant description, cash Debt Instrument, Covenant Description, Cash Debt Instrument, Covenant Description, Cash Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Purchase shares of common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Business acquisition, options, number of shares acquired (in shares) Business Acquisition, Options, Number Of Shares Acquired Business Acquisition, Options, Number Of Shares Acquired Raw materials Inventory, Raw Materials, Net of Reserves Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Operating lease obligations Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Trading Symbol Trading Symbol Entity File Number Entity File Number Incurred transaction costs Business Acquisition, Transaction Costs Trade accounts payable Accounts Payable, Trade, Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Deferred revenue, net of current portion Deferred revenue (non-current) Contract with Customer, Liability, Noncurrent Property and equipment transferred to inventory Property And Equipment Transferred To Inventory Property And Equipment Transferred To Inventory Employee severance and termination benefits Employee Severance And Termination [Member] Employee Severance And Termination Research and development Research and Development Expense RSAs Restricted stock units Restricted Stock Units (RSUs) [Member] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Evorion Biotechnologies Evorion Biotechnologies [Member] Evorion Biotechnologies Product warranty, term Product Warranty, Duration Product Warranty, Duration Total cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Business Combinations Business Combination Disclosure [Text Block] Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Prime Rate Prime Rate [Member] Concentration risk percentage Concentration Risk, Percentage Subsequent Events [Abstract] Net loss Business Acquisition, Pro Forma Net Income (Loss) Commitment fee Debt Instrument, Fee Amount Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Amortization expense Amortization of Intangible Assets Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Warrant exercise price per share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Net loss attributable to common stockholders per share, basic (in dollars per share) Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Fair value of vested IsoPlexis options attributable to pre-merger service Adjustments To Additional Paid In Capital, Fair Value Of Options Vested In Business Combination Adjustments To Additional Paid In Capital, Fair Value Of Options Vested In Business Combination Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Step up form book value of inventory acquired Business Combination, Acquired Inventory, Adjustment From Book Value Business Combination, Acquired Inventory, Adjustment From Book Value Schedule of cash and cash equivalents and restricted cash Restrictions on Cash and Cash Equivalents [Table Text Block] Inventory Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Patents and Technology Patents and Technology [Member] Patents and Technology Amortized Cost Cash Equivalents, Amortized Cost Cash Equivalents, Amortized Cost R&D tax credits receivable Tax Credit Carryforward, Amount Vesting [Domain] Vesting [Domain] Entity Interactive Data Current Entity Interactive Data Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization RSUs issued for 2022 Bonuses (in shares) Issuance Of Shares For Employee Bonus, Shares Issuance Of Shares For Employee Bonus, Shares Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2028 Long-Term Debt, Maturity, Year Five Money market funds Money market funds Money Market Funds [Member] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accumulated Deficit Retained Earnings [Member] Changes in operating assets and liabilities: Increase (Decrease) In Operating Assets And Liabilities [Abstract] Increase (Decrease) In Operating Assets And Liabilities Common Stock Common Stock [Member] Schedule of stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of supplemental cash flow information related to operating leases Lease, Cost [Table Text Block] Non labor restructuring Non-Labor Restructuring Costs [Member] Non-Labor Restructuring Costs Statement [Table] Statement [Table] Cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Issuance of vested RSUs with grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Common stock issued for IsoPlexis Merger Stock Issued During Period, Value, Acquisitions Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Document Quarterly Report Document Quarterly Report Numerator Earnings Per Share, Numerator [Abstract] Earnings Per Share, Numerator Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Letter of Credit Letter of Credit [Member] Furniture, fixtures and other Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Lease liability, long-term Total long-term operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Leasehold improvements Leasehold Improvements [Member] Contract assets, long-term, which are included in “Other assets” Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Summary of revenue by geographic areas Revenue from External Customers by Geographic Areas [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Cash equivalents Fair Value Cash Equivalents, at Carrying Value Trade accounts receivable, net Trade accounts receivable, net Trade accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Allowance assumed in IsoPlexis Merger Accounts Receivable, Allowance For Credit Loss, Increase For Business Combination Accounts Receivable, Allowance For Credit Loss, Increase For Business Combination Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Schedule of pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Schedule of estimated annual amortization of intangible assets Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Non-cash consideration for the acquisition of IsoPlexis Noncash Consideration For Acquisition Noncash Consideration For Acquisition Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Variable Rate [Domain] Variable Rate [Domain] Deferred costs Deferred Costs, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Intangible assets, gross Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Debt instrument, covenant description, minimum cash and cash equivalents balance with bank Debt Instrument, Covenant Description, Minimum Cash And Cash Equivalents Balance With Bank Debt Instrument, Covenant Description, Minimum Cash And Cash Equivalents Balance With Bank Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product Product [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] 2025 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two Exercise price per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Rent expense Operating Lease, Expense Operating lease right-of-use assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right of Use Assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right of Use Assets Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report IsoPlexis Warrant IsoPlexis Warrant [Member] IsoPlexis Warrant Local Phone Number Local Phone Number Restructuring liability assumed in IsoPlexis Merger Restructuring Reverse, Assumed From Business Combination Restructuring Reverse, Assumed From Business Combination Patented technology Patented Technology [Member] Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Prepaid expenses, other current assets and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Goodwill Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Balance, beginning of period Balance, end of period Standard Product Warranty Accrual Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Schedule of product warranty liability Schedule of Product Warranty Liability [Table Text Block] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Net loss per share Earnings Per Share, Basic [Abstract] Restricted cash Restricted Cash, Noncurrent Total cost of sales Cost of Goods and Services Sold Weighted-average shares used in calculating net loss per share, diluted (in shares) Weighted-average shares used to compute net income per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Significant Risks and Uncertainties Including Business and Credit Concentrations Concentration Risk Disclosure [Text Block] Schedule of inventory Schedule of Inventory, Current [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accounts Receivable Accounts Receivable [Member] Adjustments to existing warranties Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding 98,744,915 and 72,169,052 shares at March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Carrying Value Reported Value Measurement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Organization, Consolidation and Presentation of Financial Statement [Line Items] Organization, Consolidation and Presentation of Financial Statement [Line Items] Organization, Consolidation and Presentation of Financial Statement AbCellera and UBC AbCellera And UBC [Member] AbCellera And UBC Asia Pacific Asia Pacific [Member] Service and other revenue Service and other Service And Other [Member] Service And Other Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net loss attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Short-term marketable securities Total debt securities, available for sale Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Common stock issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Deferred revenue Deferred revenue (current) Contract with Customer, Liability, Current Income Statement Location [Domain] Income Statement Location [Domain] Recognized transaction costs Business Combination, Acquisition Related Costs Amendment Flag Amendment Flag Remaining Useful Life (Years) Finite-Lived Intangible Asset, Useful Life Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair value of IsoPlexis warrant at Acquisition Date Adjustments To Additional Paid In Capital, Fair Value Of Warrants Assumed In Business Combination Adjustments To Additional Paid In Capital, Fair Value Of Warrants Assumed In Business Combination Litigation Case [Axis] Litigation Case [Axis] Goodwill with a provisional assigned value Goodwill, Acquired During Period Warrants Warrants [Policy Text Block] Warrants Total revenue Business Acquisition, Pro Forma Revenue Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Asset acquisition Payments to Acquire Assets, Investing Activities Construction in process Construction in Progress [Member] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Loss on disposal and impairment of property and equipment Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status EWB Term Loan EWB Term Loan [Member] EWB Loan Goodwill and Intangible Assets Disclosure [Abstract] Other assets Other Assets, Noncurrent Remainder of 2023 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year Revenue Stream [Domain] Revenue Stream [Domain] Revenue Stream Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Cash payments Payments for Restructuring IsoPlexis IsoPlexis [Member] IsoPlexis Total amounts due from customers Sales-type and Direct Financing Leases, Lease Receivable Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Allowance for credit losses Business Combination, Acquired Receivables, Estimated Uncollectible Provision for new warranties Standard Product Warranty Accrual, Increase for Warranties Issued Employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of fair value of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Interest payments, loan discounts and financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Statements of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Repayment of term loan Repayments of Long-Term Debt Stock options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Other income (expense), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Restructuring Restructuring and Related Activities Disclosure [Text Block] Common stock authorized (in shares) Common Stock, Shares Authorized Statement of Comprehensive Income [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Schedule of disaggregation of revenue Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Less: tenant improvement allowances receivable Lessee, Operating Lease, Tenant Improvement Allowance Lessee, Operating Lease, Tenant Improvement Allowance Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Revenue Stream [Axis] Revenue Stream [Axis] Revenue Stream Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash, cash equivalents and restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Revenue: Revenues [Abstract] Intangible assets, net Finite-Lived Intangible Assets, Net Restricted cash Restricted Cash Remaining performance obligation, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Schedule of financial assets measured at fair value Fair Value, Assets Measured on Recurring Basis [Table Text Block] Purchase of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current [Member] Accounts Receivable, after Allowance for Credit Loss, Current Schedule of sales-type lease maturity Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block] Vendor deposits Deposits Assets, Current Organization, Consolidation and Presentation of Financial Statement [Table] Organization, Consolidation and Presentation of Financial Statement [Table] Organization, Consolidation and Presentation of Financial Statement [Table] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Schedule of cash flow, supplemental disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Sub-lease income Sublease Income Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Customer Two Customer Two [Member] Customer Two Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Trade accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security The Company and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Variable lease payments Variable Lease, Payment Total undiscounted cash flows Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Payment of debt issuance costs Payments of Debt Issuance Costs Present value of operating lease payments Operating Lease, Liability U.S. agency securities U.S. agency securities US Government Agencies Debt Securities [Member] Segments Segment Reporting Disclosure [Text Block] Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Schedule of additional information related to operating leases Lease Term And Discount Rate Information [Table Text Block] Lease Term And Discount Rate Information Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Fair Value Estimate of Fair Value Measurement [Member] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Recurring and Nonrecurring [Table] Remainder of 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Interest-only period with extension Debt Instrument, Interest-Only Period With Extension Debt Instrument, Interest-Only Period With Extension Inventory Total Inventory, Net Restructuring Restructuring charges Restructuring Charges Consideration Transferred Business Combination, Consideration Transferred [Abstract] 2027 Long-Term Debt, Maturity, Year Four Warrants to purchase common stock Warrant [Member] Entity Filer Category Entity Filer Category Prepayment penalty percentage Prepayment Penalty Percentage Prepayment Penalty Percentage Weighted-average shares used in calculating net loss per share, basic (in shares) Weighted-average shares used to compute net income per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Business acquisition, equity instruments other than options, number of shares acquired (in shares) Business Acquisition, Equity Instruments Other Than Options, Number Of Shares Acquired Business Acquisition, Equity Instruments Other Than Options, Number Of Shares Acquired Operating loss Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Loss contingency accrual Loss Contingency Accrual Total purchase price Asset Acquisition, Consideration Transferred Total stock-based compensation Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 17) Commitments and Contingencies Security Exchange Name Security Exchange Name Equipment, tooling and molds Equipment, Tooling And Molds [Member] Equipment, Tooling And Molds Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Weighted average useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Restricted stock awards Restricted Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Total revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Fair value of PhenomeX common stock issued to IsoPlexis stockholders Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Restructuring and Related Activities [Abstract] Equity and Stock Compensation Plans Share-Based Payment Arrangement [Text Block] Allowance for doubtful accounts Allowance for doubtful accounts, beginning of year Allowance for doubtful accounts, end of period Accounts Receivable, Allowance for Credit Loss Work in progress Inventory, Work in Process, Net of Reserves Revenue From Contracts With Customers Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] U.S. government securities U.S. government securities US Government Debt Securities [Member] Forecast Forecast [Member] Total liabilities and stockholders’ equity Liabilities and Equity Note payable, term (in years) Debt Instrument, Term Proceeds from issuance of common stock under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Number of company invested Number Of Company Invested Number Of Company Invested Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Cash Cash Denominator Earnings Per Share, Diluted [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Goodwill, expected tax deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Current Fiscal Year End Date Current Fiscal Year End Date RSUs issued for 2022 Bonuses Issuance Of Shares For Employee Bonus Issuance Of Shares For Employee Bonus Less: implied interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net loss attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Vesting [Axis] Vesting [Axis] Assets held for sale Disposal Group, Including Discontinued Operation, Assets Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net loss attributable to common stockholders per share, diluted (in dollars per share) Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Less: unearned income Sales-type Lease, Interest Income Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Trade Names and Trademarks Trademarks and Trade Names [Member] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Shares holding ratio Conversion ratio Business Combination, Shares Holding Ratio Business Combination, Shares Holding Ratio Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Other Other Assets, Current Schedule of trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Customer Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Schedule of changes in the allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Other income (expense): Nonoperating Income (Expense) [Abstract] Revenue Revenue from Contract with Customer Benchmark [Member] Schedule of operating lease liabilities maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Increase in borrowing capacity Line Of Credit Facility, Increase In Borrowing Capacity Line Of Credit Facility, Increase In Borrowing Capacity Entity Address, Address Line One Entity Address, Address Line One Contract liabilities Contract with Customer, Liability Product and Service [Axis] Product and Service [Axis] Fair value of vested IsoPlexis options attributable to pre-merger service Business Combination, Share-Based Payment Arrangement, Options Vested, Fair Value Business Combination, Share-Based Payment Arrangement, Options Vested, Fair Value Europe Europe [Member] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Fair Value Disclosures [Abstract] Interest expense Interest Expense Trade names Trade Names [Member] Debt Securities, Available-for-Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Credit Facility [Axis] Credit Facility [Axis] Unrealized gain on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] U.S. agency securities US Government Corporations and Agencies Securities [Member] Impairment charge Sales-Type Lease, Net Investment In Lease, Impairment Sales-Type Lease, Net Investment In Lease, Impairment Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Inventory valuation reserves Inventory Valuation Reserves Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] 2024 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One Schedule of payments due on notes payable Schedule of Long-Term Debt Instruments [Table Text Block] Interest income Interest Income, Deposits with Financial Institutions Subsequent Event [Table] Subsequent Event [Table] Entity Tax Identification Number Entity Tax Identification Number Platform Platform [Member] Platform Revenue from Contract with Customer [Abstract] Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Contract assets, which are included in “Prepaid expenses and other current assets” Contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Current Interest rate Debt Instrument, Interest Rate During Period Net increase (decrease) in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Changes in Restructuring Liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Commercial paper Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Year Ending December 31: Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and development state tax credits Research and Development Expense, Policy [Policy Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Total purchase consideration Business Combination, Consideration Transferred Warranty accrual assumed in IsoPlexis Merger Standard Product Warranty Accrual, Additions from Business Acquisition Other Other Accrued Liabilities, Current City Area Code City Area Code Accrued legal expenses Accrued Professional Fees, Current Assets Assets [Abstract] Repayment of acquired debt Business Combination, Repayment Of Acquired Debt, Including Accrued Interest And Prepayment Penalties Business Combination, Repayment Of Acquired Debt, Including Accrued Interest And Prepayment Penalties Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Notes Payable Notes Payable to Banks [Member] Partnership, License and Other (1) Partnership, License and Other Partnership, License And Other [Member] Partnership, License And Other Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Accrued expenses and other current liabilities Total Accrued Liabilities And Other Liabilities, Current Accrued Liabilities And Other Liabilities, Current Schedule of prepaid expenses and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] 2024 Long-Term Debt, Maturity, Year One Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] North America North America [Member] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of basic and diluted net loss per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets obtained for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of sales Cost of Sales [Member] Total full-time employees (in percent) Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Customer [Domain] Customer [Domain] EX-101.PRE 10 bli-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 bli-20230331_g1.jpg begin 644 bli-20230331_g1.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
Apr. 30, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-39388  
Entity Registrant Name PhenomeX Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 35-2415390  
Entity Address, Address Line One 5858 Horton Street, Suite 320  
Entity Address, City or Town Emeryville  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94608  
City Area Code 510  
Local Phone Number 858-2855  
Title of 12(b) Security Common stock, $0.00005 par value  
Trading Symbol CELL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   98,795,621
Entity Central Index Key 0001689657  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 51,606 $ 86,522
Short-term marketable securities 0 46,252
Trade accounts receivable, net 25,119 18,534
Inventory 45,539 18,861
Prepaid expenses and other current assets 9,378 6,783
Total current assets 131,642 176,952
Restricted cash 70,093 0
Property and equipment, net 33,842 23,847
Operating lease right-of-use assets 27,449 23,326
Goodwill 12,246 0
Intangible assets, net 23,072 0
Other assets 2,217 1,969
Total assets 300,561 226,094
Current liabilities:    
Trade accounts payable 17,051 10,092
Accrued expenses and other current liabilities 19,645 21,340
Current portion of long-term debt 0 4,966
Deferred revenue 10,746 9,092
Total current liabilities 47,442 45,490
Long-term debt 68,886 14,860
Deferred revenue, net of current portion 1,259 963
Lease liability, long-term 25,234 22,726
Total liabilities 142,821 84,039
Commitments and contingencies (Note 17)
Stockholders’ equity:    
Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding 98,744,915 and 72,169,052 shares at March 31, 2023 and December 31, 2022, respectively 5 4
Additional paid-in capital 542,805 503,708
Accumulated deficit (385,067) (361,648)
Accumulated other comprehensive loss (3) (9)
Total stockholders’ equity 157,740 142,055
Total liabilities and stockholders’ equity $ 300,561 $ 226,094
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.00005 $ 0.00005
Common stock authorized (in shares) 300,000,000 300,000,000
Common stock issued (in shares) 98,744,915 72,169,052
Common stock outstanding (in shares) 98,744,915 72,169,052
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Total revenue $ 18,516 $ 20,206
Cost of sales:    
Total cost of sales 5,088 6,379
Gross profit 13,428 13,827
Operating expenses:    
Research and development 8,421 17,573
Selling, general and administrative 26,547 17,527
Restructuring 1,290 0
Total operating expenses 36,258 35,100
Loss from operations (22,830) (21,273)
Other income (expense):    
Interest expense (384) (224)
Interest income 827 34
Other income (expense), net (1,012) 57
Loss before income taxes (23,399) (21,406)
Provision for income taxes 20 20
Net loss $ (23,419) $ (21,426)
Net loss attributable to common stockholders per share, basic (in dollars per share) $ (0.31) $ (0.32)
Net loss attributable to common stockholders per share, diluted (in dollars per share) $ (0.31) $ (0.32)
Weighted-average shares used in calculating net loss per share, basic (in shares) 75,759,771 67,697,488
Weighted-average shares used in calculating net loss per share, diluted (in shares) 75,759,771 67,697,488
Product    
Revenue:    
Total revenue $ 8,378 $ 9,774
Cost of sales:    
Total cost of sales 3,912 2,695
Service and other revenue    
Revenue:    
Total revenue 10,138 10,432
Cost of sales:    
Total cost of sales $ 1,176 $ 3,684
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net loss $ (23,419) $ (21,426)
Other comprehensive loss:    
Foreign currency translation adjustments (3) 0
Unrealized gain on marketable securities, net of tax 9 0
Other comprehensive income: 6 0
Comprehensive loss $ (23,413) $ (21,426)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   67,595,535      
Beginning balance at Dec. 31, 2021 $ 208,216 $ 4 $ 471,820 $ (263,608) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   81,654      
Exercise of stock options 412   412    
Vesting of restricted stock units (in shares)   27,580      
Employee stock purchase plan (in shares)   115,346      
Employee stock purchase plan 610   610    
RSUs issued for 2022 Bonuses 0        
Stock-based compensation 5,389   5,389    
Foreign currency translation adjustments 0        
Net loss (21,426)     (21,426)  
Ending balance (in shares) at Mar. 31, 2022   67,820,115      
Ending balance at Mar. 31, 2022 193,201 $ 4 478,231 (285,034) 0
Beginning balance (in shares) at Dec. 31, 2022   72,169,052      
Beginning balance at Dec. 31, 2022 142,055 $ 4 503,708 (361,648) (9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued for IsoPlexis Merger (in shares)   24,945,611      
Common stock issued for IsoPlexis Merger 31,930 $ 1 31,929    
Fair value of vested IsoPlexis options attributable to pre-merger service 306   306    
Fair value of IsoPlexis warrant at Acquisition Date 170   170    
Exercise of stock options (in shares)   78,359      
Exercise of stock options 29   29    
Vesting of restricted stock units (in shares)   285,129      
Employee stock purchase plan (in shares)   121,863      
Employee stock purchase plan 166   166    
RSUs issued for 2022 Bonuses (in shares) [1]   1,144,901      
RSUs issued for 2022 Bonuses [1] 2,107   2,107    
Stock-based compensation 4,390   4,390    
Unrealized gain (loss) on marketable securities 9       9
Foreign currency translation adjustments (3)       (3)
Net loss (23,419)     (23,419)  
Ending balance (in shares) at Mar. 31, 2023   98,744,915      
Ending balance at Mar. 31, 2023 $ 157,740 $ 5 $ 542,805 $ (385,067) $ (3)
[1] Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (23,419) $ (21,426)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 2,100 1,944
Stock-based compensation 4,388 5,393
RSUs issued for 2022 Bonuses 2,107 [1] 0
Amortization of operating lease right-of-use assets 852 735
Non-cash interest and other expense related to debt and note receivable agreements 16 16
Provision for doubtful accounts 173 0
Loss on debt extinguishment 162 0
Loss on disposal and impairment of property and equipment 151 28
Realized loss on marketable securities 6 0
Other non-cash (638) 0
Changes in operating assets and liabilities:    
Trade accounts receivable (3,684) 8,221
Inventory 964 (1,122)
Prepaid expenses, other current assets and other assets 1,865 2,057
Trade accounts payable 5,373 298
Deferred revenue 551 (2,935)
Accrued expenses and other current liabilities (9,660) (2,552)
Operating lease liabilities (860) (726)
Net cash used in operating activities (19,553) (10,069)
Cash flows from investing activities:    
Purchase of property and equipment (414) (4,375)
Purchase of marketable securities (2,451) 0
Proceeds from sales of marketable securities 36,749 0
Proceeds from maturities of marketable securities 12,400 0
Asset acquisition (264) 0
Acquisitions, net of cash acquired (40,285) 0
Net cash provided by (used in) investing activities 5,735 (4,375)
Cash flows from financing activities:    
Repayment of term loan (20,000) 0
Proceeds from issuance of debt 70,000 0
Payment of debt issuance costs (1,200) 0
Proceeds from issuance of common stock upon exercise of stock options 29 412
Proceeds from issuance of common stock under employee stock purchase plan 166 610
Net cash provided by financing activities 48,995 1,022
Net increase (decrease) in cash and cash equivalents and restricted cash 35,177 (13,422)
Cash, cash equivalents and restricted cash at beginning of period 86,522 178,366
Cash, cash equivalents and restricted cash at end of period $ 121,699 $ 164,944
[1] Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)
Mar. 03, 2023
$ / shares
Statement of Stockholders' Equity [Abstract]  
Issuance of vested RSUs with grant date fair value (in dollars per share) $ 1.84
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
The Company and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Basis of Presentation The Company and Basis of Presentation
Description of Business
PhenomeX Inc. (the “Company” or “PhenomeX”) is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
PhenomeX and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California.

Basis of Presentation
On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights.
The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates.

Liquidity
The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2023, the Company had a consolidated net loss of $23.4 million and as of March 31, 2023 had an accumulated deficit of $385.1 million. Cash, cash equivalents and marketable securities were $51.6 million as of March 31, 2023.
On March 21, 2023, the Company acquired IsoPlexis which also had experienced losses since its inception, and entered into the second amended and restated credit agreement with East West Bank (“EWB”), which increased the Company’s term loan with EWB from $20.0 million to $70.0 million, of which $52.5 million (including prepayment premium and interest) was used to repay indebtedness of IsoPlexis. The second amended and restated credit agreement with EWB requires the Company to maintain $70.0 million of cash in a deposit account with EWB that is assigned to EWB. This deposit is recorded as restricted cash on the Company’s condensed consolidated balance sheet. See Note 12 for additional information on our second amended and restated credit agreement with EWB including the covenants contained therein.
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustment that might result if the Company is unable to continue as a going concern.
Management’s intent is to implement plans that will allow the Company to continue as a going concern. The Company intends to improve operating cash flow by increasing its revenue and lowering its operational costs. New commercial leadership, geographic expansion, and a refined product roadmap are expected to drive revenue growth, and significant cost synergies as a result of the IsoPlexis Merger and are expected to lower operating expenses. Cost synergies are expected to be accomplished by eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies. In addition, the Company is evaluating financing options including the potential to raise equity and debt financing. While management is focused on these efforts, there can be no assurance that the Company will be successful in doing so.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Significant Accounting Policies
The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission.
Updates to those policies are below, including updates related to the IsoPlexis Merger.

Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer.
The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands):
March 31, 2023December 31, 2022
Cash
$45,015 $63,596 
Cash equivalents
6,591 22,926 
Restricted cash70,093 — 
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows
$121,699 $86,522 

Accounts Receivables and Allowance for Credit Losses
Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.
Inventory
Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.

Stock-based compensation
The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors.
Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant.
The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.
The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.
Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.
For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.
The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.

Business Combinations
We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed
within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.

Goodwill and Intangible Assets
Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.

Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.

Impairment of Long-Lived Assets
Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.

Foreign currency translation and transactions
The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net.
For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.

Research and development state tax credits
Research and development (“R&D”) tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits a qualified small business engaged in R&D activities within Connecticut to exchange its unused R&D tax credits for a cash amount equal to 65% of the value of exchanged credits, are
recorded as a receivable and other income in the year the R&D tax credits relate to, as it is reasonably assured that the R&D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets. The Company has recorded $0.2 million of R&D tax credits receivable as of March 31, 2023.

Warrants
On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, Distinguishing Liabilities from Equity.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
Short-Term Marketable Securities

The Company may invest in available-for-sale marketable debt securities generally consisting of commercial paper and U.S. government securities with contractual maturities due within one year.

The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands):

Marketable Securities reported as Cash Equivalents

March 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$6,591 $— $— $6,591 
   Total$6,591 $— $— $6,591 


December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$2,354 $— $— $2,354 
Commercial paper16,606 — (4)16,602 
U.S. agency securities3,969 1 — 3,970 
U.S. government securities— — — — 
   Total$22,929 $1 $(4)$22,926 
Marketable Securities reported as Short-term Marketable Securities

As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial.

Short-term marketable securities at December 31, 2022 were as follows (in thousands):

December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Commercial paper$22,158 $1 $(11)$22,148 
U.S. agency securities4,941 1 — 4,942 
U.S. government securities19,159 5 (2)19,162 
   Total$46,258 $7 $(13)$46,252 

At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of December 31, 2022.

See Note 9 for information about the fair value of the Company’s short-term marketable securities.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Risks and Uncertainties Including Business and Credit Concentrations
 3 Months Ended
Mar. 31, 2023
Risks and Uncertainties [Abstract]  
Significant Risks and Uncertainties Including Business and Credit Concentrations Significant Risks and Uncertainties Including Business and Credit Concentrations
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in financial institutions may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any material realized losses on its deposits of cash, cash equivalents and marketable securities.

The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At March 31, 2023, the Company recorded an allowance for doubtful accounts of $0.9 million. At December 31, 2022 , the Company had not recorded any material allowance for doubtful accounts.

For the three months ended March 31, 2023, three customers accounted for 39%, 10% and 10% of revenue. For the three months ended March 31, 2022, three customers accounted for 18%, 13% and 10% of revenue.
As of March 31, 2023, three customers comprised 25%, 14% and 12% of accounts receivable. As of December 31, 2022, two customers accounted for 24% and 11% of accounts receivable.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
IsoPlexis Merger
On March 21, 2023, the Company completed the IsoPlexis Merger. Under the terms of the Merger Agreement, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which was automatically converted into shares of PhenomeX common stock).
Consideration Transferred
The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands):
Fair value of PhenomeX common stock issued to IsoPlexis stockholders (1)
$31,930 
Repayment of IsoPlexis debt (2)
52,482 
Fair value of vested IsoPlexis options attributable to pre-merger service (3)
306 
Fair value of IsoPlexis warrant at Acquisition Date (4)
170 
   Total purchase consideration$84,888 
(1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.
(2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest.
(3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information).
(4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).

Fair Value of Assets Acquired and Liabilities Assumed
The Company accounted for the IsoPlexis Merger as a business combination. The identifiable assets acquired and liabilities assumed were recorded at their preliminary fair values as of the Acquisition Date and are consolidated into our financial statements. The assignment of fair market value requires significant judgments regarding the estimates and assumptions used to value the acquired assets and liabilities assumed. For the preliminary fair values of the assets acquired and liabilities assumed, we utilized the cost, income and market approaches from the perspective of a market participant.
The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed.
Cash and cash equivalents$12,197 
Accounts receivable3,075 
Inventories27,287 
Prepaid expenses and other current assets4,190 
Property and equipment, net11,206 
Intangible assets22,900 
Goodwill12,246 
Operating lease right-of-use assets4,975 
Other assets526 
    Total assets acquired98,602 
Accounts payable2,367 
Accrued expenses and other current liabilities4,912 
Deferred revenue1,399 
Operating lease obligations5,036 
     Total liabilities assumed13,714 
Total consideration transferred$84,888 
Acquired Receivables
The fair value of assets acquired includes accounts receivable of $3.1 million, which is net of an associated allowance for credit losses of $0.7 million.
Inventory
The fair value of inventory acquired was $27.3 million, which included a step up of $4.9 million from the book value as a result of the valuation at the Acquisition Date. The original cost basis of the inventory acquired from IsoPlexis was $22.4 million, which was net of a reserve for excess and obsolete inventory of $15.4 million.
Intangible Assets and Goodwill
Intangible assets includes $11.7 million of patented technology, $7.7 million of customer relationships and $3.5 million of IsoPlexis trade names and trademarks. The intangible assets will be amortized over their respective useful lives which range from eight to fourteen years. Goodwill with a provisional assigned value of $12.2 million represents the excess of the consideration transferred over the estimated fair values of assets and liabilities assumed. None of the goodwill resulting from the IsoPlexis Merger is deductible for tax purposes.
Transaction Costs
The Company recognized transaction costs associated with the IsoPlexis Merger of $3.5 million for the three months ended March 31, 2023 plus $2.8 million which was recognized in the fourth quarter of 2022. These costs are primarily related to professional services and are recorded in “Selling, general, and administrative” expenses in the Company’s condensed consolidated statement of operations.
Supplemental Pro Forma Information
The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition.
(in thousands)Three months ended March 31, 2023Three months ended March 31, 2022
Total revenue$20,170 $25,117 
Net loss$(66,463)$(50,419)
Pro forma adjustments consisted of:
•Amortization/Depreciation- Tangible and intangible assets are assumed to be recorded at their assigned fair values as of January 1, 2022. Historical depreciation and amortization for IsoPlexis has been removed and the new fair values of the assets are depreciated or amortized over their estimated useful lives.
•Interest Expense- Entry into the Second Amended Term Loan and repayment of the Perceptive Credit Agreement are assumed to have occurred on January 1, 2022. Historical interest expense has been removed and replaced with the applicable interest rate as of March 21, 2023 associated with the Second Amended Term Loan, which was 8.5%.
•Transaction costs- Both entities incurred transaction costs, which totaled $13.7 million. Of the $13.7 million, approximately $4.4 million was incurred in the first quarter of 2023 and has been eliminated as it is not recurring.
•Accounting policies adjustment- IsoPlexis historically classified certain operations, quality and facility related costs in selling, general and administrative expenses. To align with PhenomeX accounting policies, these costs were reclassified to costs of goods sold or research and development. However, since this is a reclassification between expense line items on the statement of operations, the adjustment does not have an impact on revenue or net loss for purposes of the pro forma financial information disclosed above.
For the period subsequent to the Acquisition Date, IsoPlexis contributed total revenues and operating loss of $1.0 million and $1.1 million, respectively, for the three months ended March 31, 2023, that were included in the Company’s Condensed Consolidated Statements of Operations. In addition, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (See Note 6 for additional information).
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue From Contracts With Customers
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue From Contracts With Customers Revenue From Contracts With Customers
The Company’s revenue consists of both product revenue and service and other revenue, which is primarily generated through the following revenue streams: (i) platform, (ii) recurring and (iii) partnership, license and other.
The Company in the first quarter entered into a license arrangement whereby certain patents were licensed to a third party and for which the customer agreed to pay a non-refundable fee. For licenses of intellectual property the Company recognizes revenue from non-refundable fees when the license is transferred to the customer and the customer is able to use and benefit from the license.

The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations:
Income Statement Classification
Product or Service sold
Revenue Stream
Product revenue
Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)
Platform
Software and workflow licenses
Platform
Fixed term sales-type lease arrangements with qualified customers
Platform
Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)
Recurring
Consumables and reagent kits (e.g. OptoSelect chips)
Recurring
Service and other revenue
Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types
Partnership, License and Other
Application support, installation and training
Platform
Fixed fee extended warranty and service programs
Recurring
IP license revenue
Partnership, License and Other (1)
(1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue.
The following tables provide information by revenue stream for the periods presented:

Three Months Ended March 31, 2023
(in thousands)ProductService and otherTotal
Platform$5,773 $330 $6,103 
Recurring2,605 2,558 5,163 
Partnership, License and Other (1)
— 7,250 7,250 
   Total revenue$8,378 $10,138 $18,516 
(1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter.
Three Months Ended March 31, 2022
(in thousands)ProductService and otherTotal
Platform$6,747 $657 $7,404 
Recurring3,027 2,416 5,443 
Partnership, License and Other— 7,359 7,359 
   Total revenue$9,774 $10,432 $20,206 

Revenues by geographical markets are presented in Note 19.
Performance Obligations
A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.

As of March 31, 2023, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year was $12.0 million, which, to the extent invoiced, is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 50% is expected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards.
Contract Balances
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable, net$25,119 $18,534 
Contract assets, which are included in “Prepaid expenses and other current assets”$367 $1,283 
Contract assets, long-term, which are included in “Other assets”$514 $549 
Deferred revenue (current)$10,746 $9,092 
Deferred revenue (non-current)$1,259 $963 

The contract liabilities of $12.0 million and $10.1 million as of March 31, 2023 and December 31, 2022, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2023 included $2.8 million of previously deferred revenue that was included in contract liabilities as of December 31, 2022.
Sales-type Lease Arrangements
The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three months ended March 31, 2023 and 2022.

The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands):
Year ending December 31,Sales-Type
Leases
Remainder of 2023(1)
$334 
2024445 
2025408 
2026— 
Total undiscounted cash flows1,187 
Less: unearned income(171)
Total amounts due from customers (2)
$1,016 
(1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.
(2) Of the $1.0 million, $0.1 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Accounts Balance Sheet Accounts
Trade accounts receivable, net consists of the following (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable$26,013 $18,534 
Allowance for doubtful accounts(894)— 
Total$25,119 $18,534 

Changes in the allowance for doubtful accounts were as follows (in thousands):
Three months ended March 31, 2023
Allowance for doubtful accounts, beginning of year$— 
Allowance assumed in IsoPlexis Merger(721)
Write-offs of uncollectible accounts— 
Provision for doubtful accounts(173)
Allowance for doubtful accounts, end of period$(894)

Inventory
The following table shows the components of inventory (in thousands):
March 31,
2023		December 31,
2022
Raw materials$32,816 $11,946 
Work in progress1,106 — 
Finished goods11,617 6,915 
Total$45,539 $18,861 


Prepaid expenses and other current assets
The following table shows the components of prepaid expenses and other current assets (in thousands):
March 31,
2023		December 31,
2022
Contract asset$367 $1,283 
Vendor deposits421 126 
Deferred costs365 472 
Prepaid insurance3,534 2,025 
Other (1)
4,691 2,877 
Total$9,378 $6,783 
(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
Accrued expenses and other current liabilities
The following table shows the components of accrued expenses and other current liabilities (in thousands):
March 31,
2023		December 31,
2022
Accrued payroll and employee related expenses$6,611 $7,410 
Lease liability – short-term4,958 3,291 
Accrued product warranty788 749 
Accrued legal expenses5,499 8,271 
Other (1)
1,789 1,619 
Total$19,645 $21,340 
(1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
Goodwill
On March 21, 2023, the Company completed the IsoPlexis Merger. Under the purchase method of accounting, the Company preliminarily recorded the $12.2 million excess of the Acquisition Date fair value of the consideration transferred over the estimated fair value of net tangible and identifiable intangible assets that it acquired as goodwill. At March 31, 2023, the carrying amount of this goodwill was $12.2 million.

During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. The Company considered such sustained decrease to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Based on the results of the quantitative goodwill impairment test, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2023. In future periods, if the Company were to experience a further decline in its market capitalization or expected results for a sustained period of time, the Company may be required to perform an additional quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material.

Acquired Intangible Assets
In connection with the IsoPlexis Merger, the Company identified certain intangible assets summarized in the table below (see Note 5 for further information). In addition, on February 15, 2023, the Company acquired certain tangible and intangible assets from Evorion Biotechnologies for a total purchase price of $0.3 million, of which $0.2 million related to intangible assets attributable to patents and technology. These intangible assets are also included in the table below.
March 31, 2023
 (in thousands):Remaining Useful Life (Years)GrossAccumulated AmortizationNet
Customer relationships8$7,700 $(5)$7,695 
Trade names103,500 (11)3,489 
Patented technology1411,911 (23)11,888 
Total intangible assets$23,111 $(39)$23,072 
Amortization expense was $39,000 for the three months ended March 31, 2023. In connection with the License Agreement, the Company reviewed the patented technology intangible for indicators of impairment, noting that the patented technology was valued using the relief from royalty approach based on projected revenues from products and services of IsoPlexis, which did not contemplate the License Agreement. In addition, the Company still owns, and retains certain rights to, the intellectual property that was licensed under the License Agreement. Accordingly the Company concluded that an impairment was not necessary.

The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors.
March 31, 2023
Year Ending December 31:
Remainder of 2023$1,689 
2024$2,163 
2025$2,163 
2026$2,163 
2027$2,163 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The following is a description of the valuation techniques the Company uses to measure the fair value of assets and reports fair value on a recurring basis:
•Cash equivalents: At March 31, 2023, the Company’s cash equivalents consisted of money market funds. Money market funds are highly liquid investments and are actively traded and pricing information is readily available. Accordingly, the Company classifies these securities as Level 1 of the fair value hierarchy.
•Short Term Marketable Securities: At March 31, 2023, the Company did not hold any short term marketable securities. Generally, the Company values short-term marketable securities using quoted prices in active markets for similar instruments. Accordingly, the Company classifies marketable securities as Level 2 of the fair value hierarchy.
The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of March 31, 2023 and December 31, 2022 approximate fair value due to their relatively short maturities.
At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands):
March 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$6,591 $6,591 $— $— 
Total assets measured at fair value$6,591 $6,591 $— $— 
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$2,354 $2,354 $— $— 
Commercial paper16,602 — 16,602 — 
U.S. agency securities3,970 — 3,970 — 
Total cash equivalents22,926 2,354 20,572 — 
Debt securities, available for sale:
Commercial paper22,148 — 22,148 — 
U.S. agency securities4,942 — 4,942 — 
U.S. government securities19,162 — 19,162 — 
Total debt securities, available for sale46,252 — 46,252 — 
Total assets measured at fair value$69,178 $2,354 $66,824 $— 

The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):
March 31, 2023December 31, 2022
Carrying
Value		Fair ValueCarrying
Value		Fair Value
Long-term debt, including current maturities$68,886 $70,000 $19,826 $17,443 

The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.

The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, net
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net comprised the following (in thousands):
March 31,
2023		December 31,
2022
Equipment, tooling and molds$47,577 $36,152 
Computer software and equipment8,037 2,667 
Furniture, fixtures and other2,600 2,007 
Leasehold improvements12,509 10,836 
Construction in process1,370 1,409 
Total property and equipment72,093 53,071 
Less: Accumulated depreciation(38,251)(29,224)
Property and equipment, net (1)
$33,842 $23,847 
(1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.

Depreciation expense for the three months ended March 31, 2023 and 2022 was $2.1 million and $1.9 million, respectively.

During the three months ended March 31, 2023 and 2022 losses on the impairment and disposal of property and equipment were not material.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Leases Leases
The Company leases office, manufacturing, distribution and laboratory facilities in various locations in the United States, primarily in Emeryville, California and Branford, Connecticut. The Company also leases facilities in Shanghai, China for office and laboratory facilities. On December 28, 2022, the Company entered into a sub-lease arrangement for its facility in Lexington, Massachusetts. Sub-lease income for the three months ended March 31, 2023 was $0.1 million and was recorded as an offset to rent expense.

Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands):
Operating leases
Undiscounted lease payments for the year ending December 31,
Remainder of 2023$4,691 
20246,297 
20255,952 
20265,398 
20274,759 
Thereafter7,464 
Total undiscounted lease payments34,561 
Less: implied interest(4,304)
Less: tenant improvement allowances receivable(65)
Present value of operating lease payments30,192 
Less: current portion (1)
(4,958)
Total long-term operating lease liabilities$25,234 
(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”
Rent expense, net for the three months ended March 31, 2023 and 2022 was $0.9 million and $1.1 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.8 million and $0.8 million for the three months ended March 31, 2023 and 2022, respectively, including non-lease components such as common area maintenance fees.

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):
Three months ended March 31, 2023Three months ended March 31, 2022
Right-of-use assets obtained for new operating lease liabilities$— $— 
Right-of-use lease assets assumed in IsoPlexis Merger$4,975 $— 
Cash paid for amounts included in the measurement of lease liabilities$989 $1,098 
The following summarizes additional information related to operating leases:
March 31, 2023December 31, 2022
Weighted-average remaining lease term (years)5.716.48
Weighted-average discount rate4.73 %4.66 %
The Company also enters into leasing transactions in which the Company is the lessor, which to date have been classified as sales-type leases. See Note 6 for the related lease disclosures.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Long-Term Debt Long-term Debt
On May 23, 2018, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with EWB to provide a $20.0 million term loan facility (“Term Loan”). The loan facility was fully drawn as of May 23, 2018.

On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (“Amended Loan Agreement”) with EWB. Pursuant to the Amended Loan Agreement, EWB provided a $20.0 million term loan (“Amended Term Loan”) which was used to refinance the Term Loan outstanding under the Loan Agreement dated May 23, 2018. The Amended Term Loan had a maturity of 48 months and a fixed interest rate of 4.17%. In addition, the Amended Term Loan had an initial interest-only period of 24 months, which could have been extended to up to 36 months based on the achievement of certain liquidity measures, and could have been pre-paid without penalty at any time.

On March 21, 2023, the Company entered into a Second Amended and Restated Loan and Security Agreement (“Second Amended Loan Agreement”) with EWB. Pursuant to the Second Amended Loan Agreement, EWB increased the existing Amended Term Loan amount of $20.0 million by $50.0 million to an aggregate outstanding principal of $70.0 million (“Second Amended Term Loan”). The Company used the proceeds from the Second Amended Term Loan to repay $52.5 million of indebtedness (including prepayment premium and interest) with Perceptive held by IsoPlexis (“Perceptive Credit Agreement”). Associated with these transactions, a $0.2 million loss on extinguishment of debt and a $0.7 million commitment fee associated with the Loan Agreement, was recorded in Other expense, net on our condensed consolidated statement of operations during the three months ended March 31, 2023.
The Second Amended Term Loan has a maturity of 60 months and bears interest at a variable rate per annum equal to (i) the greater of 6.25% or the variable rate of interest, per annum, most recently announced by EWB as its prime rate, plus (ii) one-half of one percent (0.5%). In addition, the Second Amended Term Loan has an initial interest-only period of 24 months, which can be extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Second Amended Loan Agreement are satisfied. The Second Amended Term loan carries a prepayment penalty equal to one percent (1%) of the amount of any prepayment of the outstanding balance, if the prepayment is made before the first anniversary of the loan closing date. The Second Amended Loan Agreement was accounted for as a debt extinguishment and the Company capitalized incremental debt issuance costs.

The Second Amended Term Loan is guaranteed by certain domestic subsidiaries of the Company (such subsidiaries, together with the Company, the “Credit Parties”). The Second Amended Loan Agreement grants EWB a security interest in and liens on substantially all assets of the Company and the other Credit Parties, excluding intellectual property, provided, that if the Company does not satisfy a liquidity test set forth in the Second Amended Loan Agreement, the Credit Parties will be required to grant a first-priority security interest in their intellectual property. In addition, certain other terms of the original agreements as previously in effect were amended by the Second Amended Loan Agreement, including certain financial covenants. For example, the Company must maintain cash and cash equivalents of no less than $70.0 million in the aggregate at all times in a deposit account with EWB that is assigned to EWB. As a result, the deposit of $70.0 million was recorded as restricted cash on the Company’s condensed consolidated balance sheet. In addition, if the Company’s cash and cash equivalents balance at EWB falls below $100.0 million, the Company is then required to maintain specific minimum EBITDA amounts at all times thereafter.

The Second Amended Loan Agreement contains customary affirmative and negative covenants, including limitations on mergers, asset sales, liens, investments and indebtedness. See Exhibit 10.1 for the Second Amended Loan Agreement. As of March 31, 2023, the Company was in compliance with the terms and covenants of the Agreement.

The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands):
March 31,
2023
Year Ending December 31:
Remainder of 2023$4,545 
20246,049 
202513,680 
202615,437 
202714,532 
202841,990 
Total payments due96,233 
Less:
Interest payments, loan discounts and financing costs(27,347)
Current portion, less loan discounts and financing costs— 
Notes payable, net of current portion$68,886 
Total interest cost incurred for the three months ended March 31, 2023 and 2022 was $0.4 million and $0.2 million, respectively.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Equity and Stock Compensation Plans
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Equity and Stock Compensation Plans Equity and Stock Compensation Plans
IsoPlexis Merger
On March 21, 2023, in connection with the completion of the IsoPlexis Merger:

•All outstanding IsoPlexis RSAs were assumed by PhenomeX and converted into PhenomeX RSAs based on the 0.612 conversion ratio (see Note 5) and on the same terms and conditions (including with respect to vesting schedules and restrictions) as applied to IsoPlexis RSAs immediately prior to the closing of the IsoPlexis Merger.

•All outstanding IsoPlexis stock options (whether vested or unvested) that had a per share exercise price of less than $1.28 and were held by continuing employees were assumed by PhenomeX and converted into PhenomeX stock options based on the 0.612 conversion ratio (and rounded down) and on the same terms and conditions (including with respect to time-based vesting) as applied to IsoPlexis stock options immediately prior to the closing of the IsoPlexis Merger, with the exercise price per share of the assumed stock options determined by dividing the per share exercise price of the IsoPlexis options by the 0.612 conversion ratio (and rounded up to the nearest whole cent). The assumed stock options expire 10 years from their original date of grant. The assumed stock options and RSAs generally vest 25% upon the one-year anniversary of the service inception date and then ratably each month over the remaining 36 months.

On March 21, 2023, PhenomeX assumed 304,619 IsoPlexis RSAs and 378,767 IsoPlexis stock options after applying the 0.612 conversion ratio. The Company accounted for the assumed equity awards as a modification under ASC 718 and recorded stock compensation expense of $0.1 million during the three months ended March 31, 2023 associated with the modification.
Future grants of equity awards will be issued under the Company’s 2020 Plan.

Warrant Certificate
On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive executed the Warrant Certificate. Under the Warrant Certificate, the outstanding warrant (“IsoPlexis Warrant”) to purchase shares of common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”), issued by IsoPlexis to Perceptive was assumed by PhenomeX and converted into a warrant (“PhenomeX Warrant”) to purchase shares of common stock, par value $0.00005, of PhenomeX (“PhenomeX Common Stock”), on the same terms and subject to the same conditions as were applicable to the IsoPlexis Warrant as of immediately prior to the Acquisition Date; provided, that the PhenomeX Warrant is exercisable for 496,560 shares of PhenomeX Common Stock (i.e., a number of shares of PhenomeX Common Stock equal to the number of shares of IsoPlexis Common Stock that were subject to the IsoPlexis Warrant multiplied by the 0.612 exchange ratio and has an exercise price of $9.80 per share of PhenomeX Common Stock (i.e., the exercise price per share of IsoPlexis Common Stock that was applicable to the IsoPlexis Warrant divided by 0.612).

Restricted stock awards
As a result of the IsoPlexis Merger and discussed above, the Company now has RSAs outstanding. RSAs are rights to receive shares of the Company’s Common Stock upon meeting specified vesting requirements. The fair value of a RSA is the market value as determined by the closing price of the Company’s stock on the original grant date.
Stock-based compensation
Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):
Three months ended March 31,
20232022
Cost of sales$16 $51 
Research and development548 1,581 
Selling, general and administrative3,824 3,761 
Total stock-based compensation$4,388 $5,393 
Stock-based compensation capitalized in inventory was not material as of March 31, 2023 and December 31, 2022.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring
 3 Months Ended
Mar. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
During 2022, the Company adopted a new strategic plan with the intention of reducing costs and better aligning the organization with the Company’s long-term goals. As a result, the Company approved a set of restructuring initiatives in 2022 and continued with similar initiatives in the first quarter of 2023. During the three months ended March 31, 2023, the Company incurred restructuring charges of $1.3 million, related to severance and other employee-related restructuring costs associated with the termination of approximately 16% of total full-time employees. As of March 31, 2023, the Company has not fully completed its restructuring efforts. It is unable to currently estimate future restructuring charges, but will record any additional restructuring-related expenses as they are incurred.
Changes in the Company’s restructuring liability are set forth in the table below (in thousands):
Employee severance and termination benefitsNon labor restructuringTotal
Accrual at January 1, 2023$130 $107 $237 
Restructuring liability assumed in IsoPlexis Merger834 — 834 
Restructuring charges1,290 — 1,290 
Cash payments(1,010)(107)(1,117)
Non-cash settlements— — — 
Accrual at March 31, 2023$1,244 $— $1,244 
Restructuring liabilities are included in accrued expenses and other current liabilities in the condensed consolidated balance sheet.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe Company’s provision for income taxes was $20,000 for the three months ended March 31, 2023 and $20,000 and for the three months ended March 31, 2022. For the three months ended March 31, 2023 and 2022, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Statements of Cash Flows Statements of Cash Flows
The supplemental cash flow information consists of the following (in thousands):
Three months ended March 31,
20232022
Cash paid for interest$439 $137 
Cash paid for income taxes$19 $— 
Non-cash investing and financing activities
Non-cash consideration for the acquisition of IsoPlexis$32,406 $— 
Property and equipment transferred to inventory$352 $— 
Customer return of Beacon transferred to property and equipment (1)
$201 $— 
Change in accounts payable and accrued liabilities related to purchases of property and equipment$684 $482 
(1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Commitment and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred.
AbCellera Biologics Litigation
In July through September 2020, AbCellera Biologics Inc. (“AbCellera”) filed a series of complaints in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936, 10,704,018, 10,718,768, 10,738,270, 10,746,737, 10,753,933, 10,775,376, 10,775,377, and 10,775,378. The University of British Columbia (“UBC”), the owner of the patents, joined AbCellera as a named plaintiff in the lawsuits. AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees, and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents, for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct, and unfair competition under state and federal law.
The Company filed a motion to transfer the lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (“Consolidated Lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court issued a Case Management Order that, among other things, requires AbCellera and UBC to further reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial.
In July 2021 and August 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent Nos. 10,421,936 and 10,739,270. In August 2021, in response to a Motion to Stay filed by the Company, the court stayed the Consolidated Lawsuit pending the outcome of the IPR proceedings.
In January 2022, the PTAB of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. And in January 2023, the PTAB issued a decision upholding the validity of the challenged claims in U.S. Patent No. 10,087,408: the Company has requested a rehearing of the PTAB’s decision. The Consolidated Lawsuit remains stayed at this time, AbCellera has filed a motion - opposed by the Company - to lift the stay. AbCellera’s motion to lift the stay is fully briefed and awaiting a decision from the court.
The Company believes that the patent assertions by AbCellera and UBC are without merit and it intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s position. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of the Company’s products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.
Securities Class Action
In December 2021, Victor J. Ng filed a securities class action complaint in the Northern District of California (“Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 Initial Public Offering (“IPO”) offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. The Company’s pending Motion to Dismiss is set for hearing on June 22, 2023. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.
Derivative Action
In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and former senior executives owe the Company contribution for violations of Sections 10(b) and 21D of the Exchange Act.
The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity.
No provision has been made for litigation because the Company believes that it is not probable that a liability has been incurred as of March 31, 2023.
Purchase commitments
The Company has entered into various purchase agreements, including inventory-related agreements with its contract manufacturers. Once these orders are placed, they are generally cancelable by providing notice prior to the expected ship date, however such cancellations could result in the Company incurring certain charges depending on the timing. The Company had non-cancellable purchase obligations to contract manufacturers and other suppliers of $29.7 million at March 31, 2023.
Product Warranty
The Company generally provides a one year assurance-type warranty on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):
Three months ended March 31,
20232022
Balance, beginning of period$749 $1,085 
Warranty accrual assumed in IsoPlexis Merger128 — 
Adjustments to existing warranties(111)(245)
Provision for new warranties133 163 
Settlement of pre-existing warranties(111)(89)
Balance, end of period$788 $914 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Attributable to Common Stockholders Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Loss Attributable to Common Stockholders Per Share Net Loss Attributable to Common Stockholders Per Share
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards and unvested restricted stock units.

The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):
Three months ended March 31,
20232022
Numerator
Net loss attributable to common stockholders, basic and diluted$(23,419)$(21,426)
Denominator
Weighted-average shares used to compute net income per share, basic and diluted75,759,77167,697,488
Net loss per share
Net loss per share attributable to common stockholders, basic and diluted$(0.31)$(0.32)
Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect:

 March 31,
20232022
Warrants to purchase common stock496,560 — 
Options to purchase common stock7,685,997 7,020,591 
Restricted stock awards290,846 — 
Restricted stock units5,517,488 3,629,310 
Total13,990,891 10,649,901 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Segments
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segments Segments
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has one operating segment. The IsoPlexis Merger on March 21, 2023 did not change the Company’s assessment about operating segments. The Company’s principal operations and decision-making functions are located in the United States.
The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):
Three months ended March 31,
20232022
North America$14,055 $13,715 
Asia Pacific (1)
3,147 5,035 
Europe1,314 1,456 
$18,516 $20,206 
(1) Asia Pacific includes Australia.

As of March 31, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets were located in the United States.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsIn April 2023, Phenomenex, Inc. (“Phenomenex”) filed a complaint against the Company in the U.S. District Court for the Central District of California, alleging trademark infringement and unfair competition in relation to the Company’s name and seeking injunctive relief and damages. As of the filing date for this Quarterly Report on Form 10-Q, the Company has not been served with the complaint from Phenomenex. The Company believes that Phenomenex’s complaint is without merit and intends to vigorously defend itself.
Restructuring
During the second quarter of 2023, the Company announced a reduction in force terminating approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $0.8 million related to this activity, substantially all of which the Company expects to incur in the second quarter of 2023.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
The Company and Basis of Presentation (Policies)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights.
The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates.
Cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer.
Accounts Receivables and Allowance for Credit Losses
Accounts Receivables and Allowance for Credit Losses
Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.
Inventory
Inventory
Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.
Stock-based compensation
Stock-based compensation
The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors.
Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant.
The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.
The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.
Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.
For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.
The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.
Business Combinations
Business Combinations
We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed
within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.

Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.
Foreign currency translation and transactions
Foreign currency translation and transactions
The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net.
For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.
Research and development state tax credits
Research and development state tax credits
Research and development (“R&D”) tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits a qualified small business engaged in R&D activities within Connecticut to exchange its unused R&D tax credits for a cash amount equal to 65% of the value of exchanged credits, are
recorded as a receivable and other income in the year the R&D tax credits relate to, as it is reasonably assured that the R&D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets.
Warrants
Warrants
On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, Distinguishing Liabilities from Equity.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents and restricted cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands):
March 31, 2023December 31, 2022
Cash
$45,015 $63,596 
Cash equivalents
6,591 22,926 
Restricted cash70,093 — 
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows
$121,699 $86,522 
Schedule of cash and cash equivalents and restricted cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands):
March 31, 2023December 31, 2022
Cash
$45,015 $63,596 
Cash equivalents
6,591 22,926 
Restricted cash70,093 — 
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows
$121,699 $86,522 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of unrealized gains and losses related to our available-for-sale marketable securities
The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands):

Marketable Securities reported as Cash Equivalents

March 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$6,591 $— $— $6,591 
   Total$6,591 $— $— $6,591 


December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Money market funds$2,354 $— $— $2,354 
Commercial paper16,606 — (4)16,602 
U.S. agency securities3,969 1 — 3,970 
U.S. government securities— — — — 
   Total$22,929 $1 $(4)$22,926 
Marketable Securities reported as Short-term Marketable Securities

As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial.

Short-term marketable securities at December 31, 2022 were as follows (in thousands):

December 31, 2022
Amortized CostUnrealized GainsUnrealized LossesFair Value
Commercial paper$22,158 $1 $(11)$22,148 
U.S. agency securities4,941 1 — 4,942 
U.S. government securities19,159 5 (2)19,162 
   Total$46,258 $7 $(13)$46,252 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations (Tables)
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of fair value of consideration transferred
The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands):
Fair value of PhenomeX common stock issued to IsoPlexis stockholders (1)
$31,930 
Repayment of IsoPlexis debt (2)
52,482 
Fair value of vested IsoPlexis options attributable to pre-merger service (3)
306 
Fair value of IsoPlexis warrant at Acquisition Date (4)
170 
   Total purchase consideration$84,888 
(1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.
(2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest.
(3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information).
(4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).
Schedule of fair value of assets acquired and liabilities assumed The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed.
Cash and cash equivalents$12,197 
Accounts receivable3,075 
Inventories27,287 
Prepaid expenses and other current assets4,190 
Property and equipment, net11,206 
Intangible assets22,900 
Goodwill12,246 
Operating lease right-of-use assets4,975 
Other assets526 
    Total assets acquired98,602 
Accounts payable2,367 
Accrued expenses and other current liabilities4,912 
Deferred revenue1,399 
Operating lease obligations5,036 
     Total liabilities assumed13,714 
Total consideration transferred$84,888 
Schedule of pro forma information
The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition.
(in thousands)Three months ended March 31, 2023Three months ended March 31, 2022
Total revenue$20,170 $25,117 
Net loss$(66,463)$(50,419)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue From Contracts With Customers (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations:
Income Statement Classification
Product or Service sold
Revenue Stream
Product revenue
Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)
Platform
Software and workflow licenses
Platform
Fixed term sales-type lease arrangements with qualified customers
Platform
Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)
Recurring
Consumables and reagent kits (e.g. OptoSelect chips)
Recurring
Service and other revenue
Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types
Partnership, License and Other
Application support, installation and training
Platform
Fixed fee extended warranty and service programs
Recurring
IP license revenue
Partnership, License and Other (1)
(1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue.
The following tables provide information by revenue stream for the periods presented:

Three Months Ended March 31, 2023
(in thousands)ProductService and otherTotal
Platform$5,773 $330 $6,103 
Recurring2,605 2,558 5,163 
Partnership, License and Other (1)
— 7,250 7,250 
   Total revenue$8,378 $10,138 $18,516 
(1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter.
Three Months Ended March 31, 2022
(in thousands)ProductService and otherTotal
Platform$6,747 $657 $7,404 
Recurring3,027 2,416 5,443 
Partnership, License and Other— 7,359 7,359 
   Total revenue$9,774 $10,432 $20,206 
Schedule of receivables, contract assets and deferred revenue from contracts with customers
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable, net$25,119 $18,534 
Contract assets, which are included in “Prepaid expenses and other current assets”$367 $1,283 
Contract assets, long-term, which are included in “Other assets”$514 $549 
Deferred revenue (current)$10,746 $9,092 
Deferred revenue (non-current)$1,259 $963 
Schedule of sales-type lease maturity
The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands):
Year ending December 31,Sales-Type
Leases
Remainder of 2023(1)
$334 
2024445 
2025408 
2026— 
Total undiscounted cash flows1,187 
Less: unearned income(171)
Total amounts due from customers (2)
$1,016 
(1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.
(2) Of the $1.0 million, $0.1 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of trade accounts receivable, net
Trade accounts receivable, net consists of the following (in thousands):
March 31,
2023		December 31,
2022
Trade accounts receivable$26,013 $18,534 
Allowance for doubtful accounts(894)— 
Total$25,119 $18,534 
Schedule of changes in the allowance for doubtful accounts
Changes in the allowance for doubtful accounts were as follows (in thousands):
Three months ended March 31, 2023
Allowance for doubtful accounts, beginning of year$— 
Allowance assumed in IsoPlexis Merger(721)
Write-offs of uncollectible accounts— 
Provision for doubtful accounts(173)
Allowance for doubtful accounts, end of period$(894)
Schedule of inventory
The following table shows the components of inventory (in thousands):
March 31,
2023		December 31,
2022
Raw materials$32,816 $11,946 
Work in progress1,106 — 
Finished goods11,617 6,915 
Total$45,539 $18,861 
Schedule of prepaid expenses and other current assets
The following table shows the components of prepaid expenses and other current assets (in thousands):
March 31,
2023		December 31,
2022
Contract asset$367 $1,283 
Vendor deposits421 126 
Deferred costs365 472 
Prepaid insurance3,534 2,025 
Other (1)
4,691 2,877 
Total$9,378 $6,783 
(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
Schedule of accrued expenses and other current liabilities
The following table shows the components of accrued expenses and other current liabilities (in thousands):
March 31,
2023		December 31,
2022
Accrued payroll and employee related expenses$6,611 $7,410 
Lease liability – short-term4,958 3,291 
Accrued product warranty788 749 
Accrued legal expenses5,499 8,271 
Other (1)
1,789 1,619 
Total$19,645 $21,340 
(1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets These intangible assets are also included in the table below.
March 31, 2023
 (in thousands):Remaining Useful Life (Years)GrossAccumulated AmortizationNet
Customer relationships8$7,700 $(5)$7,695 
Trade names103,500 (11)3,489 
Patented technology1411,911 (23)11,888 
Total intangible assets$23,111 $(39)$23,072 
Schedule of estimated annual amortization of intangible assets
The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors.
March 31, 2023
Year Ending December 31:
Remainder of 2023$1,689 
2024$2,163 
2025$2,163 
2026$2,163 
2027$2,163 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of financial assets measured at fair value
At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands):
March 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$6,591 $6,591 $— $— 
Total assets measured at fair value$6,591 $6,591 $— $— 
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Money market funds$2,354 $2,354 $— $— 
Commercial paper16,602 — 16,602 — 
U.S. agency securities3,970 — 3,970 — 
Total cash equivalents22,926 2,354 20,572 — 
Debt securities, available for sale:
Commercial paper22,148 — 22,148 — 
U.S. agency securities4,942 — 4,942 — 
U.S. government securities19,162 — 19,162 — 
Total debt securities, available for sale46,252 — 46,252 — 
Total assets measured at fair value$69,178 $2,354 $66,824 $— 
Schedule of financial instruments not measured at fair value
The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):
March 31, 2023December 31, 2022
Carrying
Value		Fair ValueCarrying
Value		Fair Value
Long-term debt, including current maturities$68,886 $70,000 $19,826 $17,443 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, net (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
Property and equipment, net comprised the following (in thousands):
March 31,
2023		December 31,
2022
Equipment, tooling and molds$47,577 $36,152 
Computer software and equipment8,037 2,667 
Furniture, fixtures and other2,600 2,007 
Leasehold improvements12,509 10,836 
Construction in process1,370 1,409 
Total property and equipment72,093 53,071 
Less: Accumulated depreciation(38,251)(29,224)
Property and equipment, net (1)
$33,842 $23,847 
(1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Table)
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Schedule of operating lease liabilities maturity
Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands):
Operating leases
Undiscounted lease payments for the year ending December 31,
Remainder of 2023$4,691 
20246,297 
20255,952 
20265,398 
20274,759 
Thereafter7,464 
Total undiscounted lease payments34,561 
Less: implied interest(4,304)
Less: tenant improvement allowances receivable(65)
Present value of operating lease payments30,192 
Less: current portion (1)
(4,958)
Total long-term operating lease liabilities$25,234 
(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”
Schedule of supplemental cash flow information related to operating leases
The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):
Three months ended March 31, 2023Three months ended March 31, 2022
Right-of-use assets obtained for new operating lease liabilities$— $— 
Right-of-use lease assets assumed in IsoPlexis Merger$4,975 $— 
Cash paid for amounts included in the measurement of lease liabilities$989 $1,098 
Schedule of additional information related to operating leases
The following summarizes additional information related to operating leases:
March 31, 2023December 31, 2022
Weighted-average remaining lease term (years)5.716.48
Weighted-average discount rate4.73 %4.66 %
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of payments due on notes payable
The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands):
March 31,
2023
Year Ending December 31:
Remainder of 2023$4,545 
20246,049 
202513,680 
202615,437 
202714,532 
202841,990 
Total payments due96,233 
Less:
Interest payments, loan discounts and financing costs(27,347)
Current portion, less loan discounts and financing costs— 
Notes payable, net of current portion$68,886 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Equity and Stock Compensation Plans (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of stock-based compensation
Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):
Three months ended March 31,
20232022
Cost of sales$16 $51 
Research and development548 1,581 
Selling, general and administrative3,824 3,761 
Total stock-based compensation$4,388 $5,393 
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring (Tables)
 3 Months Ended
Mar. 31, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Changes in Restructuring Liability
Changes in the Company’s restructuring liability are set forth in the table below (in thousands):
Employee severance and termination benefitsNon labor restructuringTotal
Accrual at January 1, 2023$130 $107 $237 
Restructuring liability assumed in IsoPlexis Merger834 — 834 
Restructuring charges1,290 — 1,290 
Cash payments(1,010)(107)(1,117)
Non-cash settlements— — — 
Accrual at March 31, 2023$1,244 $— $1,244 
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of cash flow, supplemental disclosures
The supplemental cash flow information consists of the following (in thousands):
Three months ended March 31,
20232022
Cash paid for interest$439 $137 
Cash paid for income taxes$19 $— 
Non-cash investing and financing activities
Non-cash consideration for the acquisition of IsoPlexis$32,406 $— 
Property and equipment transferred to inventory$352 $— 
Customer return of Beacon transferred to property and equipment (1)
$201 $— 
Change in accounts payable and accrued liabilities related to purchases of property and equipment$684 $482 
(1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Commitment and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of product warranty liability The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):
Three months ended March 31,
20232022
Balance, beginning of period$749 $1,085 
Warranty accrual assumed in IsoPlexis Merger128 — 
Adjustments to existing warranties(111)(245)
Provision for new warranties133 163 
Settlement of pre-existing warranties(111)(89)
Balance, end of period$788 $914 
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Attributable to Common Stockholders Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of basic and diluted net loss per common share
The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):
Three months ended March 31,
20232022
Numerator
Net loss attributable to common stockholders, basic and diluted$(23,419)$(21,426)
Denominator
Weighted-average shares used to compute net income per share, basic and diluted75,759,77167,697,488
Net loss per share
Net loss per share attributable to common stockholders, basic and diluted$(0.31)$(0.32)
Schedule of antidilutive securities excluded from computation of earnings per share The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect:
 March 31,
20232022
Warrants to purchase common stock496,560 — 
Options to purchase common stock7,685,997 7,020,591 
Restricted stock awards290,846 — 
Restricted stock units5,517,488 3,629,310 
Total13,990,891 10,649,901 
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Summary of revenue by geographic areas
The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):
Three months ended March 31,
20232022
North America$14,055 $13,715 
Asia Pacific (1)
3,147 5,035 
Europe1,314 1,456 
$18,516 $20,206 
(1) Asia Pacific includes Australia.
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
The Company and Basis of Presentation (Details) - USD ($)
 3 Months Ended
Mar. 21, 2023
Mar. 31, 2023
Mar. 31, 2022
Mar. 20, 2023
Dec. 31, 2022
Jun. 30, 2021
May 23, 2018
Organization, Consolidation and Presentation of Financial Statement [Line Items]              
Net loss   $ (23,419,000) $ (21,426,000)        
Accumulated deficit   (385,067,000)     $ (361,648,000)    
Cash, cash equivalents, and marketable securities   $ 51,600,000          
EWB Term Loan | Notes Payable              
Organization, Consolidation and Presentation of Financial Statement [Line Items]              
Maximum borrowing capacity $ 70,000,000     $ 20,000,000   $ 20,000,000 $ 20,000,000
Debt instrument, covenant description, cash 70,000,000            
Perceptive Credit Agreement | Line of Credit              
Organization, Consolidation and Presentation of Financial Statement [Line Items]              
Repayment of acquired debt $ 52,500,000            
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash $ 70,093 $ 0
Letter of Credit    
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash 100  
EWB Term Loan    
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash $ 70,000  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash $ 45,015 $ 63,596    
Cash equivalents 6,591 22,926    
Restricted cash 70,093 0    
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows $ 121,699 $ 86,522 $ 164,944 $ 178,366
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Research and development state tax credits (Details)
$ in Millions
Mar. 31, 2023
USD ($)
Research Tax Credit Carryforward  
Tax Credit Carryforward [Line Items]  
R&D tax credits receivable $ 0.2
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Abstract]    
Amortized Cost $ 6,591 $ 22,929
Unrealized Gains 0 1
Unrealized Losses 0 (4)
Fair Value 6,591 22,926
Debt Securities, Available-for-Sale [Abstract]    
Amortized Cost   46,258
Unrealized Gains   7
Unrealized Losses   (13)
Fair Value   46,252
Commercial paper    
Debt Securities, Available-for-Sale [Abstract]    
Amortized Cost   22,158
Unrealized Gains   1
Unrealized Losses   (11)
Fair Value   22,148
U.S. agency securities    
Debt Securities, Available-for-Sale [Abstract]    
Amortized Cost   4,941
Unrealized Gains   1
Unrealized Losses   0
Fair Value   4,942
U.S. government securities    
Debt Securities, Available-for-Sale [Abstract]    
Amortized Cost   19,159
Unrealized Gains   5
Unrealized Losses   (2)
Fair Value   19,162
Money market funds    
Cash and Cash Equivalents [Abstract]    
Amortized Cost 6,591 2,354
Unrealized Gains 0 0
Unrealized Losses 0 0
Fair Value $ 6,591 2,354
Commercial paper    
Cash and Cash Equivalents [Abstract]    
Amortized Cost   16,606
Unrealized Gains   0
Unrealized Losses   (4)
Fair Value   16,602
U.S. agency securities    
Cash and Cash Equivalents [Abstract]    
Amortized Cost   3,969
Unrealized Gains   1
Unrealized Losses   0
Fair Value   3,970
U.S. government securities    
Cash and Cash Equivalents [Abstract]    
Amortized Cost   0
Unrealized Gains   0
Unrealized Losses   0
Fair Value   $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Concentration Risk [Line Items]      
Allowance for doubtful accounts $ 894   $ 0
Revenue | Customer | Customer One      
Concentration Risk [Line Items]      
Concentration risk percentage 39.00% 18.00%  
Revenue | Customer | Customer Two      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 13.00%  
Revenue | Customer | Customer Three      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 10.00%  
Accounts Receivable | Customer | Customer One      
Concentration Risk [Line Items]      
Concentration risk percentage 25.00%   24.00%
Accounts Receivable | Customer | Customer Two      
Concentration Risk [Line Items]      
Concentration risk percentage 14.00%   11.00%
Accounts Receivable | Customer | Customer Three      
Concentration Risk [Line Items]      
Concentration risk percentage 12.00%    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations - Narrative (Details)
 3 Months Ended
Mar. 21, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Business Acquisition [Line Items]        
Fair value of accounts receivable acquired $ 3,100,000      
Allowance for credit losses 700,000      
Inventories 27,300,000      
Step up form book value of inventory acquired $ 4,900,000      
Inventory   $ 45,539,000 $ 18,861,000  
Incurred transaction costs   13,700,000    
Total revenue   18,516,000   $ 20,206,000
Service and other revenue        
Business Acquisition [Line Items]        
Total revenue   10,138,000   10,432,000
Partnership, License and Other (1)        
Business Acquisition [Line Items]        
Total revenue   7,250,000   7,359,000
Partnership, License and Other (1) | Service and other revenue        
Business Acquisition [Line Items]        
Total revenue   7,250,000   $ 7,359,000
Acquisition-related Costs        
Business Acquisition [Line Items]        
Incurred transaction costs   4,400,000    
IsoPlexis        
Business Acquisition [Line Items]        
Shares holding ratio 0.612      
Inventories $ 27,287,000      
Inventory 22,400,000      
Inventory valuation reserves 15,400,000      
Goodwill with a provisional assigned value 12,200,000      
Goodwill, expected tax deductible amount $ 0      
Recognized transaction costs   3,500,000 $ 2,800,000  
Revenues   1,000,000    
Operating loss   1,100,000    
IsoPlexis | Partnership, License and Other (1) | Service and other revenue        
Business Acquisition [Line Items]        
Total revenue   $ 7,300,000    
IsoPlexis | EWB Term Loan | Notes Payable        
Business Acquisition [Line Items]        
Interest rate 8.50%      
IsoPlexis | Minimum        
Business Acquisition [Line Items]        
Weighted average useful life 8 years      
IsoPlexis | Maximum        
Business Acquisition [Line Items]        
Weighted average useful life 14 years      
IsoPlexis | Patented technology        
Business Acquisition [Line Items]        
Intangible assets $ 11,700,000      
IsoPlexis | Customer Relationships        
Business Acquisition [Line Items]        
Intangible assets 7,700,000      
IsoPlexis | Trade Names and Trademarks        
Business Acquisition [Line Items]        
Intangible assets $ 3,500,000      
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations - Schedule of Acquired Assets and Liabilities (Details)
$ / shares in Units, $ in Thousands
Mar. 21, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair value of assets acquired and liabilities assumed      
Inventories $ 27,300    
Goodwill   $ 12,246 $ 0
IsoPlexis      
Consideration Transferred      
Fair value of PhenomeX common stock issued to IsoPlexis stockholders 31,930    
Repayment of acquired debt 52,482    
Fair value of vested IsoPlexis options attributable to pre-merger service 306    
Fair value of IsoPlexis warrant at merger date 170    
Total purchase consideration $ 84,888    
Fair value of common stock issued (in shares) | shares 24,945,611    
Price per share of the common stock acquired (in dollars per share) | $ / shares $ 1.28    
Shares holding ratio 0.612    
Principal repayment to retire debt $ 50,000    
Fair value of assets acquired and liabilities assumed      
Cash and cash equivalents 12,197    
Accounts receivable 3,075    
Inventories 27,287    
Prepaid expenses and other current assets 4,190    
Property and equipment, net 11,206    
Intangible assets 22,900    
Goodwill 12,246    
Operating lease right-of-use assets 4,975    
Other assets 526    
Total assets acquired 98,602    
Accounts payable 2,367    
Accrued expenses and other current liabilities 4,912    
Deferred revenue 1,399    
Operating lease obligations 5,036    
Total liabilities assumed 13,714    
Total consideration transferred $ 84,888    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations - Schedule of Pro forma Information (Details) - IsoPlexis - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Business Acquisition [Line Items]    
Total revenue $ 20,170 $ 25,117
Net loss $ (66,463) $ (50,419)
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customer (Narrative) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]      
Remaining performance obligation $ 12,000,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Contract liabilities 12,000,000   $ 10,100,000
Contract liability , revenue recognized 2,800,000    
Lease income $ 0 $ 0  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Remaining performance obligation, percentage 50.00%    
Remaining performance obligation, period 12 months    
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenue $ 18,516 $ 20,206
Platform    
Disaggregation of Revenue [Line Items]    
Total revenue 6,103 7,404
Recurring    
Disaggregation of Revenue [Line Items]    
Total revenue 5,163 5,443
Partnership, License and Other    
Disaggregation of Revenue [Line Items]    
Total revenue 7,250 7,359
Product    
Disaggregation of Revenue [Line Items]    
Total revenue 8,378 9,774
Product | Platform    
Disaggregation of Revenue [Line Items]    
Total revenue 5,773 6,747
Product | Recurring    
Disaggregation of Revenue [Line Items]    
Total revenue 2,605 3,027
Product | Partnership, License and Other    
Disaggregation of Revenue [Line Items]    
Total revenue 0 0
Service and other    
Disaggregation of Revenue [Line Items]    
Total revenue 10,138 10,432
Service and other | Platform    
Disaggregation of Revenue [Line Items]    
Total revenue 330 657
Service and other | Recurring    
Disaggregation of Revenue [Line Items]    
Total revenue 2,558 2,416
Service and other | Partnership, License and Other    
Disaggregation of Revenue [Line Items]    
Total revenue 7,250 $ 7,359
Service and other | Partnership, License and Other | IsoPlexis    
Disaggregation of Revenue [Line Items]    
Total revenue $ 7,300  
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Trade accounts receivable, net $ 25,119 $ 18,534
Contract assets, which are included in “Prepaid expenses and other current assets” 367 1,283
Contract assets, long-term, which are included in “Other assets” 514 549
Deferred revenue (current) 10,746 9,092
Deferred revenue (non-current) $ 1,259 $ 963
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Lessor, Lease, Description [Line Items]  
Remainder of 2023 $ 334
2024 445
2025 408
2026 0
Total undiscounted cash flows 1,187
Less: unearned income (171)
Total amounts due from customers 1,016
Contract asset 800
Impairment charge 600
Accounts Receivable, after Allowance for Credit Loss, Current  
Lessor, Lease, Description [Line Items]  
Total amounts due from customers $ 100
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts - Trade Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Trade accounts receivable $ 26,013 $ 18,534
Allowance for doubtful accounts (894) 0
Trade accounts receivable, net $ 25,119 $ 18,534
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Allowance for doubtful accounts, beginning of year $ 0  
Allowance assumed in IsoPlexis Merger (721)  
Write-offs of uncollectible accounts 0  
Provision for doubtful accounts (173) $ 0
Allowance for doubtful accounts, end of period $ (894)  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts - Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 32,816 $ 11,946
Work in progress 1,106 0
Finished goods 11,617 6,915
Total $ 45,539 $ 18,861
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Contract asset $ 367 $ 1,283
Vendor deposits 421 126
Deferred costs 365 472
Prepaid insurance 3,534 2,025
Other 4,691 2,877
Total $ 9,378 $ 6,783
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued payroll and employee related expenses $ 6,611 $ 7,410
Lease liability - short-term [Extensible Enumeration] Total Total
Lease liability – short-term $ 4,958 $ 3,291
Accrued product warranty 788 749
Accrued legal expenses 5,499 8,271
Other 1,789 1,619
Total $ 19,645 $ 21,340
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Feb. 15, 2023
Mar. 31, 2023
Mar. 21, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]        
Goodwill   $ 12,246   $ 0
Amortization expense   $ (39)    
Evorion Biotechnologies        
Finite-Lived Intangible Assets [Line Items]        
Total purchase price $ 300      
Evorion Biotechnologies | Patents and Technology        
Finite-Lived Intangible Assets [Line Items]        
Intangible assets acuired $ 200      
IsoPlexis        
Finite-Lived Intangible Assets [Line Items]        
Goodwill     $ 12,246  
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Intangible assets, gross $ 23,111
Accumulated Amortization (39)
Intangible assets, net $ 23,072
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Remaining Useful Life (Years) 8 years
Intangible assets, gross $ 7,700
Accumulated Amortization (5)
Intangible assets, net $ 7,695
Trade names  
Finite-Lived Intangible Assets [Line Items]  
Remaining Useful Life (Years) 10 years
Intangible assets, gross $ 3,500
Accumulated Amortization (11)
Intangible assets, net $ 3,489
Patented technology  
Finite-Lived Intangible Assets [Line Items]  
Remaining Useful Life (Years) 14 years
Intangible assets, gross $ 11,911
Accumulated Amortization (23)
Intangible assets, net $ 11,888
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Year Ending December 31:  
Remainder of 2023 $ 1,689
2024 2,163
2025 2,163
2026 2,163
2027 $ 2,163
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale $ 0 $ 46,252
Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   22,926
Total debt securities, available for sale   46,252
Total assets measured at fair value 6,591 69,178
Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   22,148
U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   4,942
U.S. government securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   19,162
Money market funds | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents 6,591 2,354
Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   16,602
U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   3,970
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   2,354
Total debt securities, available for sale   0
Total assets measured at fair value 6,591 2,354
Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents 6,591 2,354
Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   20,572
Total debt securities, available for sale   46,252
Total assets measured at fair value 0 66,824
Significant Other Observable Inputs (Level 2) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   22,148
Significant Other Observable Inputs (Level 2) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   4,942
Significant Other Observable Inputs (Level 2) | U.S. government securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   19,162
Significant Other Observable Inputs (Level 2) | Money market funds | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents 0 0
Significant Other Observable Inputs (Level 2) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   16,602
Significant Other Observable Inputs (Level 2) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   3,970
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   0
Total debt securities, available for sale   0
Total assets measured at fair value 0 0
Significant Unobservable Inputs (Level 3) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Significant Unobservable Inputs (Level 3) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Significant Unobservable Inputs (Level 3) | U.S. government securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total debt securities, available for sale   0
Significant Unobservable Inputs (Level 3) | Money market funds | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents $ 0 0
Significant Unobservable Inputs (Level 3) | Commercial paper | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   0
Significant Unobservable Inputs (Level 3) | U.S. agency securities | Fair Value, Measurements, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents   $ 0
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details) - Significant Other Observable Inputs (Level 2) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Carrying Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt, including current maturities $ 68,886 $ 19,826
Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt, including current maturities $ 70,000 $ 17,443
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 72,093 $ 53,071
Less: Accumulated depreciation (38,251) (29,224)
Property and equipment, net 33,842 23,847
Assets held for sale 100 100
Equipment, tooling and molds    
Property, Plant and Equipment [Line Items]    
Total property and equipment 47,577 36,152
Computer software and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 8,037 2,667
Furniture, fixtures and other    
Property, Plant and Equipment [Line Items]    
Total property and equipment 2,600 2,007
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 12,509 10,836
Construction in process    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 1,370 $ 1,409
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment, net - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Property, Plant and Equipment [Abstract]      
Depreciation and amortization $ 2.1 $ 1.9  
Assets held for sale $ 0.1   $ 0.1
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases [Abstract]    
Sub-lease income $ 0.1  
Rent expense 0.9 $ 1.1
Variable lease payments $ 0.8 $ 0.8
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Maturity Schedule of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Remainder of 2023 $ 4,691  
2024 6,297  
2025 5,952  
2026 5,398  
2027 4,759  
Thereafter 7,464  
Total undiscounted lease payments 34,561  
Less: implied interest (4,304)  
Less: tenant improvement allowances receivable (65)  
Present value of operating lease payments 30,192  
Less: current portion (4,958) $ (3,291)
Total long-term operating lease liabilities $ 25,234 $ 22,726
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases [Abstract]    
Right-of-use assets obtained for new operating lease liabilities $ 0 $ 0
Right-of-use lease assets assumed in IsoPlexis Merger 4,975 0
Cash paid for amounts included in the measurement of lease liabilities $ 989 $ 1,098
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule of Additional Information Related to Operating Leases (Details)
Mar. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted-average remaining lease term (in years) 5 years 8 months 15 days 6 years 5 months 23 days
Weighted-average discount rate 4.73% 4.66%
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 21, 2023
Jun. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Mar. 20, 2023
Dec. 31, 2022
May 23, 2018
Debt Instrument [Line Items]              
Loss on debt extinguishment     $ 162,000 $ 0      
Restricted cash     70,093,000     $ 0  
Interest cost     400,000 $ 200,000      
EWB Term Loan              
Debt Instrument [Line Items]              
Restricted cash     70,000,000        
Notes Payable              
Debt Instrument [Line Items]              
Loss on debt extinguishment     200,000        
Commitment fee     $ 700,000        
Notes Payable | EWB Term Loan              
Debt Instrument [Line Items]              
Maximum borrowing capacity $ 70,000,000 $ 20,000,000     $ 20,000,000   $ 20,000,000
Note payable, term (in years) 60 months 48 months          
Interest rate   4.17%          
Interest-only period 24 months 24 months          
Interest-only period with extension   36 months          
Increase in borrowing capacity $ 50,000,000            
Prepayment penalty percentage 1.00%            
Debt instrument, covenant description, cash $ 70,000,000            
Restricted cash 70,000,000            
Debt instrument, covenant description, minimum cash and cash equivalents balance with bank $ 100,000,000            
Notes Payable | EWB Term Loan | Prime Rate              
Debt Instrument [Line Items]              
Interest rate 6.25%            
Basis spread on variable rate 0.50%            
Line of Credit | Perceptive Credit Agreement              
Debt Instrument [Line Items]              
Repayment of acquired debt $ 52,500,000            
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Current portion, less loan discounts and financing costs $ 0 $ (4,966)
Notes payable, net of current portion 68,886 $ 14,860
Notes Payable    
Debt Instrument [Line Items]    
Remainder of 2023 4,545  
2024 6,049  
2025 13,680  
2026 15,437  
2027 14,532  
2028 41,990  
Total payments due 96,233  
Interest payments, loan discounts and financing costs (27,347)  
Current portion, less loan discounts and financing costs 0  
Notes payable, net of current portion $ 68,886  
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.23.1
Equity and Stock Compensation Plans (Narrative) (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 21, 2023
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Purchase shares of common stock, par value (in dollars per share)   $ 0.00005 $ 0.00005
IsoPlexis Warrant      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Purchase shares of common stock, par value (in dollars per share) $ 0.001    
PhenomeX Warrant      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Conversion ratio 0.612    
Purchase shares of common stock, par value (in dollars per share) $ 0.00005    
PhenomeX Warrant | Common Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Warrant exercisable shares (in shares) | shares 496,560    
Warrant exercise price per share (in dollars per share) $ 9.80    
IsoPlexis      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Conversion ratio 0.612    
Exercise price per share (in dollars per share) $ 1.28    
Stock-based compensation | $   $ 0.1  
IsoPlexis | Share-Based Payment Arrangement, Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting rights, percentage 25.00%    
Vesting period 1 year    
IsoPlexis | Share-Based Payment Arrangement, Tranche Two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 36 months    
IsoPlexis | RSAs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Conversion ratio 0.612    
Business acquisition, equity instruments other than options, number of shares acquired (in shares) | shares 304,619    
IsoPlexis | Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Conversion ratio 0.612    
Expiration period 10 years    
Business acquisition, options, number of shares acquired (in shares) | shares 378,767    
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.23.1
Equity and Stock Compensation Plans - Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 4,388 $ 5,393
Cost of sales    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation 16 51
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation 548 1,581
Selling, general and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 3,824 $ 3,761
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restructuring and Related Activities [Abstract]    
Restructuring charges $ 1,290 $ 0
Total full-time employees (in percent) 16.00%  
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring - Changes in Restructuring Liability (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restructuring Reserve [Roll Forward]    
Restructuring liability, beginning balance $ 237  
Restructuring liability assumed in IsoPlexis Merger 834  
Restructuring charges 1,290 $ 0
Cash payments (1,117)  
Non-cash settlements 0  
Restructuring liability, ending balance 1,244  
Employee severance and termination benefits    
Restructuring Reserve [Roll Forward]    
Restructuring liability, beginning balance 130  
Restructuring liability assumed in IsoPlexis Merger 834  
Restructuring charges 1,290  
Cash payments (1,010)  
Non-cash settlements 0  
Restructuring liability, ending balance 1,244  
Non labor restructuring    
Restructuring Reserve [Roll Forward]    
Restructuring liability, beginning balance 107  
Restructuring liability assumed in IsoPlexis Merger 0  
Restructuring charges 0  
Cash payments (107)  
Non-cash settlements 0  
Restructuring liability, ending balance $ 0  
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 20 $ 20
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash paid for interest $ 439 $ 137
Cash paid for income taxes 19 0
Non-cash investing and financing activities    
Non-cash consideration for the acquisition of IsoPlexis 32,406 0
Property and equipment transferred to inventory 352 0
Customer return of Beacon transferred to property and equipment 201 0
Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 684 $ 482
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.23.1
Commitment and Contingencies - Narrative (Details)
 1 Months Ended 3 Months Ended
Jul. 01, 2021
claim
patent
Dec. 31, 2021
investedCompany
Mar. 31, 2023
USD ($)
Loss Contingencies [Line Items]      
Number of company invested | investedCompany   3  
Loss contingency accrual     $ 0
Purchase obligations     $ 29,700,000
Product warranty, term     1 year
AbCellera and UBC      
Loss Contingencies [Line Items]      
Case management order, maximum number of patents allegedly infringed | patent 2    
Case management order, maximum asserted patent claims per patent | claim 4    
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.23.1
Commitment and Contingencies - Product Warranty (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Movement in Standard Product Warranty Accrual [Roll Forward]    
Balance, beginning of period $ 749 $ 1,085
Warranty accrual assumed in IsoPlexis Merger 128 0
Adjustments to existing warranties (111) (245)
Provision for new warranties 133 163
Settlement of pre-existing warranties (111) (89)
Balance, end of period $ 788 $ 914
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator    
Net loss attributable to common stockholders, basic $ (23,419) $ (21,426)
Net loss attributable to common stockholders, diluted $ (23,419) $ (21,426)
Denominator    
Weighted-average shares used to compute net income per share, basic (in shares) 75,759,771 67,697,488
Weighted-average shares used to compute net income per share, diluted (in shares) 75,759,771 67,697,488
Net loss per share    
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.31) $ (0.32)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.31) $ (0.32)
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from the calculation of net loss per share (in shares) 13,990,891 10,649,901
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from the calculation of net loss per share (in shares) 496,560 0
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from the calculation of net loss per share (in shares) 7,685,997 7,020,591
Restricted stock awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from the calculation of net loss per share (in shares) 290,846 0
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from the calculation of net loss per share (in shares) 5,517,488 3,629,310
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.23.1
Segments (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]    
Number of operating segments | segment 1  
Total revenue $ 18,516 $ 20,206
North America    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total revenue 14,055 13,715
Asia Pacific    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total revenue 3,147 5,035
Europe    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total revenue $ 1,314 $ 1,456
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - USD ($)
$ in Millions
 3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Subsequent Event [Line Items]    
Total full-time employees (in percent)   16.00%
Forecast    
Subsequent Event [Line Items]    
Total full-time employees (in percent) 12.00%  
Severance and employee-related restructuring costs $ 0.8  
XML 100 bli-20230331_htm.xml IDEA: XBRL DOCUMENT 0001689657 2023-01-01 2023-03-31 0001689657 2023-04-30 0001689657 2023-03-31 0001689657 2022-12-31 0001689657 us-gaap:ProductMember 2023-01-01 2023-03-31 0001689657 us-gaap:ProductMember 2022-01-01 2022-03-31 0001689657 bli:ServiceAndOtherMember 2023-01-01 2023-03-31 0001689657 bli:ServiceAndOtherMember 2022-01-01 2022-03-31 0001689657 2022-01-01 2022-03-31 0001689657 us-gaap:CommonStockMember 2022-12-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001689657 us-gaap:RetainedEarningsMember 2022-12-31 0001689657 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001689657 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001689657 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001689657 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001689657 us-gaap:CommonStockMember 2023-03-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001689657 us-gaap:RetainedEarningsMember 2023-03-31 0001689657 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001689657 us-gaap:CommonStockMember 2021-12-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001689657 us-gaap:RetainedEarningsMember 2021-12-31 0001689657 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001689657 2021-12-31 0001689657 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001689657 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001689657 us-gaap:CommonStockMember 2022-03-31 0001689657 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001689657 us-gaap:RetainedEarningsMember 2022-03-31 0001689657 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001689657 2022-03-31 0001689657 2023-03-03 2023-03-03 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2023-03-20 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2023-03-21 0001689657 bli:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember 2023-03-21 2023-03-21 0001689657 bli:EWBTermLoanMember 2023-03-31 0001689657 us-gaap:LetterOfCreditMember 2023-03-31 0001689657 us-gaap:ResearchMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember 2022-12-31 0001689657 us-gaap:CommercialPaperMember 2022-12-31 0001689657 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001689657 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 bli:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001689657 bli:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001689657 bli:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001689657 bli:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001689657 bli:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001689657 bli:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001689657 bli:IsoPlexisMember 2023-03-21 0001689657 bli:IsoPlexisMember 2023-03-21 2023-03-21 0001689657 2023-03-21 0001689657 bli:IsoPlexisMember us-gaap:PatentedTechnologyMember 2023-03-21 0001689657 bli:IsoPlexisMember us-gaap:CustomerRelationshipsMember 2023-03-21 0001689657 bli:IsoPlexisMember us-gaap:TrademarksAndTradeNamesMember 2023-03-21 0001689657 srt:MinimumMember bli:IsoPlexisMember 2023-03-21 2023-03-21 0001689657 srt:MaximumMember bli:IsoPlexisMember 2023-03-21 2023-03-21 0001689657 bli:IsoPlexisMember 2023-01-01 2023-03-31 0001689657 bli:IsoPlexisMember 2022-10-01 2022-12-31 0001689657 bli:IsoPlexisMember 2022-01-01 2022-03-31 0001689657 bli:IsoPlexisMember bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2023-03-21 2023-03-21 0001689657 us-gaap:AcquisitionRelatedCostsMember 2023-03-31 0001689657 bli:PartnershipLicenseAndOtherMember bli:ServiceAndOtherMember bli:IsoPlexisMember 2023-01-01 2023-03-31 0001689657 bli:PlatformMember us-gaap:ProductMember 2023-01-01 2023-03-31 0001689657 bli:PlatformMember bli:ServiceAndOtherMember 2023-01-01 2023-03-31 0001689657 bli:PlatformMember 2023-01-01 2023-03-31 0001689657 bli:RecurringMember us-gaap:ProductMember 2023-01-01 2023-03-31 0001689657 bli:RecurringMember bli:ServiceAndOtherMember 2023-01-01 2023-03-31 0001689657 bli:RecurringMember 2023-01-01 2023-03-31 0001689657 bli:PartnershipLicenseAndOtherMember us-gaap:ProductMember 2023-01-01 2023-03-31 0001689657 bli:PartnershipLicenseAndOtherMember bli:ServiceAndOtherMember 2023-01-01 2023-03-31 0001689657 bli:PartnershipLicenseAndOtherMember 2023-01-01 2023-03-31 0001689657 bli:PlatformMember us-gaap:ProductMember 2022-01-01 2022-03-31 0001689657 bli:PlatformMember bli:ServiceAndOtherMember 2022-01-01 2022-03-31 0001689657 bli:PlatformMember 2022-01-01 2022-03-31 0001689657 bli:RecurringMember us-gaap:ProductMember 2022-01-01 2022-03-31 0001689657 bli:RecurringMember bli:ServiceAndOtherMember 2022-01-01 2022-03-31 0001689657 bli:RecurringMember 2022-01-01 2022-03-31 0001689657 bli:PartnershipLicenseAndOtherMember us-gaap:ProductMember 2022-01-01 2022-03-31 0001689657 bli:PartnershipLicenseAndOtherMember bli:ServiceAndOtherMember 2022-01-01 2022-03-31 0001689657 bli:PartnershipLicenseAndOtherMember 2022-01-01 2022-03-31 0001689657 2023-04-01 2023-03-31 0001689657 bli:AccountsReceivableAfterAllowanceForCreditLossCurrentMember 2023-03-31 0001689657 bli:EvorionBiotechnologiesMember 2023-02-15 2023-02-15 0001689657 bli:EvorionBiotechnologiesMember bli:PatentsAndTechnologyMember 2023-02-15 2023-02-15 0001689657 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0001689657 us-gaap:CustomerRelationshipsMember 2023-03-31 0001689657 us-gaap:TradeNamesMember 2023-01-01 2023-03-31 0001689657 us-gaap:TradeNamesMember 2023-03-31 0001689657 us-gaap:PatentedTechnologyMember 2023-01-01 2023-03-31 0001689657 us-gaap:PatentedTechnologyMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001689657 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001689657 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-03-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001689657 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001689657 bli:EquipmentToolingAndMoldsMember 2023-03-31 0001689657 bli:EquipmentToolingAndMoldsMember 2022-12-31 0001689657 us-gaap:ComputerEquipmentMember 2023-03-31 0001689657 us-gaap:ComputerEquipmentMember 2022-12-31 0001689657 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001689657 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001689657 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001689657 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001689657 us-gaap:ConstructionInProgressMember 2023-03-31 0001689657 us-gaap:ConstructionInProgressMember 2022-12-31 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2018-05-23 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2021-06-30 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2021-06-30 2021-06-30 0001689657 us-gaap:NotesPayableToBanksMember 2023-01-01 2023-03-31 0001689657 us-gaap:NotesPayableToBanksMember 2023-03-31 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember 2023-03-21 2023-03-21 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember us-gaap:PrimeRateMember 2023-03-21 0001689657 bli:EWBTermLoanMember us-gaap:NotesPayableToBanksMember us-gaap:PrimeRateMember 2023-03-21 2023-03-21 0001689657 us-gaap:RestrictedStockUnitsRSUMember bli:IsoPlexisMember 2023-03-21 0001689657 us-gaap:EmployeeStockOptionMember bli:IsoPlexisMember 2023-03-21 0001689657 us-gaap:EmployeeStockOptionMember bli:IsoPlexisMember 2023-03-21 2023-03-21 0001689657 bli:IsoPlexisMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-03-21 2023-03-21 0001689657 bli:IsoPlexisMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-03-21 2023-03-21 0001689657 us-gaap:RestrictedStockUnitsRSUMember bli:IsoPlexisMember 2023-03-21 2023-03-21 0001689657 bli:IsoPlexisWarrantMember 2023-03-21 0001689657 bli:PhenomeXWarrantMember 2023-03-21 0001689657 bli:PhenomeXWarrantMember us-gaap:CommonStockMember 2023-03-21 0001689657 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001689657 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001689657 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001689657 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001689657 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001689657 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001689657 bli:EmployeeSeveranceAndTerminationMember 2022-12-31 0001689657 bli:NonLaborRestructuringCostsMember 2022-12-31 0001689657 bli:EmployeeSeveranceAndTerminationMember 2023-01-01 2023-03-31 0001689657 bli:NonLaborRestructuringCostsMember 2023-01-01 2023-03-31 0001689657 bli:EmployeeSeveranceAndTerminationMember 2023-03-31 0001689657 bli:NonLaborRestructuringCostsMember 2023-03-31 0001689657 bli:AbCelleraAndUBCMember 2021-07-01 2021-07-01 0001689657 2021-12-01 2021-12-31 0001689657 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001689657 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001689657 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001689657 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001689657 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001689657 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001689657 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001689657 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001689657 srt:NorthAmericaMember 2023-01-01 2023-03-31 0001689657 srt:NorthAmericaMember 2022-01-01 2022-03-31 0001689657 srt:AsiaPacificMember 2023-01-01 2023-03-31 0001689657 srt:AsiaPacificMember 2022-01-01 2022-03-31 0001689657 srt:EuropeMember 2023-01-01 2023-03-31 0001689657 srt:EuropeMember 2022-01-01 2022-03-31 0001689657 srt:ScenarioForecastMember 2023-04-01 2023-06-30 0001689657 srt:ScenarioForecastMember 2023-06-30 shares iso4217:USD iso4217:USD shares pure bli:patent bli:claim bli:investedCompany bli:segment 0001689657 --12-31 2023 Q1 false P8Y http://berkeleylights.com/20230331#AccruedLiabilitiesAndOtherLiabilitiesCurrent http://berkeleylights.com/20230331#AccruedLiabilitiesAndOtherLiabilitiesCurrent 10-Q true 2023-03-31 false 001-39388 PhenomeX Inc. DE 35-2415390 5858 Horton Street, Suite 320 Emeryville CA 94608 510 858-2855 Common stock, $0.00005 par value CELL NASDAQ Yes Yes Non-accelerated Filer true false false 98795621 51606000 86522000 0 46252000 25119000 18534000 45539000 18861000 9378000 6783000 131642000 176952000 70093000 0 33842000 23847000 27449000 23326000 12246000 0 23072000 0 2217000 1969000 300561000 226094000 17051000 10092000 19645000 21340000 0 4966000 10746000 9092000 47442000 45490000 68886000 14860000 1259000 963000 25234000 22726000 142821000 84039000 0.00005 0.00005 300000000 300000000 98744915 98744915 72169052 72169052 5000 4000 542805000 503708000 -385067000 -361648000 -3000 -9000 157740000 142055000 300561000 226094000 8378000 9774000 10138000 10432000 18516000 20206000 3912000 2695000 1176000 3684000 5088000 6379000 13428000 13827000 8421000 17573000 26547000 17527000 1290000 0 36258000 35100000 -22830000 -21273000 384000 224000 827000 34000 -1012000 57000 -23399000 -21406000 20000 20000 -23419000 -21426000 -0.31 -0.31 -0.32 -0.32 75759771 75759771 67697488 67697488 -23419000 -21426000 -3000 0 9000 0 6000 0 -23413000 -21426000 72169052 4000 503708000 -361648000 -9000 142055000 24945611 1000 31929000 31930000 306000 306000 170000 170000 78359 29000 29000 285129 121863 166000 166000 1144901 2107000 2107000 4390000 4390000 9000 9000 -3000 -3000 -23419000 -23419000 98744915 5000 542805000 -385067000 -3000 157740000 67595535 4000 471820000 -263608000 0 208216000 81654 412000 412000 27580 115346 610000 610000 5389000 5389000 -21426000 -21426000 67820115 4000 478231000 -285034000 0 193201000 1.84 -23419000 -21426000 2100000 1944000 4388000 5393000 2107000 0 852000 735000 16000 16000 173000 0 -162000 0 151000 28000 -6000 0 638000 0 3684000 -8221000 -964000 1122000 -1865000 -2057000 5373000 298000 551000 -2935000 -9660000 -2552000 -860000 -726000 -19553000 -10069000 414000 4375000 2451000 0 36749000 0 12400000 0 264000 0 40285000 0 5735000 -4375000 20000000 0 70000000 0 1200000 0 29000 412000 166000 610000 48995000 1022000 35177000 -13422000 86522000 178366000 121699000 164944000 The Company and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PhenomeX Inc. (the “Company” or “PhenomeX”) is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PhenomeX and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2023, the Company had a consolidated net loss of $23.4 million and as of March 31, 2023 had an accumulated deficit of $385.1 million. Cash, cash equivalents and marketable securities were $51.6 million as of March 31, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, the Company acquired IsoPlexis which also had experienced losses since its inception, and entered into the second amended and restated credit agreement with East West Bank (“EWB”), which increased the Company’s term loan with EWB from $20.0 million to $70.0 million, of which $52.5 million (including prepayment premium and interest) was used to repay indebtedness of IsoPlexis. The second amended and restated credit agreement with EWB requires the Company to maintain $70.0 million of cash in a deposit account with EWB that is assigned to EWB. This deposit is recorded as restricted cash on the Company’s condensed consolidated balance sheet. See Note 12 for additional information on our second amended and restated credit agreement with EWB including the covenants contained therein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustment that might result if the Company is unable to continue as a going concern. </span></div>Management’s intent is to implement plans that will allow the Company to continue as a going concern. The Company intends to improve operating cash flow by increasing its revenue and lowering its operational costs. New commercial leadership, geographic expansion, and a refined product roadmap are expected to drive revenue growth, and significant cost synergies as a result of the IsoPlexis Merger and are expected to lower operating expenses. Cost synergies are expected to be accomplished by eliminating duplicative costs associated with maintaining the infrastructure needed by public companies, complementary R&amp;D capabilities, marketing resources and sales operations, and manufacturing, supply chain, logistics and operations synergies. In addition, the Company is evaluating financing options including the potential to raise equity and debt financing. While management is focused on these efforts, there can be no assurance that the Company will be successful in doing so. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights. </span></div>The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. -23400000 -385100000 51600000 20000000 70000000 52500000 70000000 Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Updates to those policies are below, including updates related to the IsoPlexis Merger. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86,522 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivables and Allowance for Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency translation and transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Research and development state tax credits</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) tax credits exchanged for cash pursuant to the Connecticut R&amp;D Tax Credit Exchange Program, which permits a qualified small business engaged in R&amp;D activities within Connecticut to exchange its unused R&amp;D tax credits for a cash amount equal to 65% of the value of exchanged credits, are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">recorded as a receivable and other income in the year the R&amp;D tax credits relate to, as it is reasonably assured that the R&amp;D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&amp;D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets. The Company has recorded $0.2 million of R&amp;D tax credits receivable as of March 31, 2023.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. </span></div>The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer. 70000000 100000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86,522 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86,522 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 45015000 63596000 6591000 22926000 70093000 0 121699000 86522000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivables and Allowance for Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed </span></div>within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency translation and transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Research and development state tax credits</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) tax credits exchanged for cash pursuant to the Connecticut R&amp;D Tax Credit Exchange Program, which permits a qualified small business engaged in R&amp;D activities within Connecticut to exchange its unused R&amp;D tax credits for a cash amount equal to 65% of the value of exchanged credits, are </span></div>recorded as a receivable and other income in the year the R&amp;D tax credits relate to, as it is reasonably assured that the R&amp;D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&amp;D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets. 200000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity.</span></div> Marketable Securities<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Marketable Securities</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may invest in available-for-sale marketable debt securities generally consisting of commercial paper and U.S. government securities with contractual maturities due within one year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities reported as Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities reported as Short-term Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term marketable securities at December 31, 2022 were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See Note 9 for information about the fair value of the Company’s short-term marketable securities.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities reported as Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities reported as Short-term Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term marketable securities at December 31, 2022 were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6591000 0 0 6591000 6591000 0 0 6591000 2354000 0 0 2354000 16606000 0 4000 16602000 3969000 1000 0 3970000 0 0 0 0 22929000 1000 4000 22926000 22158000 1000 11000 22148000 4941000 1000 0 4942000 19159000 5000 2000 19162000 46258000 7000 13000 46252000 Significant Risks and Uncertainties Including Business and Credit Concentrations<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in financial institutions may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any material realized losses on its deposits of cash, cash equivalents and marketable securities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At March 31, 2023, the Company recorded an allowance for doubtful accounts of $0.9 million. At December 31, 2022 , the Company had not recorded any material allowance for doubtful accounts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, three customers accounted for 39%, 10% and 10% of revenue. For the three months ended March 31, 2022, three customers accounted for 18%, 13% and 10% of revenue. </span></div>As of March 31, 2023, three customers comprised 25%, 14% and 12% of accounts receivable. As of December 31, 2022, two customers accounted for 24% and 11% of accounts receivable. 900000 0.39 0.10 0.10 0.18 0.13 0.10 0.25 0.14 0.12 0.24 0.11 Business Combinations<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IsoPlexis Merger</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, the Company completed the IsoPlexis Merger. Under the terms of the Merger Agreement, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which was automatically converted into shares of PhenomeX common stock). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consideration Transferred</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:78.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of PhenomeX common stock issued to IsoPlexis stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Repayment of IsoPlexis debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of vested IsoPlexis options attributable to pre-merger service </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of IsoPlexis warrant at Acquisition Date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total purchase consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for the IsoPlexis Merger as a business combination. The identifiable assets acquired and liabilities assumed were recorded at their preliminary fair values as of the Acquisition Date and are consolidated into our financial statements. The assignment of fair market value requires significant judgments regarding the estimates and assumptions used to value the acquired assets and liabilities assumed. For the preliminary fair values of the assets acquired and liabilities assumed, we utilized the cost, income and market approaches from the perspective of a market participant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84,888 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Acquired Receivables</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of assets acquired includes accounts receivable of $3.1 million, which is net of an associated allowance for credit losses of $0.7 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of inventory acquired was $27.3 million, which included a step up of $4.9 million from the book value as a result of the valuation at the Acquisition Date. The original cost basis of the inventory acquired from IsoPlexis was $22.4 million, which was net of a reserve for excess and obsolete inventory of $15.4 million. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible assets includes $11.7 million of patented technology, $7.7 million of customer relationships and $3.5 million of IsoPlexis trade names and trademarks. The intangible assets will be amortized over their respective useful lives which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1MDE0MmQyOTVkMTRmOGU4NTA5YTFmMGVjM2I5OTAxL3NlYzphNTAxNDJkMjk1ZDE0ZjhlODUwOWExZjBlYzNiOTkwMV8zODQvZnJhZzo0MTNiNzZjZDZmMWM0ZjU1YjZiZTYxZGE3ZTQ2Yzg4OS90ZXh0cmVnaW9uOjQxM2I3NmNkNmYxYzRmNTViNmJlNjFkYTdlNDZjODg5XzEwOTk1MTE2NjI2MTk_6b57eae2-dceb-4668-ac87-5d779bde7bec">eight</span> to fourteen years. Goodwill with a provisional assigned value of $12.2 million represents the excess of the consideration transferred over the estimated fair values of assets and liabilities assumed. None of the goodwill resulting from the IsoPlexis Merger is deductible for tax purposes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Transaction Costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recognized transaction costs associated with the IsoPlexis Merger of $3.5 million for the three months ended March 31, 2023 plus $2.8 million which was recognized in the fourth quarter of 2022. These costs are primarily related to professional services and are recorded in “Selling, general, and administrative” expenses in the Company’s condensed consolidated statement of operations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Pro Forma Information</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(66,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(50,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pro forma adjustments consisted of:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Amortization/Depreciation- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tangible and intangible assets are assumed to be recorded at their assigned fair values as of January 1, 2022. Historical depreciation and amortization for IsoPlexis has been removed and the new fair values of the assets are depreciated or amortized over their estimated useful lives.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Interest Expense-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Entry into the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Second Amended Term Loan and repayment of the Perceptive Credit Agreement are assumed to have occurred on January 1, 2022. Historical interest expense has been removed and replaced with the applicable interest rate as of March 21, 2023 associated with the Second Amended Term Loan, which was 8.5%.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Transaction costs- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Both entities incurred transaction costs, which totaled $13.7 million. Of the $13.7 million, approximately $4.4 million was incurred in the first quarter of 2023 and has been eliminated as it is not recurring.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting policies adjustment- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IsoPlexis historically classified certain operations, quality and facility related costs in selling, general and administrative expenses. To align with PhenomeX accounting policies, these costs were reclassified to costs of goods sold or research and development. However, since this is a reclassification between expense line items on the statement of operations, the adjustment does not have an impact on revenue or net loss for purposes of the pro forma financial information disclosed above.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the period subsequent to the Acquisition Date, IsoPlexis contributed total revenues and operating loss of $1.0 million and $1.1 million, respectively, for the three months ended March 31, 2023, that were included in the Company’s Condensed Consolidated Statements of Operations. In addition, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (See Note 6 for additional information).</span></div> 0.612 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:78.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of PhenomeX common stock issued to IsoPlexis stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Repayment of IsoPlexis debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of vested IsoPlexis options attributable to pre-merger service </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value of IsoPlexis warrant at Acquisition Date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total purchase consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).</span></div> 84900000 31930000 52482000 306000 170000 84888000 24945611 1.28 0.612 50000000 The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">98,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84,888 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12197000 3075000 27287000 4190000 11206000 22900000 12246000 4975000 526000 98602000 2367000 4912000 1399000 5036000 13714000 84888000 3100000 700000 27300000 4900000 22400000 15400000 11700000 7700000 3500000 P14Y 12200000 0 3500000 2800000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(66,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(50,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 20170000 25117000 -66463000 -50419000 0.085 13700000 13700000 4400000 1000000 -1100000 7300000 Revenue From Contracts With Customers<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s revenue consists of both product revenue and service and other revenue, which is primarily generated through the following revenue streams: (i) platform, (ii) recurring and (iii) partnership, license and other.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company in the first quarter entered into a license arrangement whereby certain patents were licensed to a third party and for which the customer agreed to pay a non-refundable fee. For licenses of intellectual property the Company recognizes revenue from non-refundable fees when the license is transferred to the customer and the customer is able to use and benefit from the license. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:19.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Income Statement Classification</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Product or Service sold</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Revenue Stream</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Product revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Software and workflow licenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Fixed term sales-type lease arrangements with qualified customers</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consumables and reagent kits (e.g. OptoSelect chips)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Service and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Partnership, License and Other</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Application support, installation and training</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Fixed fee extended warranty and service programs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IP license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Partnership, License and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables provide information by revenue stream for the periods presented: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service and other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recurring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Partnership, License and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,378 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,516 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.726%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service and other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recurring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Partnership, License and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,774 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenues by geographical markets are presented in Note 19. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2023, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as $12.0 million, which, to the extent invoiced, is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 50% is e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">xpected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract assets, which are included in “Prepaid expenses and other current assets”</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract assets, long-term, which are included in “Other assets”</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue (current)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,746 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue (non-current)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of $12.0 million and $10.1 million as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of March 31, 2023 and December 31, 2022, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2023 i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ncluded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of previously deferred revenue that was included in contract liabilities as of December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sales-type Lease Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three months ended March 31, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales-Type<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total undiscounted cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: unearned income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total amounts due from customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.</span></div>(2) Of the $1.0 million, $0.1 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:19.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Income Statement Classification</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Product or Service sold</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Revenue Stream</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Product revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Software and workflow licenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Fixed term sales-type lease arrangements with qualified customers</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Consumables and reagent kits (e.g. OptoSelect chips)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Service and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Partnership, License and Other</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Application support, installation and training</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Platform</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Fixed fee extended warranty and service programs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recurring</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IP license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Partnership, License and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables provide information by revenue stream for the periods presented: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service and other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recurring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Partnership, License and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,378 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,516 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.726%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service and other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recurring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Partnership, License and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,774 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 5773000 330000 6103000 2605000 2558000 5163000 0 7250000 7250000 8378000 10138000 18516000 7300000 7300000 7300000 6747000 657000 7404000 3027000 2416000 5443000 0 7359000 7359000 9774000 10432000 20206000 12000000 0.50 P12M <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract assets, which are included in “Prepaid expenses and other current assets”</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract assets, long-term, which are included in “Other assets”</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue (current)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,746 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred revenue (non-current)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25119000 18534000 367000 1283000 514000 549000 10746000 9092000 1259000 963000 12000000 10100000 2800000 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales-Type<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total undiscounted cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: unearned income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total amounts due from customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.</span></div>(2) Of the $1.0 million, $0.1 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets. 334000 445000 408000 0 1187000 171000 1016000 800000 600000 1000000 100000 Balance Sheet Accounts<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade accounts receivable, net consists of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,119 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in the allowance for doubtful accounts were as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(894)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of inventory (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,816 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of prepaid expenses and other current assets (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vendor deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,378 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,783 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of accrued expenses and other current liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1MDE0MmQyOTVkMTRmOGU4NTA5YTFmMGVjM2I5OTAxL3NlYzphNTAxNDJkMjk1ZDE0ZjhlODUwOWExZjBlYzNiOTkwMV80OS9mcmFnOjhmYzczNjNhNTE3YzRmMDBhNDAxN2I0MWU0ODUwNmYzL3RhYmxlOmFjODZhMWQ0NTFjODQ5OTFiNmFiZjM4YzZiNTgzZjE1L3RhYmxlcmFuZ2U6YWM4NmExZDQ1MWM4NDk5MWI2YWJmMzhjNmI1ODNmMTVfMy0wLTEtMS04ODYwNw_c84957bb-7566-4ff8-a5c4-c359d4025fae"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1MDE0MmQyOTVkMTRmOGU4NTA5YTFmMGVjM2I5OTAxL3NlYzphNTAxNDJkMjk1ZDE0ZjhlODUwOWExZjBlYzNiOTkwMV80OS9mcmFnOjhmYzczNjNhNTE3YzRmMDBhNDAxN2I0MWU0ODUwNmYzL3RhYmxlOmFjODZhMWQ0NTFjODQ5OTFiNmFiZjM4YzZiNTgzZjE1L3RhYmxlcmFuZ2U6YWM4NmExZDQ1MWM4NDk5MWI2YWJmMzhjNmI1ODNmMTVfMy0wLTEtMS04ODYwNw_e1c8237e-bf12-484c-8055-7743781debda">Lease liability – short-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued product warranty</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,645 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,340 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade accounts receivable, net consists of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,119 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 26013000 18534000 894000 0 25119000 18534000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in the allowance for doubtful accounts were as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(894)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 0 721000 0 173000 894000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of inventory (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,816 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 32816000 11946000 1106000 0 11617000 6915000 45539000 18861000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of prepaid expenses and other current assets (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contract asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vendor deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,378 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,783 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.</span></div> 367000 1283000 421000 126000 365000 472000 3534000 2025000 4691000 2877000 9378000 6783000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows the components of accrued expenses and other current liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1MDE0MmQyOTVkMTRmOGU4NTA5YTFmMGVjM2I5OTAxL3NlYzphNTAxNDJkMjk1ZDE0ZjhlODUwOWExZjBlYzNiOTkwMV80OS9mcmFnOjhmYzczNjNhNTE3YzRmMDBhNDAxN2I0MWU0ODUwNmYzL3RhYmxlOmFjODZhMWQ0NTFjODQ5OTFiNmFiZjM4YzZiNTgzZjE1L3RhYmxlcmFuZ2U6YWM4NmExZDQ1MWM4NDk5MWI2YWJmMzhjNmI1ODNmMTVfMy0wLTEtMS04ODYwNw_c84957bb-7566-4ff8-a5c4-c359d4025fae"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1MDE0MmQyOTVkMTRmOGU4NTA5YTFmMGVjM2I5OTAxL3NlYzphNTAxNDJkMjk1ZDE0ZjhlODUwOWExZjBlYzNiOTkwMV80OS9mcmFnOjhmYzczNjNhNTE3YzRmMDBhNDAxN2I0MWU0ODUwNmYzL3RhYmxlOmFjODZhMWQ0NTFjODQ5OTFiNmFiZjM4YzZiNTgzZjE1L3RhYmxlcmFuZ2U6YWM4NmExZDQ1MWM4NDk5MWI2YWJmMzhjNmI1ODNmMTVfMy0wLTEtMS04ODYwNw_e1c8237e-bf12-484c-8055-7743781debda">Lease liability – short-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued product warranty</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,645 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,340 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.</span></div> 6611000 7410000 4958000 3291000 788000 749000 5499000 8271000 1789000 1619000 19645000 21340000 Goodwill and Other Intangible Assets<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, the Company completed the IsoPlexis Merger. Under the purchase method of accounting, the Company preliminarily recorded the $12.2 million excess of the Acquisition Date fair value of the consideration transferred over the estimated fair value of net tangible and identifiable intangible assets that it acquired as goodwill. At March 31, 2023, the carrying amount of this goodwill was $12.2 million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. The Company considered such sustained decrease to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Based on the results of the quantitative goodwill impairment test, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2023. In future periods, if the Company were to experience a further decline in its market capitalization or expected results for a sustained period of time, the Company may be required to perform an additional quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the IsoPlexis Merger, the Company identified certain intangible assets summarized in the table below (see Note 5 for further information). In addition, on February 15, 2023, the Company acquired certain tangible and intangible assets from Evorion Biotechnologies for a total purchase price of $0.3 million, of which $0.2 million related to intangible assets attributable to patents and technology. These intangible assets are also included in the table below. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Remaining Useful Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,695 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patented technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,111 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense was $39,000 for the three months ended March 31, 2023. In connection with the License Agreement, the Company reviewed the patented technology intangible for indicators of impairment, noting that the patented technology was valued using the relief from royalty approach based on projected revenues from products and services of IsoPlexis, which did not contemplate the License Agreement. In addition, the Company still owns, and retains certain rights to, the intellectual property that was licensed under the License Agreement. Accordingly the Company concluded that an impairment was not necessary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 12200000 12200000 300000 200000 These intangible assets are also included in the table below. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Remaining Useful Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,695 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patented technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,111 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,072 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P8Y 7700000 5000 7695000 P10Y 3500000 11000 3489000 P14Y 11911000 23000 11888000 23111000 39000 23072000 39000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1689000 2163000 2163000 2163000 2163000 Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a description of the valuation techniques the Company uses to measure the fair value of assets and reports fair value on a recurring basis:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Cash equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> At March 31, 2023, the Company’s cash equivalents consisted of money market funds. Money market funds are highly liquid investments and are actively traded and pricing information is readily available. Accordingly, the Company classifies these securities as Level 1 of the fair value hierarchy. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Short Term Marketable Securities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At March 31, 2023, the Company did not hold any short term marketable securities. Generally, the Company values short-term marketable securities using quoted prices in active markets for similar instruments. Accordingly, the Company classifies marketable securities as Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of March 31, 2023 and December 31, 2022 approximate fair value due to their relatively short maturities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Debt securities, available for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total debt securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,178 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66,824 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,826 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,591 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Debt securities, available for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total debt securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,178 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66,824 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6591000 6591000 0 0 6591000 6591000 0 0 2354000 2354000 0 0 16602000 0 16602000 0 3970000 0 3970000 0 22926000 2354000 20572000 0 22148000 0 22148000 0 4942000 0 4942000 0 19162000 0 19162000 0 46252000 0 46252000 0 69178000 2354000 66824000 0 <div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,826 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 68886000 70000000 19826000 17443000 Property and Equipment, net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net comprised the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment, tooling and molds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,093 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">53,071 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(29,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br/>Depreciation expense for the three months ended March 31, 2023 and 2022 was $2.1 million and $1.9 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022 losses on the impairment and disposal of property and equipment were not material.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net comprised the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment, tooling and molds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,093 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">53,071 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(29,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.</span></div> 47577000 36152000 8037000 2667000 2600000 2007000 12509000 10836000 1370000 1409000 72093000 53071000 38251000 29224000 33842000 23847000 100000 100000 2100000 1900000 Leases<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company leases office, manufacturing, distribution and laboratory facilities in various locations in the United States, primarily in Emeryville, California and Branford, Connecticut. The Company also leases facilities in Shanghai, China for office and laboratory facilities. On December 28, 2022, the Company entered into a sub-lease arrangement for its facility in Lexington, Massachusetts. Sub-lease income for the three months ended March 31, 2023 was $0.1 million and was recorded as an offset to rent expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Undiscounted lease payments for the year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: implied interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: tenant improvement allowances receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”</span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rent expense, net for the three months ended March 31, 2023 and 2022 was $0.9 million and $1.1 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.8 million and $0.8 million for the three months ended March 31, 2023 and 2022, respectively, including non-lease components such as common area maintenance fees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained for new operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use lease assets assumed in IsoPlexis Merger</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,975 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>The Company also enters into leasing transactions in which the Company is the lessor, which to date have been classified as sales-type leases. See Note 6 for the related lease disclosures. 100000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Undiscounted lease payments for the year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: implied interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: tenant improvement allowances receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”</span></div> 4691000 6297000 5952000 5398000 4759000 7464000 34561000 4304000 65000 30192000 4958000 25234000 900000 1100000 800000 800000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained for new operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use lease assets assumed in IsoPlexis Merger</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,975 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 4975000 0 989000 1098000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P5Y8M15D P6Y5M23D 0.0473 0.0466 Long-term Debt<div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 23, 2018, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with EWB to provide a $20.0 million term loan facility (“Term Loan”). The loan facility was fully drawn as of May 23, 2018.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (“Amended Loan Agreement”) with EWB. Pursuant to the Amended Loan Agreement, EWB provided a $20.0 million term loan (“Amended Term Loan”) which was used to refinance the Term Loan outstanding under the Loan Agreement dated May 23, 2018. The Amended Term Loan had a maturity of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> months and a fixed interest rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.17%</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition, the Amended Term Loan had an initial interest-only period of 24 months, which could have been extended to up to 36 months based on the achievement of certain liquidity measures, and could have been pre-paid without penalty at any time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, the Company entered into a Second Amended and Restated Loan and Security Agreement (“Second Amended Loan Agreement”) with EWB. Pursuant to the Second Amended Loan Agreement, EWB increased the existing Amended Term Loan amount of $20.0 million by $50.0 million to an aggregate outstanding principal of $70.0 million (“Second Amended Term Loan”). The Company used the proceeds from the Second Amended Term Loan to repay $52.5 million of indebtedness (including prepayment premium and interest) with Perceptive held by IsoPlexis (“Perceptive Credit Agreement”). Associated with these transactions, a $0.2 million loss on extinguishment of debt and a $0.7 million commitment fee associated with the Loan Agreement, was recorded in Other expense, net on our condensed consolidated statement of operations during the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Second Amended Term Loan has a maturity of 60 months and bears interest at a variable rate per annum equal to (i) the greater of 6.25% or the variable rate of interest, per annum, most recently announced by EWB as its prime rate, plus (ii) one-half of one percent (0.5%). In addition, the Second Amended Term Loan has an initial interest-only period of 24 months, which can be extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Second Amended Loan Agreement are satisfied. The Second Amended Term loan carries a prepayment penalty equal to one percent (1%) of the amount of any prepayment of the outstanding balance, if the prepayment is made before the first anniversary of the loan closing date. The Second Amended Loan Agreement was accounted for as a debt extinguishment and the Company capitalized incremental debt issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Second Amended Term Loan is guaranteed by certain domestic subsidiaries of the Company (such subsidiaries, together with the Company, the “Credit Parties”). The Second Amended Loan Agreement grants EWB a security interest in and liens on substantially all assets of the Company and the other Credit Parties, excluding intellectual property, provided, that if the Company does not satisfy a liquidity test set forth in the Second Amended Loan Agreement, the Credit Parties will be required to grant a first-priority security interest in their intellectual property. In addition, certain other terms of the original agreements as previously in effect were amended by the Second Amended Loan Agreement, including certain financial covenants. For example, the Company must maintain cash and cash equivalents of no less than $70.0 million in the aggregate at all times in a deposit account with EWB that is assigned to EWB. As a result, the deposit of $70.0 million was recorded as restricted cash on the Company’s condensed consolidated balance sheet. In addition, if the Company’s cash and cash equivalents balance at EWB falls below $100.0 million, the Company is then required to maintain specific minimum EBITDA amounts at all times thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Second Amended Loan Agreement contains customary affirmative and negative covenants, including limitations on mergers, asset sales, liens, investments and indebtedness. See Exhibit 10.1 for the Second Amended Loan Agreement. As of March 31, 2023, the Company was in compliance with the terms and covenants of the Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total payments due</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">96,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest payments, loan discounts and financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(27,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current portion, less loan discounts and financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div>Total interest cost incurred for the three months ended March 31, 2023 and 2022 was $0.4 million and $0.2 million, respectively. 20000000 20000000 P48M 0.0417 P24M P36M 20000000 50000000 70000000 52500000 -200000 700000 P60M 0.0625 0.005 P24M 0.01 70000000 70000000 100000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total payments due</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">96,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest payments, loan discounts and financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(27,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current portion, less loan discounts and financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">68,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 4545000 6049000 13680000 15437000 14532000 41990000 96233000 27347000 0 68886000 400000 200000 Equity and Stock Compensation Plans<div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IsoPlexis Merger</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, in connection with the completion of the IsoPlexis Merger: </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">All outstanding IsoPlexis RSAs were assumed by PhenomeX and converted into PhenomeX RSAs based on the 0.612 conversion ratio (see Note 5) and on the same terms and conditions (including with respect to vesting schedules and restrictions) as applied to IsoPlexis RSAs immediately prior to the closing of the IsoPlexis Merger.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">All outstanding IsoPlexis stock options (whether vested or unvested) that had a per share exercise price of less than $1.28 and were held by continuing employees were assumed by PhenomeX and converted into PhenomeX stock options based on the 0.612 conversion ratio (and rounded down) and on the same terms and conditions (including with respect to time-based vesting) as applied to IsoPlexis stock options immediately prior to the closing of the IsoPlexis Merger, with the exercise price per share of the assumed stock options determined by dividing the per share exercise price of the IsoPlexis options by the 0.612 conversion ratio (and rounded up to the nearest whole cent). The assumed stock options expire 10 years from their original date of grant. The assumed stock options and RSAs generally vest 25% upon the one-year anniversary of the service inception date and then ratably each month over the remaining 36 months. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023, PhenomeX assumed 304,619 IsoPlexis RSAs and 378,767 IsoPlexis stock options after applying the 0.612 conversion ratio. The Company accounted for the assumed equity awards as a modification under ASC 718 and recorded stock compensation expense of $0.1 million during the three months ended March 31, 2023 associated with the modification.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future grants of equity awards will be issued under the Company’s 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Warrant Certificate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive executed the Warrant Certificate. Under the Warrant Certificate, the outstanding warrant (“IsoPlexis Warrant”) to purchase shares of common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”), issued by IsoPlexis to Perceptive was assumed by PhenomeX and converted into a warrant (“PhenomeX Warrant”) to purchase shares of common stock, par value $0.00005, of PhenomeX (“PhenomeX Common Stock”), on the same terms and subject to the same conditions as were applicable to the IsoPlexis Warrant as of immediately prior to the Acquisition Date; provided, that the PhenomeX Warrant is exercisable for 496,560 shares of PhenomeX Common Stock (i.e., a number of shares of PhenomeX Common Stock equal to the number of shares of IsoPlexis Common Stock that were subject to the IsoPlexis Warrant multiplied by the 0.612 exchange ratio and has an exercise price of $9.80 per share of PhenomeX Common Stock (i.e., the exercise price per share of IsoPlexis Common Stock that was applicable to the IsoPlexis Warrant divided by 0.612).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result of the IsoPlexis Merger and discussed above, the Company now has RSAs outstanding. RSAs are rights to receive shares of the Company’s Common Stock upon meeting specified vesting requirements. The fair value of a RSA is the market value as determined by the closing price of the Company’s stock on the original grant date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,393 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Stock-based compensation capitalized in inventory was not material as of March 31, 2023 and December 31, 2022. 0.612 1.28 0.612 0.612 P10Y 0.25 P1Y P36M 304619 378767 0.612 0.612 100000 0.001 0.00005 496560 0.612 9.80 0.612 <div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,393 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 16000 51000 548000 1581000 3824000 3761000 4388000 5393000 Restructuring<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During 2022, the Company adopted a new strategic plan with the intention of reducing costs and better aligning the organization with the Company’s long-term goals. As a result, the Company approved a set of restructuring initiatives in 2022 and continued with similar initiatives in the first quarter of 2023. During the three months ended March 31, 2023, the Company incurred restructuring charges of $1.3 million, related to severance and other employee-related restructuring costs associated with the termination of approximately 16% of total full-time employees. As of March 31, 2023, the Company has not fully completed its restructuring efforts. It is unable to currently estimate future restructuring charges, but will record any additional restructuring-related expenses as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in the Company’s restructuring liability are set forth in the table below (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee severance and termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non labor restructuring</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrual at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring liability assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrual at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restructuring liabilities are included in accrued expenses and other current liabilities in the condensed consolidated balance sheet.</span></div> 1300000 0.16 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in the Company’s restructuring liability are set forth in the table below (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee severance and termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non labor restructuring</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrual at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring liability assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrual at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 130000 107000 237000 834000 0 834000 1290000 0 1290000 1010000 107000 1117000 0 0 0 1244000 0 1244000 Income TaxesThe Company’s provision for income taxes was $20,000 for the three months ended March 31, 2023 and $20,000 and for the three months ended March 31, 2022. For the three months ended March 31, 2023 and 2022, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance. 20000 20000 Statements of Cash Flows<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The supplemental cash flow information consists of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash consideration for the acquisition of IsoPlexis</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment transferred to inventory</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer return of Beacon transferred to property and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in accounts payable and accrued liabilities related to purchases of property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The supplemental cash flow information consists of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash consideration for the acquisition of IsoPlexis</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment transferred to inventory</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer return of Beacon transferred to property and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in accounts payable and accrued liabilities related to purchases of property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.</span></div> 439000 137000 19000 0 32406000 0 352000 0 201000 0 684000 482000 Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">AbCellera Biologics Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July through September 2020, AbCellera Biologics Inc. (“AbCellera”) filed a series of complaints in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936, 10,704,018, 10,718,768, 10,738,270, 10,746,737, 10,753,933, 10,775,376, 10,775,377, and 10,775,378. The University of British Columbia (“UBC”), the owner of the patents, joined AbCellera as a named plaintiff in the lawsuits. AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees, and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents, for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct, and unfair competition under state and federal law.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company filed a motion to transfer the lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (“Consolidated Lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court issued a Case Management Order that, among other things, requires AbCellera and UBC to further reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2021 and August 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent &amp; Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent Nos. 10,421,936 and 10,739,270. In August 2021, in response to a Motion to Stay filed by the Company, the court stayed the Consolidated Lawsuit pending the outcome of the IPR proceedings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2022, the PTAB of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. And in January 2023, the PTAB issued a decision upholding the validity of the challenged claims in U.S. Patent No. 10,087,408: the Company has requested a rehearing of the PTAB’s decision. The Consolidated Lawsuit remains stayed at this time, AbCellera has filed a motion - opposed by the Company - to lift the stay. AbCellera’s motion to lift the stay is fully briefed and awaiting a decision from the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that the patent assertions by AbCellera and UBC are without merit and it intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s position. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of the Company’s products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Securities Class Action</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2021, Victor J. Ng filed a securities class action complaint in the Northern District of California (“Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 Initial Public Offering (“IPO”) offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. The Company’s pending Motion to Dismiss is set for hearing on June 22, 2023. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Derivative Action</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and former senior executives owe the Company contribution for violations of Sections 10(b) and 21D of the Exchange Act. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No provision has been made for litigation because the Company believes that it is not probable that a liability has been incurred as of March 31, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has entered into various purchase agreements, including inventory-related agreements with its contract manufacturers. Once these orders are placed, they are generally cancelable by providing notice prior to the expected ship date, however such cancellations could result in the Company incurring certain charges depending on the timing. The Company had non-cancellable purchase obligations to contract manufacturers and other suppliers of $29.7 million at March 31, 2023. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Product Warranty</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company generally provides a one year assurance-type warranty on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.973%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warranty accrual assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to existing warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for new warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Settlement of pre-existing warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2 4 3 0 29700000 P1Y The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.973%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warranty accrual assumed in IsoPlexis Merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to existing warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for new warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Settlement of pre-existing warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 749000 1085000 128000 0 -111000 -245000 133000 163000 111000 89000 788000 914000 Net Loss Attributable to Common Stockholders Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards and unvested restricted stock units. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(21,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net income per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75,759,771</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67,697,488</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:68.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">496,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,685,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,020,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,517,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,629,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,990,891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,649,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(21,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net income per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75,759,771</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67,697,488</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -23419000 -23419000 -21426000 -21426000 75759771 75759771 67697488 67697488 -0.31 -0.31 -0.32 -0.32 The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:68.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">496,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,685,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,020,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,517,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,629,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,990,891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,649,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 496560 0 7685997 7020591 290846 0 5517488 3629310 13990891 10649901 Segments<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> operating segment. The IsoPlexis Merger on March 21, 2023 did not change the Company’s assessment about operating segments. The Company’s principal operations and decision-making functions are located in the United States. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asia Pacific</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,516 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Asia Pacific includes Australia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets were located in the United States</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div> 1 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asia Pacific</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,516 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) Asia Pacific includes Australia.</span></div> 14055000 13715000 3147000 5035000 1314000 1456000 18516000 20206000 Subsequent EventsIn April 2023, Phenomenex, Inc. (“Phenomenex”) filed a complaint against the Company in the U.S. District Court for the Central District of California, alleging trademark infringement and unfair competition in relation to the Company’s name and seeking injunctive relief and damages. As of the filing date for this Quarterly Report on Form 10-Q, the Company has not been served with the complaint from Phenomenex. The Company believes that Phenomenex’s complaint is without merit and intends to vigorously defend itself.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Restructuring</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">During the second quarter of 2023, the Company announced a reduction in force terminating approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $0.8 million related to this activity, substantially all of which the Company expects to incur in the second quarter of 2023.</span></div> 0.12 800000 Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned. EXCEL 101 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

8LWTE=R@H)F55#4SU%5K7V\4LL*!ZLJ/@B#U M:\:%ETW=V+W*IK(Q%1=XKT W=^+HT=\+/IAJWQ$ZWG]D_.._D9FG'G7'A2X8DUE M'N3N+^S\))8OEY5V3]AUL8$'>:.-K#LP*:BY:-_LJ8]/'H)]RF'?2*C/I&1XXM?2>1J/Y&TF'MYA&^W M2^W&OP_9;?E'P_QV-]_H#Y&*N$]%?(H] M^ZQ8@;1!<]D(*@G5U\L%"#1#UEN^U/'9;14D83J;^=M_3<51XG<2C/NJ% MV%$O=G12;+]4S!7P!>Q*GI? %%)]YE534!U3H;Y[TXK*=:7 M!E7]BNE/SM^KOI(CS4DX.O U$#.:#-M*>UOI25O]::.Z'7C6K<3YD,CT.+'! M>)0>R#R.F@23:%CGN-)8>;XCAHDAX6BK]W/]B[F8[. M-1<:*EP1*K@:DU/5WG=MQ\B-NS*6TM#)Y9HE_2*@L@$TOY+2/'?L+=3_=&3_ M 5!+ P04 " "W@:]6GU!QJG$# "P"@ &0 'AL+W=OH[_SR5,RK]S@4I6?16:+63 )(,.(HX X/A,0[P)BK[LA\BKON>7SJ59;T&XU MH;D'GZJ/)G%"NEUYL9K>"HJS\V?@)#PH5!KPV5FIJ$EA8XG3'=J M[AHU\1DU WA/$@H#?\H,L^_C0\JL32_>IW<7]P*^Y_H:!NP*XB@>P,>7>[AX M<]F#.VC+-O"X@S.XCVB,TE=--:[@'DVJ1>W/V=^/M!8>+%;FGZX*-,##;F!W M"6]-S5./[&$K>]B'3KOM+FJ&&E3N2](EL(%(/(2[ MU)OY8#"+N&E%W/2*<$?^ED0@UY($")F2-W21WYR0OV5CUDW.HH-/1?^C!KQR^1O( MR+)R9UGIWJ,ZS28ZK4/$DC-2CBR3]4K9VR1P8]!V$K,3XDETYA"P^, ;]_(^ M5#47VGDNI 77J\[J[S".J9.SU >[8[VV-%^D:5/X9TQ1;/AK2:['5'YR4]5OI M3]V#T8FELY,S$1XU$02T\JV2 ;_O33_1SK;MV*)I0@[+FUZ.OKHK(0V4F%-H M=#TF?MVT1\W JMJW)*_*DFK_6%!+B=HMH/>Y4G8_< 1MDSK_#U!+ P04 M" "W@:]67O'R:9\" "Q!@ &0 'AL+W=O,!J-8-'A /;G+;6G/L8#OMX-=S M[:2A6[,)(5X2^^:>XW-/;FZ&6ZD>]!K D,>""SWRUL:4E[ZOLS445)_)$@0^ M64I54(-;M?)UJ8#F#E1P/PJ"@5]0)KQTZ&(SE0YE93@3,%-$5T5!U<\KX'([ M\D)O%[AEJ[6Q 3\=EG0%[^9"/O, * @Z9L0P4;QN8 .>6"&7\:#B]]D@+W%_OV*]=[5C+ M@FJ82/Z5Y68]\LX]DL.25MSNA;U"?/<7/&BU7M9;H!2T?J3HC<=@C41#% M'?#)Z_ I9"T\>@KWT976FJBU)G)\\0M\G]6*"O:+VG;KD8D46G*6T[K[1$YF M"C0(4P?DDEPS@58RRLD<@X"MCKY]&R^T4=BLW[O\J 7TNP78#_A2ES2#D5?: ML]0&O/3MFW 0O.]RYS^1/?$J;KV*7V-/ZVZANVY1;;=T55U3#1R5G3*;-!H$ M(;[QS7XYAUGA>1+WVZPG.ONMSOZK.L<!R ))?5PBPKW@KO4EL3)GLZ M3L\O^L_$'B8%W4*35FCR;X;VB #3I3,Y=#4)PXMG0@^SNESU]P:*'>;X9:Z8 MT(3#$G'!V3ND4?6 K#=&EF[&+*3!B>66:_RG@+()^'PII=EM[-AJ_U+I;U!+ M P04 " "W@:]6CJK(R"D# "#"0 &0 'AL+W=OL@!!(V](F75M&&ZGMF.!AHEKY\8!X<)-+8^'8 MP7;:P5_/V4FSKLLB&+RTMN/[[OONSF=/=E)]UQF (;%,P%(17>8Y M53_GP.5NZO6]_<(-VV3&+OC1I* ;6('Y5"P5SOP&)6$Y",VD( K2J3?K7RS& M=K_;\)G!3A^,B56REO*[G;Q/IE[/$@(.L;$(%/^VL #.+1#2^%%C>HU+:W@X MWJ-?.>VH94TU+"3_PA*33;VQ1Q)(:O3C MFM>\XA4\PBLDUU*83).W(H'DOKV/&ANAP5[H/.@$O*;JC(3]$Q+T@K"%S^+/ MS8,..F$3]]#AA8_@?5 ;*M@O:FOYA"RDT)*SA%:E+1*R5*!!F&I!IN2*"

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end XML 102 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 103 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 199 373 1 true 73 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet http://berkeleylights.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Disclosure - The Company and Basis of Presentation Sheet http://berkeleylights.com/role/TheCompanyandBasisofPresentation The Company and Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://berkeleylights.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Marketable Securities Sheet http://berkeleylights.com/role/MarketableSecurities Marketable Securities Notes 11 false false R12.htm 0000012 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations Sheet http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrations Significant Risks and Uncertainties Including Business and Credit Concentrations Notes 12 false false R13.htm 0000013 - Disclosure - Business Combinations Sheet http://berkeleylights.com/role/BusinessCombinations Business Combinations Notes 13 false false R14.htm 0000014 - Disclosure - Revenue From Contracts With Customers Sheet http://berkeleylights.com/role/RevenueFromContractsWithCustomers Revenue From Contracts With Customers Notes 14 false false R15.htm 0000015 - Disclosure - Balance Sheet Accounts Sheet http://berkeleylights.com/role/BalanceSheetAccounts Balance Sheet Accounts Notes 15 false false R16.htm 0000016 - Disclosure - Goodwill and Other Intangible Assets Sheet http://berkeleylights.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 16 false false R17.htm 0000017 - Disclosure - Fair Value of Financial Instruments Sheet http://berkeleylights.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 17 false false R18.htm 0000018 - Disclosure - Property and Equipment, net Sheet http://berkeleylights.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 18 false false R19.htm 0000019 - Disclosure - Leases Sheet http://berkeleylights.com/role/Leases Leases Notes 19 false false R20.htm 0000020 - Disclosure - Long-Term Debt Sheet http://berkeleylights.com/role/LongTermDebt Long-Term Debt Notes 20 false false R21.htm 0000021 - Disclosure - Equity and Stock Compensation Plans Sheet http://berkeleylights.com/role/EquityandStockCompensationPlans Equity and Stock Compensation Plans Notes 21 false false R22.htm 0000022 - Disclosure - Restructuring Sheet http://berkeleylights.com/role/Restructuring Restructuring Notes 22 false false R23.htm 0000023 - Disclosure - Income Taxes Sheet http://berkeleylights.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 0000024 - Disclosure - Statements of Cash Flows Sheet http://berkeleylights.com/role/StatementsofCashFlows Statements of Cash Flows Notes 24 false false R25.htm 0000025 - Disclosure - Commitment and Contingencies Sheet http://berkeleylights.com/role/CommitmentandContingencies Commitment and Contingencies Notes 25 false false R26.htm 0000026 - Disclosure - Net Loss Attributable to Common Stockholders Per Share Sheet http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShare Net Loss Attributable to Common Stockholders Per Share Notes 26 false false R27.htm 0000027 - Disclosure - Segments Sheet http://berkeleylights.com/role/Segments Segments Notes 27 false false R28.htm 0000028 - Disclosure - Subsequent Events Sheet http://berkeleylights.com/role/SubsequentEvents Subsequent Events Notes 28 false false R29.htm 0000029 - Disclosure - The Company and Basis of Presentation (Policies) Sheet http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies The Company and Basis of Presentation (Policies) Policies http://berkeleylights.com/role/SummaryofSignificantAccountingPolicies 29 false false R30.htm 0000030 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://berkeleylights.com/role/SummaryofSignificantAccountingPolicies 30 false false R31.htm 0000031 - Disclosure - Marketable Securities (Tables) Sheet http://berkeleylights.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://berkeleylights.com/role/MarketableSecurities 31 false false R32.htm 0000032 - Disclosure - Business Combinations (Tables) Sheet http://berkeleylights.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://berkeleylights.com/role/BusinessCombinations 32 false false R33.htm 0000033 - Disclosure - Revenue From Contracts With Customers (Tables) Sheet http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables Revenue From Contracts With Customers (Tables) Tables http://berkeleylights.com/role/RevenueFromContractsWithCustomers 33 false false R34.htm 0000034 - Disclosure - Balance Sheet Accounts (Tables) Sheet http://berkeleylights.com/role/BalanceSheetAccountsTables Balance Sheet Accounts (Tables) Tables http://berkeleylights.com/role/BalanceSheetAccounts 34 false false R35.htm 0000035 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://berkeleylights.com/role/GoodwillandOtherIntangibleAssets 35 false false R36.htm 0000036 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://berkeleylights.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://berkeleylights.com/role/FairValueofFinancialInstruments 36 false false R37.htm 0000037 - Disclosure - Property and Equipment, net (Tables) Sheet http://berkeleylights.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://berkeleylights.com/role/PropertyandEquipmentnet 37 false false R38.htm 0000038 - Disclosure - Leases (Table) Sheet http://berkeleylights.com/role/LeasesTable Leases (Table) Tables http://berkeleylights.com/role/Leases 38 false false R39.htm 0000039 - Disclosure - Long-Term Debt (Tables) Sheet http://berkeleylights.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://berkeleylights.com/role/LongTermDebt 39 false false R40.htm 0000040 - Disclosure - Equity and Stock Compensation Plans (Tables) Sheet http://berkeleylights.com/role/EquityandStockCompensationPlansTables Equity and Stock Compensation Plans (Tables) Tables http://berkeleylights.com/role/EquityandStockCompensationPlans 40 false false R41.htm 0000041 - Disclosure - Restructuring (Tables) Sheet http://berkeleylights.com/role/RestructuringTables Restructuring (Tables) Tables http://berkeleylights.com/role/Restructuring 41 false false R42.htm 0000042 - Disclosure - Statements of Cash Flows (Tables) Sheet http://berkeleylights.com/role/StatementsofCashFlowsTables Statements of Cash Flows (Tables) Tables http://berkeleylights.com/role/StatementsofCashFlows 42 false false R43.htm 0000043 - Disclosure - Commitment and Contingencies (Tables) Sheet http://berkeleylights.com/role/CommitmentandContingenciesTables Commitment and Contingencies (Tables) Tables http://berkeleylights.com/role/CommitmentandContingencies 43 false false R44.htm 0000044 - Disclosure - Net Loss Attributable to Common Stockholders Per Share (Tables) Sheet http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareTables Net Loss Attributable to Common Stockholders Per Share (Tables) Tables http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShare 44 false false R45.htm 0000045 - Disclosure - Segments (Tables) Sheet http://berkeleylights.com/role/SegmentsTables Segments (Tables) Tables http://berkeleylights.com/role/Segments 45 false false R46.htm 0000046 - Disclosure - The Company and Basis of Presentation (Details) Sheet http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails The Company and Basis of Presentation (Details) Details http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies 46 false false R47.htm 0000047 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 47 false false R48.htm 0000048 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 48 false false R49.htm 0000049 - Disclosure - Summary of Significant Accounting Policies - Research and development state tax credits (Details) Sheet http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails Summary of Significant Accounting Policies - Research and development state tax credits (Details) Details 49 false false R50.htm 0000050 - Disclosure - Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) Sheet http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) Details 50 false false R51.htm 0000051 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) Sheet http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) Details http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrations 51 false false R52.htm 0000052 - Disclosure - Business Combinations - Narrative (Details) Sheet http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 52 false false R53.htm 0000053 - Disclosure - Business Combinations - Schedule of Acquired Assets and Liabilities (Details) Sheet http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails Business Combinations - Schedule of Acquired Assets and Liabilities (Details) Details 53 false false R54.htm 0000054 - Disclosure - Business Combinations - Schedule of Pro forma Information (Details) Sheet http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails Business Combinations - Schedule of Pro forma Information (Details) Details 54 false false R55.htm 0000055 - Disclosure - Revenue from Contracts with Customer (Narrative) (Details) Sheet http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails Revenue from Contracts with Customer (Narrative) (Details) Details 55 false false R56.htm 0000056 - Disclosure - Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) Sheet http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) Details http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables 56 false false R57.htm 0000057 - Disclosure - Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) Sheet http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) Details http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables 57 false false R58.htm 0000058 - Disclosure - Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details) Sheet http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details) Details http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables 58 false false R59.htm 0000059 - Disclosure - Balance Sheet Accounts - Trade Accounts Receivable, Net (Details) Sheet http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails Balance Sheet Accounts - Trade Accounts Receivable, Net (Details) Details 59 false false R60.htm 0000060 - Disclosure - Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details) Sheet http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details) Details 60 false false R61.htm 0000061 - Disclosure - Balance Sheet Accounts - Inventory (Details) Sheet http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails Balance Sheet Accounts - Inventory (Details) Details 61 false false R62.htm 0000062 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) Sheet http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) Details 62 false false R63.htm 0000063 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) Sheet http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) Details 63 false false R64.htm 0000064 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) Sheet http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets - Narrative (Details) Details 64 false false R65.htm 0000065 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) Details 65 false false R66.htm 0000066 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details) Sheet http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details) Details 66 false false R67.htm 0000067 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities (Details) Sheet http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails Fair Value of Financial Instruments - Assets and Liabilities (Details) Details 67 false false R68.htm 0000068 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details) Sheet http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details) Details 68 false false R69.htm 0000069 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details) Sheet http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails Property and Equipment, net - Schedule of Property and Equipment (Details) Details 69 false false R70.htm 0000070 - Disclosure - Property and Equipment, net - Narrative (Details) Sheet http://berkeleylights.com/role/PropertyandEquipmentnetNarrativeDetails Property and Equipment, net - Narrative (Details) Details 70 false false R71.htm 0000071 - Disclosure - Leases - Narrative (Details) Sheet http://berkeleylights.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 71 false false R72.htm 0000072 - Disclosure - Leases - Maturity Schedule of Operating Lease Liabilities (Details) Sheet http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails Leases - Maturity Schedule of Operating Lease Liabilities (Details) Details 72 false false R73.htm 0000073 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://berkeleylights.com/role/LeasesScheduleofSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) Details 73 false false R74.htm 0000074 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details) Sheet http://berkeleylights.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails Leases - Schedule of Additional Information Related to Operating Leases (Details) Details 74 false false R75.htm 0000075 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://berkeleylights.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 75 false false R76.htm 0000076 - Disclosure - Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) Notes http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) Details 76 false false R77.htm 0000077 - Disclosure - Equity and Stock Compensation Plans (Narrative) (Details) Sheet http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails Equity and Stock Compensation Plans (Narrative) (Details) Details http://berkeleylights.com/role/EquityandStockCompensationPlansTables 77 false false R78.htm 0000078 - Disclosure - Equity and Stock Compensation Plans - Stock-Based Compensation (Details) Sheet http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails Equity and Stock Compensation Plans - Stock-Based Compensation (Details) Details 78 false false R79.htm 0000079 - Disclosure - Restructuring - Narrative (Details) Sheet http://berkeleylights.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 79 false false R80.htm 0000080 - Disclosure - Restructuring - Changes in Restructuring Liability (Details) Sheet http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails Restructuring - Changes in Restructuring Liability (Details) Details 80 false false R81.htm 0000081 - Disclosure - Income Taxes (Details) Sheet http://berkeleylights.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://berkeleylights.com/role/IncomeTaxes 81 false false R82.htm 0000082 - Disclosure - Statements of Cash Flows (Details) Sheet http://berkeleylights.com/role/StatementsofCashFlowsDetails Statements of Cash Flows (Details) Details http://berkeleylights.com/role/StatementsofCashFlowsTables 82 false false R83.htm 0000083 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 83 false false R84.htm 0000084 - Disclosure - Commitment and Contingencies - Product Warranty (Details) Sheet http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails Commitment and Contingencies - Product Warranty (Details) Details 84 false false R85.htm 0000085 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) Sheet http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) Details 85 false false R86.htm 0000086 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) Sheet http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) Details 86 false false R87.htm 0000087 - Disclosure - Segments (Details) Sheet http://berkeleylights.com/role/SegmentsDetails Segments (Details) Details http://berkeleylights.com/role/SegmentsTables 87 false false R88.htm 0000088 - Disclosure - Subsequent Events (Details) Sheet http://berkeleylights.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://berkeleylights.com/role/SubsequentEvents 88 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife - bli-20230331.htm 4 bli-20230331.htm bli-20230331.xsd bli-20230331_cal.xml bli-20230331_def.xml bli-20230331_lab.xml bli-20230331_pre.xml ex-311cellx20230331x10q.htm ex-312cellx20230331x10q.htm ex-321cellx20230331x10q.htm ex-322cellx20230331x10q.htm bli-20230331_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bli-20230331.htm": { "axisCustom": 1, "axisStandard": 32, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 719, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 199, "dts": { "calculationLink": { "local": [ "bli-20230331_cal.xml" ] }, "definitionLink": { "local": [ "bli-20230331_def.xml" ] }, "inline": { "local": [ "bli-20230331.htm" ] }, "labelLink": { "local": [ "bli-20230331_lab.xml" ] }, "presentationLink": { "local": [ "bli-20230331_pre.xml" ] }, "schema": { "local": [ "bli-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 601, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 3, "http://xbrl.sec.gov/dei/2022": 5, "total": 8 }, "keyCustom": 41, "keyStandard": 332, "memberCustom": 19, "memberStandard": 50, "nsprefix": "bli", "nsuri": "http://berkeleylights.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://berkeleylights.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://berkeleylights.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Marketable Securities", "menuCat": "Notes", "order": "11", "role": "http://berkeleylights.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations", "menuCat": "Notes", "order": "12", "role": "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrations", "shortName": "Significant Risks and Uncertainties Including Business and Credit Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "13", "role": "http://berkeleylights.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Revenue From Contracts With Customers", "menuCat": "Notes", "order": "14", "role": "http://berkeleylights.com/role/RevenueFromContractsWithCustomers", "shortName": "Revenue From Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Balance Sheet Accounts", "menuCat": "Notes", "order": "15", "role": "http://berkeleylights.com/role/BalanceSheetAccounts", "shortName": "Balance Sheet Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Goodwill and Other Intangible Assets", "menuCat": "Notes", "order": "16", "role": "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Fair Value of Financial Instruments", "menuCat": "Notes", "order": "17", "role": "http://berkeleylights.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Property and Equipment, net", "menuCat": "Notes", "order": "18", "role": "http://berkeleylights.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Leases", "menuCat": "Notes", "order": "19", "role": "http://berkeleylights.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Long-Term Debt", "menuCat": "Notes", "order": "20", "role": "http://berkeleylights.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Equity and Stock Compensation Plans", "menuCat": "Notes", "order": "21", "role": "http://berkeleylights.com/role/EquityandStockCompensationPlans", "shortName": "Equity and Stock Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Restructuring", "menuCat": "Notes", "order": "22", "role": "http://berkeleylights.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "23", "role": "http://berkeleylights.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Statements of Cash Flows", "menuCat": "Notes", "order": "24", "role": "http://berkeleylights.com/role/StatementsofCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Commitment and Contingencies", "menuCat": "Notes", "order": "25", "role": "http://berkeleylights.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Net Loss Attributable to Common Stockholders Per Share", "menuCat": "Notes", "order": "26", "role": "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShare", "shortName": "Net Loss Attributable to Common Stockholders Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Segments", "menuCat": "Notes", "order": "27", "role": "http://berkeleylights.com/role/Segments", "shortName": "Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "28", "role": "http://berkeleylights.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - The Company and Basis of Presentation (Policies)", "menuCat": "Policies", "order": "29", "role": "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies", "shortName": "The Company and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "30", "role": "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Marketable Securities (Tables)", "menuCat": "Tables", "order": "31", "role": "http://berkeleylights.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Business Combinations (Tables)", "menuCat": "Tables", "order": "32", "role": "http://berkeleylights.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Revenue From Contracts With Customers (Tables)", "menuCat": "Tables", "order": "33", "role": "http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables", "shortName": "Revenue From Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Balance Sheet Accounts (Tables)", "menuCat": "Tables", "order": "34", "role": "http://berkeleylights.com/role/BalanceSheetAccountsTables", "shortName": "Balance Sheet Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "menuCat": "Tables", "order": "35", "role": "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Fair Value of Financial Instruments (Tables)", "menuCat": "Tables", "order": "36", "role": "http://berkeleylights.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Property and Equipment, net (Tables)", "menuCat": "Tables", "order": "37", "role": "http://berkeleylights.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases (Table)", "menuCat": "Tables", "order": "38", "role": "http://berkeleylights.com/role/LeasesTable", "shortName": "Leases (Table)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Long-Term Debt (Tables)", "menuCat": "Tables", "order": "39", "role": "http://berkeleylights.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Equity and Stock Compensation Plans (Tables)", "menuCat": "Tables", "order": "40", "role": "http://berkeleylights.com/role/EquityandStockCompensationPlansTables", "shortName": "Equity and Stock Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "41", "role": "http://berkeleylights.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Statements of Cash Flows (Tables)", "menuCat": "Tables", "order": "42", "role": "http://berkeleylights.com/role/StatementsofCashFlowsTables", "shortName": "Statements of Cash Flows (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Commitment and Contingencies (Tables)", "menuCat": "Tables", "order": "43", "role": "http://berkeleylights.com/role/CommitmentandContingenciesTables", "shortName": "Commitment and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Net Loss Attributable to Common Stockholders Per Share (Tables)", "menuCat": "Tables", "order": "44", "role": "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareTables", "shortName": "Net Loss Attributable to Common Stockholders Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Segments (Tables)", "menuCat": "Tables", "order": "45", "role": "http://berkeleylights.com/role/SegmentsTables", "shortName": "Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - The Company and Basis of Presentation (Details)", "menuCat": "Details", "order": "46", "role": "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails", "shortName": "The Company and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "47", "role": "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i44a552341e5e4e5191e737707e67bd38_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "48", "role": "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i4ebb4866047b418b90b54bb409ef7f3c_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Summary of Significant Accounting Policies - Research and development state tax credits (Details)", "menuCat": "Details", "order": "49", "role": "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails", "shortName": "Summary of Significant Accounting Policies - Research and development state tax credits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i4ebb4866047b418b90b54bb409ef7f3c_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bli:CashEquivalentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details)", "menuCat": "Details", "order": "50", "role": "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails", "shortName": "Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bli:CashEquivalentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Significant Risks and Uncertainties Including Business and Credit Concentrations (Details)", "menuCat": "Details", "order": "51", "role": "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails", "shortName": "Significant Risks and Uncertainties Including Business and Credit Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "if4d5fb8d810e49cca7421ef9faf35fc1_D20230101-20230331", "decimals": "2", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "iaae7a9ce922c40d08a292d7ef4a962a7_I20230321", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquiredReceivablesFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Business Combinations - Narrative (Details)", "menuCat": "Details", "order": "52", "role": "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "shortName": "Business Combinations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "iaae7a9ce922c40d08a292d7ef4a962a7_I20230321", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquiredReceivablesFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "iaae7a9ce922c40d08a292d7ef4a962a7_I20230321", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Business Combinations - Schedule of Acquired Assets and Liabilities (Details)", "menuCat": "Details", "order": "53", "role": "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "shortName": "Business Combinations - Schedule of Acquired Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "iaf9efbe05e7b41489b9aa57e32154dcb_D20230321-20230321", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ifd3bdd8f580e40f0850db5da2a30cb4e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Business Combinations - Schedule of Pro forma Information (Details)", "menuCat": "Details", "order": "54", "role": "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails", "shortName": "Business Combinations - Schedule of Pro forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ifd3bdd8f580e40f0850db5da2a30cb4e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Revenue from Contracts with Customer (Narrative) (Details)", "menuCat": "Details", "order": "55", "role": "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails", "shortName": "Revenue from Contracts with Customer (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details)", "menuCat": "Details", "order": "56", "role": "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails", "shortName": "Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i86e7041546bb4f119092efa95a653a2d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details)", "menuCat": "Details", "order": "57", "role": "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails", "shortName": "Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details)", "menuCat": "Details", "order": "58", "role": "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails", "shortName": "Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Balance Sheet Accounts - Trade Accounts Receivable, Net (Details)", "menuCat": "Details", "order": "59", "role": "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails", "shortName": "Balance Sheet Accounts - Trade Accounts Receivable, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic4d040d7e4c9415fa73d277d39d9ce12_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic4d040d7e4c9415fa73d277d39d9ce12_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic860a632c4c8418db20f9286c6320aa0_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details)", "menuCat": "Details", "order": "60", "role": "http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails", "shortName": "Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "bli:AccountsReceivableAllowanceForCreditLossIncreaseForBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Balance Sheet Accounts - Inventory (Details)", "menuCat": "Details", "order": "61", "role": "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails", "shortName": "Balance Sheet Accounts - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "62", "role": "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepositsAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "63", "role": "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "menuCat": "Details", "order": "64", "role": "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details)", "menuCat": "Details", "order": "65", "role": "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details)", "menuCat": "Details", "order": "66", "role": "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities (Details)", "menuCat": "Details", "order": "67", "role": "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "shortName": "Fair Value of Financial Instruments - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i68d54167db004d99bc581029edefffec_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i5b703d677e7d4019a0862727a1386263_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details)", "menuCat": "Details", "order": "68", "role": "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails", "shortName": "Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i5b703d677e7d4019a0862727a1386263_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)", "menuCat": "Details", "order": "69", "role": "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "shortName": "Property and Equipment, net - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Property and Equipment, net - Narrative (Details)", "menuCat": "Details", "order": "70", "role": "http://berkeleylights.com/role/PropertyandEquipmentnetNarrativeDetails", "shortName": "Property and Equipment, net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "71", "role": "http://berkeleylights.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Leases - Maturity Schedule of Operating Lease Liabilities (Details)", "menuCat": "Details", "order": "72", "role": "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Maturity Schedule of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details)", "menuCat": "Details", "order": "73", "role": "http://berkeleylights.com/role/LeasesScheduleofSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bli:LeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Leases - Schedule of Additional Information Related to Operating Leases (Details)", "menuCat": "Details", "order": "74", "role": "http://berkeleylights.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails", "shortName": "Leases - Schedule of Additional Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bli:LeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Long-Term Debt - Narrative (Details)", "menuCat": "Details", "order": "75", "role": "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Long-Term Debt - Schedule of Payment Due on Notes Payable (Details)", "menuCat": "Details", "order": "76", "role": "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails", "shortName": "Long-Term Debt - Schedule of Payment Due on Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i90e358cb3e794e83bf6d4be16f711369_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i6f4b6546759f4247bd52fcd9fd367ece_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Equity and Stock Compensation Plans (Narrative) (Details)", "menuCat": "Details", "order": "77", "role": "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "shortName": "Equity and Stock Compensation Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ifd7131259cb14dd3b30df4398f81e444_I20230321", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Equity and Stock Compensation Plans - Stock-Based Compensation (Details)", "menuCat": "Details", "order": "78", "role": "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails", "shortName": "Equity and Stock Compensation Plans - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Restructuring - Narrative (Details)", "menuCat": "Details", "order": "79", "role": "http://berkeleylights.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i7e5bcea946ac41ec9c5d511751e735c9_D20230303-20230303", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i7e5bcea946ac41ec9c5d511751e735c9_D20230303-20230303", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic860a632c4c8418db20f9286c6320aa0_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Restructuring - Changes in Restructuring Liability (Details)", "menuCat": "Details", "order": "80", "role": "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails", "shortName": "Restructuring - Changes in Restructuring Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic860a632c4c8418db20f9286c6320aa0_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "81", "role": "http://berkeleylights.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Statements of Cash Flows (Details)", "menuCat": "Details", "order": "82", "role": "http://berkeleylights.com/role/StatementsofCashFlowsDetails", "shortName": "Statements of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i1317026b095c40f88701ddf4b7e19647_D20211201-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bli:NumberOfCompanyInvested", "reportCount": 1, "unique": true, "unitRef": "investedcompany", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Commitment and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "83", "role": "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails", "shortName": "Commitment and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i1317026b095c40f88701ddf4b7e19647_D20211201-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bli:NumberOfCompanyInvested", "reportCount": 1, "unique": true, "unitRef": "investedcompany", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic860a632c4c8418db20f9286c6320aa0_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Commitment and Contingencies - Product Warranty (Details)", "menuCat": "Details", "order": "84", "role": "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails", "shortName": "Commitment and Contingencies - Product Warranty (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "ic860a632c4c8418db20f9286c6320aa0_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)", "menuCat": "Details", "order": "85", "role": "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails", "shortName": "Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details)", "menuCat": "Details", "order": "86", "role": "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails", "shortName": "Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Segments (Details)", "menuCat": "Details", "order": "87", "role": "http://berkeleylights.com/role/SegmentsDetails", "shortName": "Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "88", "role": "http://berkeleylights.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i96463a4b4ff34a018a63e871ede101bf_D20230401-20230630", "decimals": "2", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - The Company and Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://berkeleylights.com/role/TheCompanyandBasisofPresentation", "shortName": "The Company and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bli-20230331.htm", "contextRef": "i033690ecae4b4883bccd3dcb1f52d2fe_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "bli_AbCelleraAndUBCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AbCellera And UBC", "label": "AbCellera And UBC [Member]", "terseLabel": "AbCellera and UBC" } } }, "localname": "AbCelleraAndUBCMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "bli_AccountsReceivableAfterAllowanceForCreditLossCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, after Allowance for Credit Loss, Current", "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Member]", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current" } } }, "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "domainItemType" }, "bli_AccountsReceivableAllowanceForCreditLossIncreaseForBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Allowance For Credit Loss, Increase For Business Combination", "label": "Accounts Receivable, Allowance For Credit Loss, Increase For Business Combination", "negatedLabel": "Allowance assumed in IsoPlexis Merger" } } }, "localname": "AccountsReceivableAllowanceForCreditLossIncreaseForBusinessCombination", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities And Other Liabilities, Current", "label": "Accrued Liabilities And Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "bli_AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsVestedInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Fair Value Of Options Vested In Business Combination", "label": "Adjustments To Additional Paid In Capital, Fair Value Of Options Vested In Business Combination", "terseLabel": "Fair value of vested IsoPlexis options attributable to pre-merger service" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsVestedInBusinessCombination", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bli_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Fair Value Of Warrants Assumed In Business Combination", "label": "Adjustments To Additional Paid In Capital, Fair Value Of Warrants Assumed In Business Combination", "terseLabel": "Fair value of IsoPlexis warrant at Acquisition Date" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInBusinessCombination", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bli_BusinessAcquisitionAssumedWarrant": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Assumed Warrant", "label": "Business Acquisition, Assumed Warrant", "terseLabel": "Fair value of IsoPlexis warrant at merger date" } } }, "localname": "BusinessAcquisitionAssumedWarrant", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessAcquisitionEquityInstrumentsOtherThanOptionsNumberOfSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Equity Instruments Other Than Options, Number Of Shares Acquired", "label": "Business Acquisition, Equity Instruments Other Than Options, Number Of Shares Acquired", "terseLabel": "Business acquisition, equity instruments other than options, number of shares acquired (in shares)" } } }, "localname": "BusinessAcquisitionEquityInstrumentsOtherThanOptionsNumberOfSharesAcquired", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bli_BusinessAcquisitionOptionsNumberOfSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Options, Number Of Shares Acquired", "label": "Business Acquisition, Options, Number Of Shares Acquired", "terseLabel": "Business acquisition, options, number of shares acquired (in shares)" } } }, "localname": "BusinessAcquisitionOptionsNumberOfSharesAcquired", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bli_BusinessCombinationAcquiredInventoryAdjustmentFromBookValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Acquired Inventory, Adjustment From Book Value", "label": "Business Combination, Acquired Inventory, Adjustment From Book Value", "terseLabel": "Step up form book value of inventory acquired" } } }, "localname": "BusinessCombinationAcquiredInventoryAdjustmentFromBookValue", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses And Other Current Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right of Use Assets", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right of Use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessCombinationRepaymentOfAcquiredDebtIncludingAccruedInterestAndPrepaymentPenalties": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Repayment Of Acquired Debt, Including Accrued Interest And Prepayment Penalties", "label": "Business Combination, Repayment Of Acquired Debt, Including Accrued Interest And Prepayment Penalties", "terseLabel": "Repayment of acquired debt" } } }, "localname": "BusinessCombinationRepaymentOfAcquiredDebtIncludingAccruedInterestAndPrepaymentPenalties", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessCombinationShareBasedPaymentArrangementOptionsVestedFairValue": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Share-Based Payment Arrangement, Options Vested, Fair Value", "label": "Business Combination, Share-Based Payment Arrangement, Options Vested, Fair Value", "terseLabel": "Fair value of vested IsoPlexis options attributable to pre-merger service" } } }, "localname": "BusinessCombinationShareBasedPaymentArrangementOptionsVestedFairValue", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_BusinessCombinationSharesHoldingRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Shares Holding Ratio", "label": "Business Combination, Shares Holding Ratio", "terseLabel": "Shares holding ratio", "verboseLabel": "Conversion ratio" } } }, "localname": "BusinessCombinationSharesHoldingRatio", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "pureItemType" }, "bli_CashEquivalentsAmortizedCost": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents, Amortized Cost", "label": "Cash Equivalents, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "CashEquivalentsAmortizedCost", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_CashEquivalentsUnrealizedGain": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "bli_CashEquivalentsAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents, Unrealized Gain", "label": "Cash Equivalents, Unrealized Gain", "terseLabel": "Unrealized Gains" } } }, "localname": "CashEquivalentsUnrealizedGain", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_CashEquivalentsUnrealizedLoss": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "bli_CashEquivalentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents, Unrealized Loss", "label": "Cash Equivalents, Unrealized Loss", "negatedLabel": "Unrealized Losses" } } }, "localname": "CashEquivalentsUnrealizedLoss", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "bli_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Three", "label": "Customer Three [Member]", "terseLabel": "Customer Three" } } }, "localname": "CustomerThreeMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "bli_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two", "label": "Customer Two [Member]", "terseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "bli_DebtInstrumentCovenantDescriptionCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Cash", "label": "Debt Instrument, Covenant Description, Cash", "terseLabel": "Debt instrument, covenant description, cash" } } }, "localname": "DebtInstrumentCovenantDescriptionCash", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "bli_DebtInstrumentCovenantDescriptionMinimumCashAndCashEquivalentsBalanceWithBank": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Minimum Cash And Cash Equivalents Balance With Bank", "label": "Debt Instrument, Covenant Description, Minimum Cash And Cash Equivalents Balance With Bank", "terseLabel": "Debt instrument, covenant description, minimum cash and cash equivalents balance with bank" } } }, "localname": "DebtInstrumentCovenantDescriptionMinimumCashAndCashEquivalentsBalanceWithBank", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bli_DebtInstrumentInterestOnlyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest-Only Period", "label": "Debt Instrument, Interest-Only Period", "terseLabel": "Interest-only period" } } }, "localname": "DebtInstrumentInterestOnlyPeriod", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "bli_DebtInstrumentInterestOnlyPeriodWithExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest-Only Period With Extension", "label": "Debt Instrument, Interest-Only Period With Extension", "terseLabel": "Interest-only period with extension" } } }, "localname": "DebtInstrumentInterestOnlyPeriodWithExtension", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "bli_DebtInstrumentPrincipalRepaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Principal Repaid", "label": "Debt Instrument, Principal Repaid", "terseLabel": "Principal repayment to retire debt" } } }, "localname": "DebtInstrumentPrincipalRepaid", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_EWBTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EWB Loan", "label": "EWB Term Loan [Member]", "terseLabel": "EWB Term Loan" } } }, "localname": "EWBTermLoanMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "bli_EarningsPerShareNumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Numerator", "label": "Earnings Per Share, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "EarningsPerShareNumeratorAbstract", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "bli_EmployeeSeveranceAndTerminationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Severance And Termination", "label": "Employee Severance And Termination [Member]", "terseLabel": "Employee severance and termination benefits" } } }, "localname": "EmployeeSeveranceAndTerminationMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "domainItemType" }, "bli_EquipmentToolingAndMoldsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment, Tooling And Molds", "label": "Equipment, Tooling And Molds [Member]", "terseLabel": "Equipment, tooling and molds" } } }, "localname": "EquipmentToolingAndMoldsMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "bli_EvorionBiotechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evorion Biotechnologies", "label": "Evorion Biotechnologies [Member]", "terseLabel": "Evorion Biotechnologies" } } }, "localname": "EvorionBiotechnologiesMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bli_IncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Assets And Liabilities", "label": "Increase (Decrease) In Operating Assets And Liabilities [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "bli_IsoPlexisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IsoPlexis", "label": "IsoPlexis [Member]", "terseLabel": "IsoPlexis" } } }, "localname": "IsoPlexisMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_IsoPlexisWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IsoPlexis Warrant", "label": "IsoPlexis Warrant [Member]", "terseLabel": "IsoPlexis Warrant" } } }, "localname": "IsoPlexisWarrantMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "bli_IssuanceOfSharesForEmployeeBonus": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Of Shares For Employee Bonus", "label": "Issuance Of Shares For Employee Bonus", "terseLabel": "RSUs issued for 2022 Bonuses" } } }, "localname": "IssuanceOfSharesForEmployeeBonus", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bli_IssuanceOfSharesForEmployeeBonusShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Of Shares For Employee Bonus, Shares", "label": "Issuance Of Shares For Employee Bonus, Shares", "terseLabel": "RSUs issued for 2022 Bonuses (in shares)" } } }, "localname": "IssuanceOfSharesForEmployeeBonusShares", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "bli_LeaseTermAndDiscountRateInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Term And Discount Rate Information", "label": "Lease Term And Discount Rate Information [Table Text Block]", "terseLabel": "Schedule of additional information related to operating leases" } } }, "localname": "LeaseTermAndDiscountRateInformationTableTextBlock", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LeasesTable" ], "xbrltype": "textBlockItemType" }, "bli_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease Liability, Payments Due After Year Four", "label": "Lessee, Operating Lease Liability, Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_LesseeOperatingLeaseTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tenant Improvement Allowance", "label": "Lessee, Operating Lease, Tenant Improvement Allowance", "negatedTerseLabel": "Less: tenant improvement allowances receivable" } } }, "localname": "LesseeOperatingLeaseTenantImprovementAllowance", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bli_LineOfCreditFacilityIncreaseInBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Increase In Borrowing Capacity", "label": "Line Of Credit Facility, Increase In Borrowing Capacity", "terseLabel": "Increase in borrowing capacity" } } }, "localname": "LineOfCreditFacilityIncreaseInBorrowingCapacity", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bli_LossContingencyCaseManagementOrderMaximumAssertedPatentClaimsPerPatentNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Case Management Order, Maximum Asserted Patent Claims Per Patent, Number", "label": "Loss Contingency, Case Management Order, Maximum Asserted Patent Claims Per Patent, Number", "terseLabel": "Case management order, maximum asserted patent claims per patent" } } }, "localname": "LossContingencyCaseManagementOrderMaximumAssertedPatentClaimsPerPatentNumber", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "bli_LossContingencyCaseManagementOrderMaximumPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Case Management Order, Maximum Patents Allegedly Infringed, Number", "label": "Loss Contingency, Case Management Order, Maximum Patents Allegedly Infringed, Number", "terseLabel": "Case management order, maximum number of patents allegedly infringed" } } }, "localname": "LossContingencyCaseManagementOrderMaximumPatentsAllegedlyInfringedNumber", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "bli_NonLaborRestructuringCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Labor Restructuring Costs", "label": "Non-Labor Restructuring Costs [Member]", "terseLabel": "Non labor restructuring" } } }, "localname": "NonLaborRestructuringCostsMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "domainItemType" }, "bli_NoncashConsiderationForAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Consideration For Acquisition", "label": "Noncash Consideration For Acquisition", "terseLabel": "Non-cash consideration for the acquisition of IsoPlexis" } } }, "localname": "NoncashConsiderationForAcquisition", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "bli_NoncashIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToPurchaseOfFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Increase (Decrease) In Accounts Payable And Accrued Liabilities Related to Purchase Of Fixed Assets", "label": "Noncash Increase (Decrease) In Accounts Payable And Accrued Liabilities Related to Purchase Of Fixed Assets", "terseLabel": "Change in accounts payable and accrued liabilities related to purchases of property and equipment" } } }, "localname": "NoncashIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToPurchaseOfFixedAssets", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "bli_NumberOfCompanyInvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Company Invested", "label": "Number Of Company Invested", "terseLabel": "Number of company invested" } } }, "localname": "NumberOfCompanyInvested", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "bli_OrganizationConsolidationAndPresentationOfFinancialStatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, Consolidation and Presentation of Financial Statement", "label": "Organization, Consolidation and Presentation of Financial Statement [Line Items]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statement [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementLineItems", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "bli_OrganizationConsolidationAndPresentationOfFinancialStatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, Consolidation and Presentation of Financial Statement [Table]", "label": "Organization, Consolidation and Presentation of Financial Statement [Table]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statement [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementTable", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "bli_PartnershipLicenseAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Partnership, License And Other", "label": "Partnership, License And Other [Member]", "terseLabel": "Partnership, License and Other (1)", "verboseLabel": "Partnership, License and Other" } } }, "localname": "PartnershipLicenseAndOtherMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_PatentsAndTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents and Technology", "label": "Patents and Technology [Member]", "terseLabel": "Patents and Technology" } } }, "localname": "PatentsAndTechnologyMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bli_PerceptiveCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Credit Agreement", "label": "Perceptive Credit Agreement [Member]", "terseLabel": "Perceptive Credit Agreement" } } }, "localname": "PerceptiveCreditAgreementMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "bli_PhenomeXWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PhenomeX Warrant", "label": "PhenomeX Warrant [Member]", "terseLabel": "PhenomeX Warrant" } } }, "localname": "PhenomeXWarrantMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "bli_PlatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Platform", "label": "Platform [Member]", "terseLabel": "Platform" } } }, "localname": "PlatformMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_PrepaymentPenaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Penalty Percentage", "label": "Prepayment Penalty Percentage", "terseLabel": "Prepayment penalty percentage" } } }, "localname": "PrepaymentPenaltyPercentage", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "bli_ProductWarrantyDuration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Warranty, Duration", "label": "Product Warranty, Duration", "terseLabel": "Product warranty, term" } } }, "localname": "ProductWarrantyDuration", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "bli_PropertyAndEquipmentTransferredToInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property And Equipment Transferred To Inventory", "label": "Property And Equipment Transferred To Inventory", "terseLabel": "Property and equipment transferred to inventory" } } }, "localname": "PropertyAndEquipmentTransferredToInventory", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "bli_RecurringMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recurring", "label": "Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "RecurringMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_RestructuringReverseAssumedFromBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring Reverse, Assumed From Business Combination", "label": "Restructuring Reverse, Assumed From Business Combination", "terseLabel": "Restructuring liability assumed in IsoPlexis Merger" } } }, "localname": "RestructuringReverseAssumedFromBusinessCombination", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "bli_RevenueStreamAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Stream", "label": "Revenue Stream [Axis]", "terseLabel": "Revenue Stream [Axis]" } } }, "localname": "RevenueStreamAxis", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "bli_RevenueStreamDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Stream", "label": "Revenue Stream [Domain]", "terseLabel": "Revenue Stream [Domain]" } } }, "localname": "RevenueStreamDomain", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_RightOfUseAssetAssumed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right Of Use Asset Assumed", "label": "Right Of Use Asset Assumed", "terseLabel": "Right-of-use lease assets assumed in IsoPlexis Merger" } } }, "localname": "RightOfUseAssetAssumed", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/LeasesScheduleofSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "bli_SalesTypeLeaseNetInvestmentInLeaseContractAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales-Type Lease, Net Investment In Lease, Contract Asset", "label": "Sales-Type Lease, Net Investment In Lease, Contract Asset", "terseLabel": "Contract asset" } } }, "localname": "SalesTypeLeaseNetInvestmentInLeaseContractAsset", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "bli_SalesTypeLeaseNetInvestmentInLeaseImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales-Type Lease, Net Investment In Lease, Impairment", "label": "Sales-Type Lease, Net Investment In Lease, Impairment", "terseLabel": "Impairment charge" } } }, "localname": "SalesTypeLeaseNetInvestmentInLeaseImpairment", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "bli_ServiceAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service And Other", "label": "Service And Other [Member]", "terseLabel": "Service and other revenue", "verboseLabel": "Service and other" } } }, "localname": "ServiceAndOtherMember", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "bli_TransferToPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer To Property And Equipment", "label": "Transfer To Property And Equipment", "terseLabel": "Customer return of Beacon transferred to property and equipment" } } }, "localname": "TransferToPropertyAndEquipment", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "bli_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants", "label": "Warrants [Policy Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://berkeleylights.com/20230331", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://berkeleylights.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r310", "r652", "r727", "r782" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r365", "r366", "r367", "r368", "r436", "r582", "r597", "r623", "r624", "r648", "r662", "r670", "r724", "r771", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r365", "r366", "r367", "r368", "r436", "r582", "r597", "r623", "r624", "r648", "r662", "r670", "r724", "r771", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r310", "r652", "r727", "r782" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "North America [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r306", "r585", "r650", "r668", "r719", "r720", "r727", "r781" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r306", "r585", "r650", "r668", "r719", "r720", "r727", "r781" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r365", "r366", "r367", "r368", "r429", "r436", "r467", "r468", "r469", "r558", "r582", "r597", "r623", "r624", "r648", "r662", "r670", "r715", "r724", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r365", "r366", "r367", "r368", "r429", "r436", "r467", "r468", "r469", "r558", "r582", "r597", "r623", "r624", "r648", "r662", "r670", "r715", "r724", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r437", "r700" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r263", "r437", "r677", "r700" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r307", "r308", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r651", "r669", "r727" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r307", "r308", "r607", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r651", "r669", "r727" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r263", "r437", "r677", "r678", "r700" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r4", "r19" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of changes in the allowance for doubtful accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r216", "r312", "r313", "r630" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r312", "r313" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net", "totalLabel": "Trade accounts receivable, net", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails", "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r96", "r210" ], "calculation": { "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r34", "r35", "r217", "r593", "r602", "r603" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r32", "r35", "r157", "r548", "r598", "r599", "r685", "r686", "r687", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition-related Costs" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r667" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r476", "r477", "r478", "r697", "r698", "r699", "r761" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r130", "r131", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r218", "r316", "r323", "r325", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedPeriodEndLabel": "Allowance for doubtful accounts, end of period", "negatedPeriodStartLabel": "Allowance for doubtful accounts, beginning of year", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails", "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r218", "r316", "r323" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTradeAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs of uncollectible accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r400", "r527", "r646", "r647", "r692" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest and other expense related to debt and note receivable agreements" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r56", "r83", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from the calculation of net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r665", "r758", "r759", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Total purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r757" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r177", "r189", "r214", "r246", "r293", "r297", "r302", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r499", "r501", "r517", "r667", "r722", "r723", "r769" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r205", "r222", "r246", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r499", "r501", "r517", "r667", "r722", "r723", "r769" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r161" ], "calculation": { "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r2", "r98", "r203", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetNarrativeDetails", "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r76" ], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r77" ], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Debt Securities, Available-for-Sale [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r497", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r139", "r140", "r497", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Incurred transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Fair value of common stock issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r755", "r756" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of pro forma information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill, expected tax deductible amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Price per share of the common stock acquired (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r494", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r494", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Total revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesEstimatedUncollectible": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the best estimate at the acquisition date of the contractual cash flows not expected to be collected, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.", "label": "Business Combination, Acquired Receivables, Estimated Uncollectible", "terseLabel": "Allowance for credit losses" } } }, "localname": "BusinessCombinationAcquiredReceivablesEstimatedUncollectible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesFairValue": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of acquired receivable from business combination, excluding certain loans and debt securities acquired in transfer.", "label": "Business Combination, Acquired Receivable, Fair Value", "terseLabel": "Fair value of accounts receivable acquired" } } }, "localname": "BusinessCombinationAcquiredReceivablesFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r136" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Recognized transaction costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r148", "r149", "r150" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r148", "r149" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "verboseLabel": "Fair value of PhenomeX common stock issued to IsoPlexis stockholders" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r153", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "negatedTerseLabel": "Operating loss" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenues" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "terseLabel": "Operating lease obligations" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r141", "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r141", "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r141", "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r143" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Fair value of assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r605", "r606", "r667", "r679" ], "calculation": { "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r58", "r208", "r628" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r59", "r176" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r683" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "verboseLabel": "Cash, cash equivalents, and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r52", "r58", "r61" ], "calculation": { "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r169" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r679" ], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "bli_CashEquivalentsAmortizedCost", "weight": 1.0 }, "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "verboseLabel": "Fair Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Statements of Cash Flows" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlows" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price per share (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrant exercisable shares (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r728", "r762" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r181", "r194" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r102", "r361", "r362", "r610", "r721" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r697", "r698", "r761" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "verboseLabel": "Purchase shares of common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r667" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00005 par value. Authorized 300,000,000 shares at March\u00a031, 2023 and December\u00a031, 2022; issued and outstanding 98,744,915 and 72,169,052 shares at March\u00a031, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r36", "r228", "r230", "r235", "r589", "r594" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer software and equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r67", "r68", "r166", "r167", "r310", "r609" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r67", "r68", "r166", "r167", "r310", "r604", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r67", "r68", "r166", "r167", "r310", "r609", "r783" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Significant Risks and Uncertainties Including Business and Credit Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r67", "r68", "r166", "r167", "r310" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r65", "r67", "r68", "r69", "r166", "r168", "r609" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r67", "r68", "r166", "r167", "r310", "r609" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of receivables, contract assets and deferred revenue from contracts with customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r411", "r413", "r426" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets, which are included in \u201cPrepaid expenses and other current assets\u201d", "verboseLabel": "Contract asset" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r411", "r413", "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Contract assets, long-term, which are included in \u201cOther assets\u201d" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r411", "r412", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r649" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Contract liability , revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r411", "r412", "r426" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Deferred revenue (current)" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r411", "r412", "r426" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue (non-current)" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofReceivablesContractAssetsandDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r41", "r585" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Total cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of sales:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r66", "r310" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "verboseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r118", "r245", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r394", "r401", "r402", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r6", "r7", "r8", "r178", "r179", "r188", "r249", "r378", "r379", "r380", "r381", "r382", "r384", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r528", "r643", "r644", "r645", "r646", "r647", "r694" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r8", "r179", "r188", "r405" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total payments due" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Commitment fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r25", "r171", "r397" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r25", "r379" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r27", "r249", "r378", "r379", "r380", "r381", "r382", "r384", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r528", "r643", "r644", "r645", "r646", "r647", "r694" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r27", "r120", "r121", "r122", "r123", "r170", "r171", "r173", "r187", "r249", "r378", "r379", "r380", "r381", "r382", "r384", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r528", "r643", "r644", "r645", "r646", "r647", "r694" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Note payable, term (in years)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r172", "r390", "r406", "r644", "r645" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails_1": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Interest payments, loan discounts and financing costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "auth_ref": [ "r333" ], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "auth_ref": [ "r711" ], "calculation": { "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "auth_ref": [ "r711" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current", "netLabel": "Total debt securities, available for sale", "verboseLabel": "Short-term marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r704" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "negatedLabel": "Realized loss on marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of unrealized gains and losses related to our available-for-sale marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r682" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred Costs, Current", "terseLabel": "Deferred costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r682" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets, Current", "terseLabel": "Vendor deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r56", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r56", "r291" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r425", "r650", "r651", "r652", "r653", "r654", "r655", "r656" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r441", "r472", "r473", "r475", "r480", "r663" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity and Stock Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r236", "r255", "r256", "r257", "r258", "r259", "r264", "r267", "r274", "r275", "r276", "r280", "r505", "r506", "r590", "r595", "r637" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss attributable to common stockholders per share, basic (in dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r236", "r255", "r256", "r257", "r258", "r259", "r267", "r274", "r275", "r276", "r280", "r505", "r506", "r590", "r595", "r637" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss attributable to common stockholders per share, diluted (in dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Denominator" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r277", "r278", "r279", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Attributable to Common Stockholders Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r119", "r202", "r231", "r232", "r233", "r250", "r251", "r252", "r254", "r260", "r262", "r284", "r322", "r410", "r476", "r477", "r478", "r485", "r486", "r504", "r518", "r519", "r520", "r521", "r522", "r523", "r548", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r392", "r516", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r507", "r508", "r513" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets measured at fair value" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r161", "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r392", "r430", "r431", "r432", "r433", "r434", "r435", "r508", "r555", "r556", "r557", "r644", "r645", "r657", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r161", "r163", "r392", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r507", "r508", "r509", "r510", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r392", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Measurement Basis [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "terseLabel": "Schedule of financial instruments not measured at fair value" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r392", "r430", "r435", "r508", "r555", "r657", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r392", "r430", "r435", "r508", "r556", "r644", "r645", "r657", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r392", "r430", "r431", "r432", "r433", "r434", "r435", "r508", "r557", "r644", "r645", "r657", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r392", "r430", "r431", "r432", "r433", "r434", "r435", "r555", "r556", "r557", "r644", "r645", "r657", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r511", "r514" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r318", "r319", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r403", "r408", "r503", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r640", "r706", "r707", "r708", "r784", "r785", "r786", "r787", "r788", "r789", "r790" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Remaining Useful Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r212", "r345" ], "calculation": { "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated annual amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r342", "r344", "r345", "r346", "r586", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Year Ending December 31:" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedAnnualAmortizationofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r89", "r587" ], "calculation": { "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r84", "r88" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r89", "r586" ], "calculation": { "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Intangible assets acuired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency translation and transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture, fixtures and other" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r56", "r116", "r117" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt extinguishment", "negatedTerseLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r211", "r340", "r588", "r642", "r667", "r713", "r714" ], "calculation": { "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r341", "r642" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill with a provisional assigned value" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r81", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r40", "r246", "r293", "r296", "r301", "r304", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r517", "r639", "r722" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r56", "r93" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Loss on disposal and impairment of property and equipment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r38", "r174", "r182", "r196", "r293", "r296", "r301", "r304", "r591", "r639" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r347", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r247", "r482", "r483", "r484", "r487", "r489", "r491", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r248", "r261", "r262", "r292", "r481", "r488", "r490", "r596" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r53", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r55" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r55" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r691" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r583", "r691" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r55" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r691", "r765" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses, other current assets and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r82", "r87" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r172", "r185", "r234", "r290", "r526" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r43", "r398", "r407", "r646", "r647" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest cost" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": { "auth_ref": [ "r184", "r625", "r626" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.", "label": "Interest Income, Deposits with Financial Institutions", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeDepositsWithFinancialInstitutions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r240", "r242", "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r80", "r632" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r220", "r629", "r667" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails", "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r207", "r219", "r282", "r337", "r338", "r339", "r584", "r635" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r80", "r634" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r79", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "verboseLabel": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r80", "r633" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r78", "r175", "r186", "r197", "r627" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r766" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information related to operating leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesTable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r767" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of operating lease liabilities maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesTable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r767" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r539" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: implied interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r22", "r246", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r500", "r501", "r502", "r517", "r638", "r722", "r769", "r770" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r180", "r192", "r667", "r695", "r709", "r763" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r24", "r206", "r246", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r500", "r501", "r502", "r517", "r667", "r722", "r769", "r770" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails_1": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Current portion, less loan discounts and financing costs", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Long-term debt, including current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r114", "r249", "r396" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r114", "r249", "r396" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2028" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r114", "r249", "r396" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r114", "r249", "r396" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r114", "r249", "r396" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r696" ], "calculation": { "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r215" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails_1": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Notes payable, net of current portion", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r27", "r115" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r104", "r105", "r364", "r365", "r366", "r717", "r718" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r364", "r677" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r241" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r241" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r54", "r57" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r39", "r57", "r183", "r195", "r204", "r226", "r229", "r233", "r246", "r253", "r255", "r256", "r257", "r258", "r261", "r262", "r272", "r293", "r296", "r301", "r304", "r321", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r506", "r517", "r639", "r722" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r255", "r256", "r257", "r258", "r264", "r265", "r273", "r276", "r293", "r296", "r301", "r304", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r266", "r268", "r269", "r270", "r271", "r273", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment [Axis]" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment [Domain]" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/LongTermDebtScheduleofPaymentDueonNotesPayableDetails", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r293", "r296", "r301", "r304", "r639" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r764" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r530" ], "calculation": { "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of operating lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r530" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 }, "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: current portion", "terseLabel": "Lease liability \u2013 short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Lease liability - short-term [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r530" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Total long-term operating lease liabilities", "verboseLabel": "Lease liability, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/LeasesMaturityScheduleofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r532", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesScheduleofSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r529" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r692" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r538", "r666" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r537", "r666" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "The Company and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r221", "r667" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r213" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r223", "r224", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r31" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r154", "r155", "r156", "r227", "r230" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r223", "r225" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentedTechnologyMember": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.", "label": "Patented Technology [Member]", "terseLabel": "Patented technology" } } }, "localname": "PatentedTechnologyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r350", "r690" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r51" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [ "r688" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedLabel": "Asset acquisition" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r46", "r75", "r238" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedTerseLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r47" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsNotMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r683" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails", "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r631", "r641", "r712" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r689" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r49", "r128" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r75", "r238", "r239" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r45", "r75", "r238" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r49", "r128" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "verboseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r23", "r103", "r106" ], "calculation": { "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "bli_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Accrued product warranty" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r99", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r95", "r209" ], "calculation": { "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r97", "r193", "r592", "r667" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r237", "r326" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "negatedTerseLabel": "Provision for doubtful accounts", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsChangesinAllowanceforDoubtfulAccountsDetails", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Purchase obligations" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r50" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of term loan" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r132", "r198", "r777" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development state tax credits" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r679", "r693", "r778", "r780" ], "calculation": { "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r608", "r680", "r693" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "verboseLabel": "RSAs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r348", "r350", "r353", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r349", "r352", "r356", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Severance and employee-related restructuring costs" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Total full-time employees (in percent)" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringNarrativeDetails", "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r56", "r354", "r356", "r716" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring", "verboseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails", "http://berkeleylights.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r349", "r350", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r350", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring liability, ending balance", "periodStartLabel": "Restructuring liability, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r350", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedTerseLabel": "Non-cash settlements" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r124", "r191", "r601", "r603", "r667" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r202", "r250", "r251", "r252", "r254", "r260", "r262", "r322", "r476", "r477", "r478", "r485", "r486", "r504", "r598", "r600" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r288", "r289", "r295", "r299", "r300", "r306", "r307", "r310", "r424", "r425", "r585" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/RevenueFromContractsWithCustomersScheduleofDisaggregationofRevenueDetails", "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r310", "r702" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SignificantRisksandUncertaintiesIncludingBusinessandCreditConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r414", "r415", "r416", "r417", "r418", "r419", "r422", "r423", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue From Contracts With Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Summary of revenue by geographic areas" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Remaining performance obligation, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Remaining performance obligation, percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r536", "r666" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesScheduleofSupplementalCashFlowInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "auth_ref": [ "r543", "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "terseLabel": "Total amounts due from customers" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]", "terseLabel": "Schedule of sales-type lease maturity" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "auth_ref": [ "r543" ], "calculation": { "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r543" ], "calculation": { "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One", "terseLabel": "2024" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r768" ], "calculation": { "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year", "verboseLabel": "Remainder of 2023" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r543" ], "calculation": { "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails": { "order": 4.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three", "terseLabel": "2026" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r543" ], "calculation": { "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails": { "order": 3.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two", "terseLabel": "2025" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseInterestIncome": { "auth_ref": [ "r283", "r541", "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income from net investment in sales-type lease.", "label": "Sales-type Lease, Interest Income", "negatedLabel": "Less: unearned income" } } }, "localname": "SalesTypeLeaseInterestIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersSaletypeLeaseArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseLeaseIncome": { "auth_ref": [ "r283", "r542", "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.", "label": "Sales-type Lease, Lease Income", "terseLabel": "Lease income" } } }, "localname": "SalesTypeLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenuefromContractswithCustomerNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of trade accounts receivable, net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-Sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r139", "r140", "r497" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofAcquiredAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/BusinessCombinationsScheduleofProformaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of fair value of consideration transferred" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of cash flow, supplemental disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/StatementsofCashFlowsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r27", "r120", "r121", "r122", "r123", "r170", "r171", "r173", "r187", "r644", "r646", "r696" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of payments due on notes payable" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r127", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r84", "r88", "r586" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r84", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r5", "r16", "r17", "r18" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of product warranty liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of fair value of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r61", "r176", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r61", "r176", "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents and restricted cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r349", "r350", "r351", "r352", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Changes in Restructuring Liability" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r37", "r73" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r438", "r440", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r285", "r286", "r287", "r293", "r294", "r298", "r302", "r303", "r304", "r305", "r306", "r309", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/Segments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issuance of vested RSUs with grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Exercise price per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r445", "r464", "r465", "r466", "r467", "r470", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from a business acquisition. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Additions from Business Acquisition", "terseLabel": "Warranty accrual assumed in IsoPlexis Merger" } } }, "localname": "StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Settlement of pre-existing warranties" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease": { "auth_ref": [ "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard product warranty accrual from changes in estimates attributable to preexisting product warranties. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties", "terseLabel": "Adjustments to existing warranties" } } }, "localname": "StandardProductWarrantyAccrualPreexistingIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for new warranties" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CommitmentandContingenciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r29", "r119", "r202", "r231", "r232", "r233", "r250", "r251", "r252", "r254", "r260", "r262", "r284", "r322", "r410", "r476", "r477", "r478", "r485", "r486", "r504", "r518", "r519", "r520", "r521", "r522", "r523", "r548", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r250", "r251", "r252", "r284", "r585" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r9", "r10", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common stock issued for IsoPlexis Merger (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r10", "r119", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r9", "r10", "r119", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r119", "r124", "r451" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r29", "r119", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common stock issued for IsoPlexis Merger" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r10", "r119", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r29", "r119", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r74", "r667", "r695", "r709", "r763" ], "calculation": { "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://berkeleylights.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r534", "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sub-lease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r524", "r550" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r549", "r551" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Accounts" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BalanceSheetAccounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "R&D tax credits receivable" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/SummaryofSignificantAccountingPoliciesResearchanddevelopmentstatetaxcreditsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r199", "r200", "r201", "r314", "r315", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivables and Allowance for Credit Losses" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/TheCompanyandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade Names and Trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r318", "r319", "r403", "r408", "r503", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r706", "r707", "r708", "r784", "r785", "r786", "r787", "r788", "r789", "r790" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r349", "r350", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/RestructuringChangesinRestructuringLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r636", "r657", "r779" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. agency securities", "verboseLabel": "U.S. agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r779" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. agency securities" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r779" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities", "verboseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesDetails", "http://berkeleylights.com/role/MarketableSecuritiesUnrealizedGainsandLossesRelatedtoourAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeasePayment": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.", "label": "Variable Lease, Payment", "terseLabel": "Variable lease payments" } } }, "localname": "VariableLeasePayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/EquityandStockCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r266", "r276" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in calculating net loss per share, diluted (in shares)", "verboseLabel": "Weighted-average shares used to compute net income per share, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r264", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used to compute net income per share, basic (in shares)", "verboseLabel": "Weighted-average shares used in calculating net loss per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://berkeleylights.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://berkeleylights.com/role/NetLossAttributabletoCommonStockholdersPerShareScheduleofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(4))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498357-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919101-209958", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r672": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r673": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r674": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r675": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r676": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 108 0001689657-23-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001689657-23-000025-xbrl.zip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®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

\] V ?/70V X YX84U&:11"A03&4*]$#?)1XOKH MWW!2O!VNG'ZG9Z[74+DU-W3Y]ZW!H>]KN^&+Z8]\>%AL[U@6.)5''-61A$QGYXL33OO3DAAE:0@*$5Q945F1[U)[6+,H2B@]"NM;1KIT(&_=8'0(]]TP. M;JB?#L[8G9BJ:6>QSLV>GM.O?"B?Z=-E(7E>F\4E.YNTSV"DJU<@A>3JI(<2 M,R:I$RNY=0^+-I2/>SIW ]NV&GX.N/Y\@8N+U7SZ55Q)*&(6&=C(JN5L.+AB M'"3'-!=D.O/0NG%Y6PZZV)Y/BL'6R^!P0#R'Y7#C-'C& JX.N%SG:4@AB'.7 MP 9OG."(7G6WU7<2;7H.R^ P(#R5)4 ?QHJ(KWGBDQ0I% $D;0:*HX:0.0=: M]2K%+!7Q-P;.;TA\XGOZ@4@Z!- 'JO6IH/8A*=,_F,X3GP@7I>"N@ FI=HS5 MNB;Z,9 "H\O%!2]'@?,.M#_Q3?N$.&\-A X6P#:_:).&]W.2M*KA0P2,4=:( M=H1Z5;EWZ]5\CO"@#(W;P'-T<)\4 M#QTLCL]XEI=?Z)=7=3>K+U>W.I/:^3H*H:%H@>2 < >!.PV&&^1N;<+'NEV[R][U_=K_.5K$MV&ZO(W36]GO M?TR7^/7K(E_M9O.R_J='WVHV>'=;A;06QHGO0:--&!D=(<:*ZDN@AZ!$!.1! MF*"CQ] ZN>9$]Z"_"OW#1NA7L2_/F>$N6>#DJX,*:,!C-J 9S\8GG\BS:LSV M0_1T$8)IBI6[IT\S;8QHT2P7%Y./BWFZC!2[N@- MFC>K9-V?:+C.>KS1(%22%Y R&G3,)PO(X2EH"9,ZL98]KI'93_VX/'O15I M;D <+[R1*ZY^(7Z]$) 91?",D!,6$D0@001!^*45(A)B$D[MJ_LQ+8(&2KI/ MW0=(;&2%?SS#BQK_W9Q3/(I"6QM@4;1-<4[GE"QT;*&+BE?8,[.#KG]]:B=J M/D0Y\R:2&GU1UQ;DJ!D.<6D!K:^H-#^!-*1!TB5('Y5#:G1;T+X\= M9RMOK>5C9#7V4L;%Q8R>]&WZ_1T9(+=FI:UY\>A0H\Y@3:(3K9 -$D*TM,_Q MY"P=;@%WT?MC[QGG^KCY-+<&6PJ^@WC!XY7J/AIM''J2#R>7*6I/VR8M/7)T7,E6 M2ZN'&E[]Q%H\[*7ZO5L\[*.'SEH\E.(5>ILA\3I_IW;Q<]PDX#E[8Z3QMNQB M@#ZQ%@][*>R!%@_[2*^#'>6>'??==:ZAWKP8$IK:(8/E4"T2T('^:AY M^J,N^>7F5Z^:?>(LW>GA?I*,EP/H.7T6S+%".W%F3$!GE% 9L&A.)WEQ@&@Y M,*>M=:E8ZUOGA)\H,V8S5>=&(>_SQ7H809TPG:66"HJC/8,L9 \A\@"8BY&6 M,2RR=6.$A^AY&IDQ^V#E[I;;3!M=A#BVBJFN\EM,V8 B1/*Z0F!T0*6()"W4 M]"4HX3C/DK5N';8#65V4!PV*M-:ZZ<#(?(BEF\&7$XD\:L$*^.KG*R23R&5? M;Y)1.W+)R&1JW>UX-\J>1J'/4* [4$.=XNZFPF/-$R_12L842)]KQH&-@(XE M<"EJR6(TO'F_U5WH>AKU-ZTQ=Y1VNCU:K[FZM9288*9.: -O!/ECIK:5K*,Y M<@I.!W+6;/,2W1U)>QI%-H,A[T =/6V?&<_RQ:;HZ,5B46O?SNG=0[K%C[SR M9)[O/JR?V+GU2D21G(1BF 'E P=/GX%/*EN!01;^1)W;=WFYG"]6,O\C+^-B M^OVFXXDB3\KHPH!'2\:M561D*!- "!YHUS?,WLVA.YKK!\AY&J[M/DBYNQNV MTD4'!M]+/*L%NI^_Y7SQKO[VYAZ1HXV*3%0PVGOB ^G<8"%#BI&1@ZZLO-L1 M_?@;UWMH&1=0S91]][*UA>0[1=#Z\E$E$4JP) ]7QUHS#("2%S B9IDDN>2F M^:W]O=2,?%/;1-L[0.@ T8]\4?][H/!%H2>_.#N;_UW9>S-?O"**IA>U7?+: MR]FD2BKG-#(!Y&+;JX[=Z'@$4XK,5O':5&.'._W#*>@/5(?H?WYR972P;VW? MUV^N&Q6Y*]'S##;85=JVK%U;,FCM-N@ 5M?M M*%[,TA_318X7;Z8S6CG3V=<5C\O5UYOE]1%_5N=I^67^]_)^%L!16G\FA\"7O^=UV2\G7C.?6?9@I8^@3)U![1P"#Z+6 ME<7LFALB+>D?]RJP=Z0?I.7G@G!":[[B/MC$;#2&+,9:(YG,R@N.$%55@>(J MYM81S+8!SBL%C!/362?,OG4>=+(.U8+^R/*7R%J5C/LU[][ZMUQXJ)EV00/)M96:S8[ M6CTA06$F^Y)2<*QU#L>^-.Z$/?NDL3>$MD:^1/AU7:TF+/Z@A55W[;>SU6>_ MY.9/@F3(,Y-@5WEY10H(UFI@.>I@=!'&[M1S:+_7[H0M]Y2P-;3LNX?5V_/O M.%V%UFI)\ML\L!A+-0<8R[P)IF[>N1.@_/,#U(%2[[?+ M\^VKO,T=W)<%IKRUC.+P++/#WM,HM:P!DXWRR3XLON)L^K\K+FAS6L[/INEJ MV7!!29#22*^\-^VO M")L0WK[0ZE^+F^O@2O#%(U[VW1Z MK#U>BG6POCH(R=S.1?AC?ADNRN79[QQNF&.6!>,CR4W49HL,"[@DZ+3@A@OR MMNB_UMU']R)PW(N@#K YF#:[\) ?K(*,AEL=90%._CVH2#9P%1=PFY-BPDHO M6T==CJY)'>RFI@,HMM)5LVC?2BF6WY=B6XMSKU<.:'P>SGI7 M=FCQ4M0^HH Z&5")<7 Q%$B)Q^!49MB\I+\/.W2GLV,BE&;"&PY%U.XU53+> M60O>:/3(E=>L]5",W2A[#G;I/M@[[.S?2W_''OI78R!7PZR'2&S>FD;[=A87 M-:A!'VX:>KV:GP<2>A7_Q.4ZB*3.K1*%S',K''A,'G(2=-H5@\*D1_;@=M0\ M!W/U$,B.I,\^;-B=ENE?B^E%_E!*G7_ALDJ107&E#G\G2]W;4J"08+VP*AG3 M.BRR)XG/P=(=?N,]3*/'0O9+RS$D/Z9+$N06+B?9L5QDSB!B[4##% =?B"49 M;; %JV1;9U,_1,^X^4/C([*9KOJ!WX[6C;-:!F$4>&GKI7\2$)AGD#6*Q+5P M.;1.#FIHG0Z6_C,^) ?07QOK]/4LG3I&4"_@9@3WGVWC +\]=D!?_V$6NO+G M.=,Q)%4(M;5XC^ $P88$AM>F04)9U[QNM@M__EI%G_#O/^GA"WK+\GV^J,U MEWGQ(R\G41EA1!W.J.N5 M.KACNN;HK_GBO]_.R#J)Y,7]RE)&A2I&#CDZ\N-81D"N&:0L?6;>*F]:1^]W M(.LY..A-L-A(;K#4A"NSJG-D#%94#5KU.LZR#:G0C9) M5F0(#07&^\EZ#GYV$S VTEQ/8"0N)C86,J"+ Q\\@O)1@D/I@3L5BA/)>!F& M0MW['=,I.W>:F\!K7UT\K0M*$N9WG*;7_WROPY)J6^W5M*3US>Q5K^VV?LD^ M;QS093F8\:Z\&668-DE;2%&2Z1>E@J"-@"*]UAB-8LW#P5UX,SNU)9;6V< C M)&$8K?YLP15%R]<4543R+N76&VBKEM&=^S/[H.Z@AM)[:*Z+;@Q_Y._SY90D MM-HVKKO%1J:*-!Y$2$2\B.27:<6A:#*(7='),-\8@%L)>0YNRS&0.UX['=B& MFVD7K^;+&QY*";;4"8D!=>7!"4#A/; 0+^71J>@P]R#*Z. MTDD'F%I9U+_NNFBU%=)(P!2( U,'=B=44+QCT274(K<^$W^GXCG-C-^?V7)1!ER+;THE1%E23A!9P962I:09.=\Z\-Q![+&+;\?'WNM M-?>TPBWTY^(RWQ=UV'3]G^;&,9>]7SM@X.4X$705?4DB.)/(<5#%TZ89HH,@ MK*$540Q#F]&49QE]>4TPG/_,M!K.5HF0-SJ[&90B2ZPF+U>UEDBH!*X6I$=R M[0U)1K+0NI/@HT0]A\C+/HB[N_.VU5H'1L"'[WE!,EMWV+@[K.=:>K3%QFJP?EB6=9\*"J@-^T)C:,3SFDE3@LOF,AU:T/X?8 MSC&@'@4#W6-_8GU&CB1-:94 E[#%#V'$-%P.-U+ M7QV@[^-BGB[CQ5]8)Q1=_%R9='CVZ@R7RVF9YK1A*ZC,A$D*O")K7JE WU77 M$E,==BZD=JYU2ZH=27L.H:5C\#B$!CL YMJY(.Y*7M:4=SQ[DV\,')58UEIG M\$Q&$ELAQQ51@$6K!;?!*C= 4?@#%#V'2-0Q,&RHKP[0=Q7*N&)IBWD=M2Q% M.@2-0H/RN@Z]S[6S90XF98%.M^[=\C!%SR$6==2AW$Y?X\_YNW2DW?LOI M\BROEN_T@KRK'_FWUUX-4^):&E<2@VR36/GVX%8[O/5..V16-!_JOCMUXP8H MA\/4;[URA]%7!P;@IB7!B_@_E].K,--J$&%,-K ZO@VK,:NT(?=>" $18R&) MU3[ S0=^;B=E7(P-I?F[LQL;J*%3--5O%SFO)Q$&6V.4DD,*]2*6RP1H1 !I MBA*."R6P]<[^*%$CCVULH?H=X'2X'D;V%-XNYQ_/,HED/5F2V^B33Q:XK$Z. M] Z\\ '0YQ(XH@YBEPXX=Q[;'PB.4-B\C?0ZV%%6&^S=I<'K=$EA"ODUM0-$ M(9<&N2+G1A;ON=2L?:'1-CK&OV MVI<__\3_.U^L+J162TCJ& K7"DR@+RIE.K&=U1#(#^7"%BF%;+R][$'>N-?; M)SJ\AE)7WTB\8>P]GF_L1^6E\Y'$J#B/H$1 \%YJT$RG$#0*95IG#.U)XKB; MWF!0V1V21^MMY%/S(UZLKA]FZQP9M[_AF[!<[Q2Y\TEW/?V]>YZ8E"V3%J?ZZZ? RB5 CB>$43DQ;A@ M7%0G/$&OZ1HW$V?\H_,P!74 NLV%P<1:9T7@'K31&A3C%H(3=4R UZ4$7EV? M@>Z7NMVH#M3JO(&(.X#&79^G7KI/TRH#@:UXL<''+-5=,!W%Z\ M+&31"LL1F*CU+^3#0ZC-;*5 SKQVBM;F_\O+:HRI(_*R]M%7!Z?T/N%(S[1F M2G!P+I"K)>CD<;DFCB0L664Z-'SK([OU14,/^5M[(>2(BX9]U-4W$K?&-G7. MT22T4%#75GA>@).<0_"<6:-3B;EUYN"SO6C8"RI'7C3LH[<.8+GIQ+CJ#4"J M6WZ;?M]<*BM;DI%D+X="EK/B=3H<&@,D,U.DL*T&T5>Q;.AWAJLDJ_LE#"U%)1FXQ#1D;IGG&HUJ7I]^EX9NXWO-@724 M]#M S]4]7?[]EBXP[H.,"C2]%52V"0+7&AR6% U'[GWS\O)[:.DV=-<<34VT MT0&J=HM%I1V(AIWA M=J!JNNA,_H#8_K68+Y<3QT62T04HB47:M8L$^L@#9L&5=:XXV;HAZV,T=6N9 M#0VT U32]9Y6>SU>GE^NVLW=OIF96%Z*S4[7Q&11J]PEH&$*$BN"&U8TYZTS M1O:GLEN3;G 8ME!;%].U'^"QCO41A2R2G"04,D:NIH5C3@ZD*HY[F8J+K=L! M/4S14[B='09R^ZKCZ?:^N+F9?+V\F)ZO%MEL=HEGMY?:.'>V!Q%T\@O=X\4V MRFVO#=E%7XN/L2:VE.S(Y]8<8DQ.9UV*1-YXLSGI;>\#B_O-Y45]T2U%;=I_ M;X3C21*HO +KBB4)J0R!)P$Z"2Y"R5Z;UC6HQ]#[E&Z$]\'='AMV6YUV;L;^ MSN6G7 -II.<:!%E&//NOC(N)2RB#)&XQVSI%@4<(OACP5C/N-+F'IPP7[4IV MMXY]8XSM80 /H? GA_'W=$Y^^3N?_@)PH)WS?SR\7$LZ"YSKY>"B*M4L;!9<\!,3LM ME7$BMNX4+_\2SRSR_:0;\=D92O;SJ!KP2 M \Y2DUE=1[RL4=BM%;N-0FK7Y-P$,FX:,&?KHM2.063:@^+H@'PMVB>ES#E[ MI['Y0+^'Z#EZ]]P\>[VT?A'RGQGKR]*'V:<<+Q>+Z>PK_<+[^6RQ^>M+7$XW M618*0S Y0T2NJF $^$C^J.'*FJ #_=%\0VU%_,C!AU9X^VT/'46Y/=@$&\9? M_KS^]C^F>4%$??OY+O_(9U=-7SPC!JJESD2H35\BN%(3\[(\?E1P76(1CH%E]QTPP[*:N\EI")K70G3M$Z2!/21(T:G M;6I=U?, .2-'SD<%UR$:Z0!FDWUK5">AD:XZ0-VG3 [_-%[DM)VG[9]N M5A@O)D1C(02OZF") H$'#EDXE[1BR6'K._%CZ!W7G&N%F?E("NP K'_.9_GG MG[CX[WSQYG*6K@N"F:%*5TL'']^_._YH34636$7\T7W^=7K2:K^?+B:YY%LET^5Q-E M;<5<^496F9"" 1&%JY,2+'CN2(:60L! ;.D?RJ+P (V3@I93(AAA&L8V43IS<<:\K&FBI [!MFNY6 M,7[.BQ_32"+ZL/5:_@L]^%G;F(2 XEBH-:2Q'@X(Q:#15D5:ZJU/ M[);TCYZ2?CR@?F_",HYV.T#V'?OE_?SB[2R>7::<_II>?'OP@))UV#J+BHR< M&AU-B. ,LQAH[1*21ZNN RC>2AJY=2GV9I'_YY+6 MV\^5B24\Q\PDL<0P7P7,O X)>/:"I2*8LX-=(=Y/ULAE#'UX68VUUQ,@MS&T M7L",%ECDA8,('D$%5HL[C8:@B:*3OHQ\GJ)"NG%11V2/TZ1B^=0FUY MO6+7^[GW48LB#&2KZI!Z3$ R#!"8XYB,E.GN+/9A<@[OT-4)V%J!89<\PV,T MTQ/:7N(962;Y\[><+_ZUF%]^)Y:NK97/I,05NZ_P^RIR^^ZZRT]4C@D>/ AO MR&RQ7()'Y!"%95Q:%GUH'N \DN:1B[4Z.Z-/H/<.<+X]EK"EJ&."06NA5"U. M5K>!&!>7JS++3&J_>$6[ 0E@DDTRQGH%613: P*QC4'6 MWKG1%IM*+*%U=2#S<&@D^GZ",Z*EZTF75W57N\97%*%HJ*1@!)TH%* MP0*6VE5>,4_&DDC9M8XAW4M,)S>B8V"QC8+Z;:WX2+'R38O ;3]]/[_8V&%X M<2.CH6JWCR'F-+7=S<1UBMIO[A0*S@U(0[!5LE:2Q=J=B*R!J(PNQ@U6XCQD M[??+G]LVBBM/P!F6?$D:N'+KRA G4(/(FJ'*MH@P&,\/T-6)N7HL2AZ(;[91 M20=6Z/9 W82D3L#5# ,[ M!=$/4TA/^+I9C-6*>7$^O[RY K.>&\XRTGJL38U<=!"JO+R3N6!T++1O]KX# M7=T@[7@@W >R5EKI &D?:]\A4LV-*;*%RTVP-NB,@HQ=;DEL2DR![D=8*[9MBX.QYJ($5U@,%7N%C\I&/@4_Y.3*YF(Y#0'F O&1^9 MD9"Q#C\*7 Z*4$[^H.31<)CZ^N-PTPO]0=EAK,F4R M5U"!L>3\D]L?(92L07.>4RZ2EEOK0;+[T-=)U&8H) ZFJ@Y@N&,O&.$SMYD7 M0/3DD46R;;S1#KPNVC.%1J3AKA2/[OAT@N#U\"Y'*_7T!+J=VBL496C-B +2 M,:REX"?R"53: 83?S4EJ>7%>K\JO>9^H MR(U#8L))LJ25\K0$G2$F>(RNY" 9MK[=V$I()WOB2; P;ZV8?OMX?US,O^?% MQ4^ANWO>1H'WQXM9+KR_L MA/>,Z2S!)*6J3\WI'$[D[T931!'H"="M0[6/$77L=G5UV=(2(X9:V0 M$*,AYHM)$+SWX&-2/G"3O&E],;(K;>-NBFUQM4UOY M[UR*-E=,SWBI# M:R=.2"=U7:+1NUS3,#PX9C30VB4KQ4NKFG?'VX&L3G>W0Z&P*]0.U,N(4",S M:W)#_GQ^=E4Y\>?\[+K#&GKF=(X(0M6H/&.%[%8N(4<6L6B651*/V&Z/OZ53 MP!RJT/D@TNU@2WHU/_]^28^[YFK-1C(2I>4<4KU,45XD\"@XQ&0B*T%8'UM7 M%=]#RKB7#4,AJ:7\.X#1F\O%;+J:L#5+;Z;_U.^N%T3107$Z_CGMP:!,J@W3 M;"VY%RZ+&$ML/Q;B7FK&C9,-#:9&6N@ 3^\R+O,WVE;?GG]?S'](&?<1@=#(ZJ5'CJ U*OY*E4_5M6\ MG9'@OI*NKKLL%B,CK03P)JHJ(]INI2[ HRZYD//B5>O0ZD/TC%N9._R9UT@3 M':#J7EG=Q)NQ..XR;;V)T6)10DH2%4:PK/"4,PM!MVXL^#A5XUI5XP80#E-- MSV#[UV*^7$Z8ER9R[D$4K^F,-\2-]Q:R2;GFAWJE6V]B#U/4J1-XH/YWA=?^ MRN@ 6B]BO#R_/,.+G/[(1$2)@;)H M:"?'0NXP"41XPQVVOI]H17NGGF8;N(ZBX",*L+]62K\,OW6^S\22-[I@=B!# M[5++(QDS1M-:M4DQ+5DD(9]JXR1Z.G52!]XV]U5$LZ+K8\O[/Y0_ILOO\R6> MK;(0KCJW3F=?:Y;R?'8QG5WF](%X7FEPPB.7// ,QN?*HN/@K8_ ,E.Z1"6* MP];[X_YD=NK5-MH*!U;;DTOQ>(^+RN:/(VK[=WWRL(D;#S-RLAP-%Y@5G'DH MB>7:H\0 .L/!$HI2*(&IYJ.:!\_1N&TT3 3WB-9%\L@L!Y5D K19@?21.1UM M*,TK$VZ_OU._XB#]_]X=YT Y]^!$'+"Q&F-8U,F!]:M&A,(#8M @R*9DS@NC MFD_ '.H\/+UKT 1Q0VNMW^-P%=U>-CC][GE0H\-N%S(;G6U7K[J&E?5&(,\! MBJ"M1V6O +52H(U@1FL?T;>NQ_V5@J,S"R_#67T@P7E^GB>.P!50D@%7?,U! M)\0&C RXI 6BDLXZ-L\?_(6"<4^N([3[6TK@X8+MX*!:;V2SKRN)O/[G>YXM M:Q_15,BIR#6R0:>M)GEX3SNI]J&HD 3+S]@T!,GQ8NX *_^)BVF] MBUCQ\!%_KH)@(CIM'!&=C"#W4WH-KA3Z:V9%$;7OZ\*2WX=7'TM+_\G<]^Y#_)I?RVG*3:1Y5G \IDXK/." Q)D]L:B[:N%K'VN6N7,!5>NBG[V)'/=* M<"ST[:V>)X:_-_/+Q<3FF&E5.9*AE"3-+"%(7B"I6+QBW*!N'?C8E\9Q,V)' M0M_>RAFY\&Q7WEX4>M\U@PY3Q,P4Z%KOHDHJ0*M-@N/DV,;,8@EW"D2VUJ,= M]/*=8&4ZAM5IQ/Z$-K6)"]84:S64(.IZ(>9JZ DR5R$7Z9T>X,YB-]IV0IOM M&&V#*J.#A*X'^?KW+-6[T,O914ZO_XGTJU?=+B?<(5?.D(\N@J>55&@E(:\- M+WE2R-!+T3KE]2!"=X*?>^KP:Z*F\1-7[]O8O^09SBYNE6.].#N;_UT;(4UR M,MYDA343+M5!.+49+_>@64H:41EVUXO8^2"]_ZT[@-?.U^E]WKB_?_K FOZG.;>>*(3E,K0>= MMWDU8/Q#(-'-ZCQ9<@J_X>QK'3A[GYFFHL'H%9VLEME:XRC! M25> N92<)MN-B];,'T%N5QD3^^#F[OET*I6-'":_PR9]N3S/:6*T$\%858L? MD6PZ5( ^!^!):"8%(Y?3/;+YW?_TKM(7#L%((\%U$,G^%<&;:.E$>PPQ%@6Y M3JY1K%XWRJ2(BX3"VLR4:=TG:SLE7:49'+.=-!!T[S;NC47Q(J5I?6H=27Q" M\^J@UPYD5!TO@F%,J!,U79SSB1(B2# M&J_1EBP+CBPW$!YK^R"FP L5P E3D@U,,=/ZSF [)<-#&_:U5F/ MC@Q2>",>)NH-3K"Z_B_7R MN^Y9SZ)2(:$%D;,"%5&"=S: YM&B%4F;,,1 I[MTC(^7HY2[943349+N$"WK MIJM2EB!]\L!*[89I>(&0+7FN.GDRW+B@'P^,EQ[&01ROX4<@BY:,+L:Y#K3[6MW:(KZ7F+Z@ MIVD*K06 MFZ:S,I-4F%(V>;G+[?@CK^GI &F B)9"[> XV70)J@'EU5;IF=7> M1@G1.E8[!$D(C&PG([QS+"B)HG7C[KLTC'M;WMKD.$K"G2%DLW;H-0I-)I(Y MB8-YI.,T:9#9,T'[8F*^==#D=RK&/6F.T^H#$#E Q!V Y.-B>KXB?[T+^F2D M9:E 22G3JDD2O"6/WAO'?X/%V\'Z/AU2WUWW7&> MTPHQ @OP6BJM$,D[EW0:NR*Y=%J@E4-<7&TA9=Q.',-ZN8?)NP/8W [JO,&X M2DK]$_^9GE^>OYPO%O._I[.OK_ [_:0FJSIN5O&=9#+)"W,"IWP!B\1="D5[ MV3R0OP=]/?E%!P+B@9!;4^UT@+P["Y(\P(E6,D8;%41!JU!I1U)R*H 2BM>V M\9G9]OWY[U+1DR_5!D5'2KH[K+R=T9/SUU MS4A;UKD3Y+?F8J*':'0M]3 ,7-(1I)#"FV*8XJ4!7'YYZ;BMQTZ-G3PX(;DDYI;+5_/S,)VM2TF^7]40?2@OXO]<3A=UE&85Z'I4SHL8 M%Y>U7/%J3;V8I8^+S3_YF&=X5FNO)UPS#*)X(*'2DN(D<&]KWE)QRN5HLQ6X M ^Z&HF_<'F6M =J%%CNP^_^%T]GRW7RYS,L/,]K>B<_+Z?+;E1@J^Q/OK1<\ M(YBDR7W128'7Q) STD65N)6Y=8[8HT2-V[!L""N_K1[ZZ>SRJZS>Y+SNN59, MD0I5@E"XJ%/L:)E$P=;T*QLO<3E= M?B9:,'V8W;Z8X!.96.3*UL&K6&U17^IE-0*9#5%FJ0V+K?N4[4K;R(W+AD=7 M([6,G6-RYR#_>2NH8H3SQC$!4B8-RM(.[!7Y/"X;(;S/:'8RRQYXQ=G(_<:BT$' 'A]8G\@P6TT@VU(IZS2Q'<36ROK:4P$A';L[D MX7JGZ?_2B]9#;'^E8#?,/*F ^!$B[GU+^7,ZJS>/E2]R+^L?=:+O#SRC7U^^ MQ+/:9+;&X6HQR81I[GSF$DHQ9,[I7-N5U-EZ(@L,403F]@]Y'DG4;G![HO'T M4RJL@ZUL$^A8C^>\RGT1+AIB7/NNG2'Y=Y/KM=*->F5\+N[QF@B<*!3 [;72%DXXO3&7C0 MK&+)53-*0LXAV((!_8WA^.2Z*WAA:&EA!IOK))S",CD4BC96U-R88KQL/G3W MJ717V$?ONW17V$?4'9QA6RO">72*.2%!"T'[JF,*G""+,7AM/$^*L]A\$,R3 MZ*ZPEW)WZ:ZPCZ0[1,LZYSDS+8U-$M"Y4(>N&L!H G#K5#:KS)KF4]">2G>% MO32\6W>%?<3= 6CN+_-W-@9.1AQYIG4:2& >0O "DA3)JE!M_]:X>5K=%?;2 M],[=%?81>P?XN<^;B"9Z[8H K;RKMS4)T-*.'+4R*!0+I;1NL7!,6<%)B^>/ M.:A:R+L#V-SV.-8=_J=Y>9W#L/Q0/BZFLSC]CF?;1XDKJ827@@%WJDZ]LHZ\ M56)?J6"845FSYJ')8VGNR6(Z$#A;CL"3:?%IH?;M[+=!XU(*+8*SP%&0I&DW M!\=R@J!24BEFAYF/!]G?">YIXSPY7H_4WU,#ZV8D>8K1,)DL:/JSCN'10$XV MG4\QH$,7K+A[(7A:C'8Q,GYT:!ZBK2>)R-68\E($U]QRB"D84+;4G P=($6' MBHM@BA_QJ+]%:9_5&*=%Y=X:>XJX7 V:EA(%2\F!3;5<2=16:;4]8Y9:>_K( MB!S&AN7X(^:[0.7>^GJ2H)S^R!/,9*"XK,%S269T* ZA[ M926TSWJ1TX)R7WUU ,H[&06X6/RLI057";J99^X]3Z!+J"T3@@,411-#EN?D M:X/L81-9?Z6GSXJ/8R#63/H=C.#]E9=_S_!\OKB8_F].F^D*'Q?Y?'IY_F)V M5<:R7%[6;)17\^7%\GV^F AG"EY(DONL M^FB'QV%UV$]-R.V-?C.W6*J2'/<,4JT"5)I<,D><@.SN,R;Z MY+4@K0[50V3=)VIN#29&=#)X0K_C6M4.0Q%<4!DX%ID$\DA6P(# V7<:],E+ M/5J!YT"1/[.\M,,&01_XIC%STX88 5U38R]^XBQ]OIC'_WXU/Z^ICBN6/I[A M;-E@7M*^;V@DX:,8:Y7W=YW[]:'YQL5L*'LGK'R_J.VU2\()W-OJYZ MXBY?_KSYG34=+_[&15I?1J>45/068F ,5!WDX-!RD*7F&Y087/.Q1(P)BWUU*G8+MJK;%) 6.FE,R9AN 9F: T^%Z&+F*[NUR_O$LDTC6^7[".W* M309OL.00'>;F [1_(6#P!C(Z7>QL>'*N\ M@Y'X(R_"O!$67Y]_/YO_S'G%S(>K,OK-U"'.1"T B2:1B!UT M*-A\JN2]Q(Q\M/>&P39*ZP)_K\YPN?Q0_JI1V=G%A\6G&LU=G3*FV)PMF=.\ MU.Y$.I,9+"7)2]=A),8(HUO/>[F7F'$3=/LP+=MHJH/C=RLCZU7I8I;D;)& M(K.@N%+@8D%RP*0CX\8*:UM'0!X@9]RCMY'"=X'1 =+O)>ZQ9F2]_P:I9)3! M !=(^R\=^N \B2?9P&T14>IX)XOVX?#'+T_O$ Z'*&Y;_.-P*8[=K/!;GLW/ M\__W*P.1"ZE524 .4@ 50P(?0SV&DQ$ATS9LV0XPV/KP<6VA(5!PO P[.%56 M\S_J<7MU_US/Y_EL=4-6=\S"3(RU+W_)CD0C'!EZB1F@;30YEW)AHGD4XB&" MQJWMZ,.@::>Q#N!WAX?UBBS">)&*!/21G Q7+V6S-2!%(E_4%&-"ZZ*.K82, M'$-HI^B[CMC14N\ .D3^^7RV\B776R_SL>:R6F"L1C%RO8'@%J&4F(WWUI2[ MS0R/MX+O$C$N9!HH]J[=>Y24.X#)?^9E;82_6C-:NQ!X1 C:*S+0) ,4TH(P MR6GK4_"^=>WWK=>/6P+6Q^%UJ#;Z =)Z326FK=+.0!%(JR"0K1?J#6CB2M," MJ(,[6N>Z_4+ R$-]#U7C=C@<(-,. ''/.EHM%%I+M-X^S#9CBDMQP4B&P%2A M->.\ *?HW-9&RA(]RY*WOAW9@[PNP'0("':[I3M:(T\";%_^GJ]94^@S"SH" M\IK;4R>L!S5+NZU_R-+_/ZT8?+B^4%SJI@_LHUF$V_0V3CU_SZ MG[R(TV7^N)C&/+&)?'(E/%A;,FT%2H /,H+.R@N=;3;-!VV/RW'G.1?#K)\^ M1+\7V'HQ<\+CT@IWI472F2ZN:O.N1F)+&Y/%&H=-]8N/-9':.> \>!Y51)M: MW[\W(W[D))$.%LS)(?"4L;_ZLO:B5K>HRUNCV0I7B-9XDGVHTTN"!<=4 !-U M2D*I5%+K7/I!&!GYGO&)KHEFT.AE?1RB@]M"N-H:^,0'6PIY^>!UI'.Q:%7G M[SA 9S";E*/*K7,"6](_\L5%!ZMA#"!TXAG?JAZ[NEV\:1"R_'#Q+2^^?,/9 MVGQ\?UFC7>OXQ7(S 'VB#-/,>>(U\6H61@YHBP,3A,B<24P[#9EK1]'(<9[Q M?>P3*[4_*#_,F\/$1< "LG;#4K)8",G6(0$RRZ*8VVTJXK[O';=77E^P;*>@ MIVQ,U.*+/^=I6J9Q]4_>SN)B]0_P[/:3:I.+"4E"6NX]:,5+[:B4 7V(4+1! M(QQG1C5O(7("OL9MV/=4C8^A@-/!8KJ5D?01%Q\6JS2Y])]X=IG)S%J)8Z*# MERR)#,YH7>_;2.;9AMK8T&O#&++F16 [D#5N9\"1H=Q:;5T$][>FE5^?63FN M^P^_PK.SG%[^7/_> MN4/AV" ^H;Y[V&JWL?M+R/_ZA]<\\DG.M75(3*!1T7E2&VECB!:$$B%I%2(V M'SIV$*&[0?FY7;6>3K?]MNU\I-?BZM/?-#-81\F'7W>:]I)[L-Q'KTE3N"PQ M!]#.U8X%5I#1X#1MI\8SYU!$WCK7OY=>D]=E]'GQ@Y;I/?O(V>J1U9,NGW*< M?YW5EN!7<<@5I>M,(<.L,(+V#6_K#I(Y>%&[.F=AG4U!)]<\/6 (1IYT#\I] ML'Q_#\JQ8-&!G4+>[?P\7]=+O5NSN$I/IX,P2BL#%!&K<*4%+,Z BB4[J8W1 MMG4BX@/D]-*7#5&N-= "RS_F,?O3U M7WF6%WA&C+U(Y]/9M!JR=3C!FK?KOK!6>9VR!LR2MG+$6&NL'!091(Y)JYA: M.VE[$3ANZN-PP!M.2QU L(WI>A-$TZ84(U6A)<>K^1HE8!V8ZFPQ"2TS7+>> M8=:8A5XZ"/?B5(R)D X6R)JSG+8SOE[]$^UR#K47/-DY&>JP-T";)1DZMB09 M@_:E=5+B;I2-W$)C3/#<;8O=7I/]!N57'6HO8YW9.OO:8([3P\]K%%;?@^A& M7C]=A14W_0T&V).V;@F!1BXZU"R"E=1Y]R4&U+DK9 MF;@FO:@W+WI%J^-K7DZ<2Z1_P2 80X:,4@R\0P?(@K7>*I&;5^%LHV/<_6L8 M?&QM)WV,_+M(W[A'5G4'WUSJ?YQ?Y2,N7Y]-SVM9ZF:;7YQU1,CJG35FLJ1.WUZUP-BWFC2"+RR"4J%8) MQ!Q02P%8$G)K MPKA6LBA:?YK(5U8F",@C+<*D:S%K"-@ZGWT;'1TAZ5A%[P"BO:1^,'*^KP*S MGR]P<7&TY72'BQ\5E"^6R\OSG-Z0.+>THIQ(59"V<0&E*.+1\ R8/>WQ]*G, MY+RHNZ[<5EMJ_S=W%*IOA*43:*"W_6ES19:Y](EQ"^/(W^%HUG^6CV++X,:2I_SQ<593G]-+[[- M+R]>X?*;F'"4EH[Q L'44QR-!%]*AFIP%F8+>3.G,,BWD#9N [I3FU/'ZJ9O MY$T,%R5)9+5>7=8VWA[02@:.:2T$)JG<*6 V;@^XDYOH^TC]2!/]]2P-FWQ]6VPJS-+:T*_%J5.-=&,W#'/ M 5%C+-F3$%JOL ?(:5-728]>I[N^S+-BB).QX)VVLICY-[ORE1UV4WRWFI1^R;L_G?1^PG#SZNT?Q2F>W=!XC<&8'6J) M&C)7A)<4"WCG)421LW*AM@]M?;'0A/#C]RT",1W%'W&:WF=:BVBL8+7WM><) ME,B>3#A/Q[ HL98\\^):UU[>(6'KT:/I]1SM<(QT$E&Y9%I6#B7 =QISR! .@FRH!\% M+L5$&$"&VIR1X M=;Y%.@#4;A-Y/@& ,=2>=*:V M!5%4.9.HIEG5/FVY5.:VS&=[R#ZKS=OGQY0Q%D5/T:YKS6* _:#*]$2DH'WI M8XV"E]%82AQZR(0GS20+$0=K'G']3GM3V[WW>:T^C&:"QH!Z.Q^^PGQY6QID MX0#6Y1Q*K\_%1I(/0U'L#/_][42R1%-"9\*E](H4:W^6VHA=4\?L9_5ER2[Y"N%@M8+B:1<>%]"J4^%VH7=4H\Q5G%O:!) M.YFXYZ?OFV.(V/9XLO6&V]SH_3)_I1#]=+GNA3!+Z)@4LP :!!85B@X\X>&5 M6,%SAU.)([Q__>)J[_T'4,TCQ^B$*2(DR)*( 230B)&+T8P'XZ358_1E.%G M2R/J5T-)67KPBDUJ,,\8K84+\J<-3X#K\/J*5/3H;B06B9$1I=<>2N\M3;+0-'A% MG8:3)@\^_@&"\-L]>@Z_N2UJ:MARJ*;8KF!1KKYL[[J 22"=ML1E#*4EMZ@. M(2()BK(4:; IGD0&/PD<]^]O Y$:]CP*C3.5V]CIOPHOX.8&YAY7V(]_O-A> M6))6*IN8)$G@*&0PFMB8##%@6?*EU"3S)[CK!Q_>B^G/M==04WD=L/H_K9>O M[FZ/9.9,R#&2I$*9&$82&V0BW@2@H)WGL7;]X./2M"6L*NXJE17?> 'Y<12W M96;]Y6=^TY+F3;'*7_[[],OJRUL,%8LGAQ/F$Z2;VY>S7!+.(&V*ZTPL1JXL MV4 R51@R4IZ("Q$(SAGP3N,4C:>05+7DZ]S=W7#Y.J$VT M-"EK"0/.T;>EI5P89Q@?V418D :XUY!9[9Y()XK6]J;/2%@;PRSM,R'2*BZW M#2)O_UQM4CLFGFJ@"BP1PB?T)5%Z&[(@F5%E#8<<]^_?'TM[./3XMG=V1MC? M:JCQ=SQIVQ_W".=M1UXQ^JG;*4-K_AF_KJ.+E['TQBI^G/5-L]_B'U^R$ESFK* GE#(B$DGL6)2-6 MI>"HR2;KVA7#SQ#S=SJU>PK*]O?)L2W8@8?VZX%-P"DF=>:XT*.7*0$] *^M M)TG(X+GPH'+U:KB_E*@M]$8'Q'XIW'K6:5[FYK0Q7:6-/[IX6'3E878NSUXF M[1U1MF3GQAPP @I +&79"@C9GG:N6 V1CTG!:-NT>O-NO MZ%2]7"Q6D"8J4 P!,XY.JD(]24>L-(HPPYW(%*SFU3NS/TG"MK1@7S"]R'K= M8W-7#VE" TXI@<-0,7@BN3#$6N6)IM'A%\-YJLT;GB996]JP+RR>9:U^:@8] MXH/+Z!BS*1'J2Q% 8+9TTJ-$2)>T$-2R5/L6?84(:31.LB_H/@W+ MPO=>+9?S:5@M2W+0L42#3KE@?XR0(U MA&KK:8)HF#BE3<"C+VK=:<=PP@=8.IO*)XS MRE]Z47V"7:+C>FB+-ZOEH@1:.-[-^NV\5M(Y09*-J+@<@ 2C/6&1@N Y956] M=MR3!.S+L[L(&L-SV:E?$&[U]],8)RPH9C4+Q'A?X\WJ[3I MW%:NZJUV56SW!=I>LH^92PF"B%0J^^BHB86R,R@I>69.9EW]#+?J"/K:OL]" MW$\'N^U,W(&W>.&8_[@]_(!U-1K)I95")Y*H*RU;/2/.Z4 $5P9TJ4Y3G1T< M<3AMH=\2I4.?D.EV]KSV7W;U>'20QB8CB);6$PD&O3QAB8P=BT]LWF MQV1JB^-NP',2J,^T9 ?(W.8G;0LYY4"UTDF0I#Q.]R Q#G4 ) I.7;+@E5.5 M8?B# #UB[ES;[K.39RNZ Y1<8[PTW *L0XLW7XM!M@/QUKGDJ$##&MP6#%@< M2"Y);3*;K)A+^R5B+O?ACPG3-N0?%3UU#- !DM:M%Z>Q$/)E*'<%Y +E,7 B M:("2#)Z(C]&0Y$K7V$1Y?>[ZH"!M.>M1$72YXOM#S\?9=+EX]_[C=C#"V02& M:J(C_I BE@M$@DI<,8X]Z#3N"CZ4:"V]S^>$TT7&*(#5%WH:[ZZ*W*A#;.& M.4Z4%*4HA<.UV#B<5Y8E $<5ZK>O0/95'[4F_W^BUO/ \/M/@JLOI7?"1)DL M;':&^.#*R08M391QT"F#-XI2 ZQV_D,5P7L,/,;&7%W@GP& ?NORO(=/ZQMB M%[2[W7M"K0ZWOQ*LTGG-]AWOX.LP7W=DV;'G+!F7>!!$B5)3$&,-XI,TA!D: M?$G?$E"]TL$16>J=U[R#;S!;P;H P#4J<#[S-R]6B^7P!4%V-4NOAMFG5S@E MMBU>MAL,ITEE+4DNM6"E\KZTL63X0RCKJ8DY5-?$11(W)J5K(.KX>6_8?@T]U\_3Z._63.9'$P(*0>B%* +[S4EKF13:LJ==!:4%R=U>'^D MI\%1 7HYZQ@? 4-M<[3&U&9*/AS"-BR,7H.,##=O5YH 4AJ(RPS#N,!=D#EX MP6OTR3@J0+MN"94,.]36W(:Z& <3EVFU,22N5Z4?Z%9N;2T+ZQ9# M-*/<##AQD!1A-E,+QL5\6B+Q(VAX^,XV[/TX0#A;EQU024_TQN[I"RIX,$PE MXJ&0%L%EXD/(I8:]+R6!+*]^F'BNK+WPI<_F^3ZK<3L \>[ZT)NOZZ;LLT\[ MZF7BC,V9*2!4,-RD@^7$IJQBF X1M MM;=A5F=K0N3OZ?+S3H$;YK6P):@\_)4^^.\3:4"X9,LEM7*RAML_<0*WDW)C M3[\%$%K M<>A[[[IC/!UX[0S#K1=<:;SH#=I<."(,,&9X"DY6+[-Z1):+.?0?G[MQ+50* MAMJ8T3<-Q=^5.(=N"[:UC_)[[[4G6W9AQW[-K["#,_ MGPZ;7%R-DTWA *@IUW&-CB04>LU0I3G%GT*?-!].9; ?OKPKD)QAST.<]-G* M;8V.K=P?9XNO4/@/2-L(VD$4(B5!C+:X*Y?;C4%P1YBD -1:R%6XQJ,"=,!' MGV_4H;:&.X')OX8Y1+_8I5-;C_X]4YYDQCQ.&R6W :U7NC0FSHZ=E'AU(D9^ M?'M#@-0QZ0&07*#?#B*KO:7UWL/GW!7:#0CPB&J)'E=6AU\ECTIJ;IC;;RY9 MVSOIA4"JM?E457D'T%DGMJ[BW@Z;WA"+ZYOI ME^FL_/';=<%=_(G3![V\D(3(I>VJ]#A09P1QB5+B.0,05L4D1\EFOTSLKKRA M,_%S*$OY&8W9-WZOO^,FL?W,)MJ$(&FD)+%"/D1GB:/*X89AF';<"T-KIS"= M*EM72^/H2#S?+.-S0ML_*#^"7\ ___$_4$L#!!0 ( +>!KU:B=,,SI@@ M 'TL ; 97@M,S$Q8V5L;'@R,#(S,#,S,7@Q,'$N:'1M[5IKJ3%@\ 3' MDYAQ3:J"Z=:5=*_NT=&1T/%/WK'@E-')&KF]/S?H<42I7*YWJG4ND. MN^1L^,LY:92K'ADJFFAAA$QH5*GT+@JD$!J3MBJ5R612GM3+4MU6AH,*-M6H M1%)J7F:&%4Z.\0U\D5,JM M.C*=*G$;&E*KUNKDLU1W8DQ=N1$FXB>S=HXK[OFX8CLY'DDV/3EF8DP$^U@0 MG!T&M4-OC]8I;;#Z/O7\H-YLU@_VFZQ)V>@_'CA9 7-71YMIQ#\68I&40H[] MMVK[J3F:"&;"EE>M_K-@[4Z. YD8Z$Q!9??5M;':$E6WT)B1*52'E@R_-R4: MB=ND9>,KN*9FYKZ,I&J]J]I_1UA2"F@LHFGKPU#$7),+/B$#&=/D0U%#3DJ: M*Q$X0RW^QUN>!YW8QXGS?Q_:B43"9_%X-0RB]^6L?]H?DKI7]I8CV,QW'T:> MJU=ROM,;#/N?^IWVL']Y02X_D:M!_Z+3OVJ?D]Z77N=FV/]W#UZ#16_P9'#; M$LS5S>#ZIGTQ),-+\+YSUK[X5X^T.T,RN#GO71.O3DM>8X?NDO9%EWA-YIZV M/JSV-6EW+Z^&O2Y9C/"ZU[%)JU=KF+CA68]G[8O>=>GRRWGO-QLZE-2J MU=JS@UPS(?\ SBEE#*BG%/' M.I[Z?>?BXVU0]4ODFO!6$B5"2GYF3)!B\3G MRHA@2N"5>?^N>7#T;6'MU9?G[7\SC! ]$E(QYPH/A9\ @N4"84FOV:0'JZB*1GP5"I#9$(^2143KUKZE=%E3;E<,0D^)!(T M!W1!14)H,B598E3&(010(5:00!(IB>%)"1J1@/KP2A$9"T.,='8K!@GWN=94 M3=$DIG<<^EUH4\,[!LY EY%5,] '&OA"@7H!LP2J@R>,*S()A1\2G>''O/Z$ M*YXW@@'$0D<@([RB: S7'B'[4-T#X7 I8Q]T#K!<72"-R" 0\&BSV"=4 M<8L7R+\811SS2CB =!0)':(YFL5 H4BC^,R$]B.I,ZB'Y*IDY("3*NES!J\U MV0&<, [ [P75O5BEQ\HKP-O \2Z1+T.8NG6(+99ML/0Y1H& M"O)GU\&O@ZN(2[1/,[UY%5PK1QR DO?D5E^9*6@ V&LLM.5$L.*);0;1&RO370WIC55A"^.1]N#'28'&/!$+]4RX0B\5,-V$=YBJ"F MBLT !I 7="0B8::H"-9UB]/-8M'"S,V4)=,%>6O7E_L\H#13* M!" SQ1@RI=?(11 ?&Y"S>URO'2UVH2(0JW8*=20S\W3?FRP?],&:H_P.OKZ- M(J.9L+?3D;LQ '\L]+"#-PH_MD7PRRG5)7@5*+B_S\6?+7F$PV=0**[]TOU#$[^[\R*RLV(< (J!T![9Y6["?HO;@P@\HTBR M!U]VG2RYB-0YSCO/;#V5[^Z%BV&I9_:!\6/>>+*Z6GR[[HV8/RHV]PS^]U<8AA/ET M\6*S%3L0;C!@N'5*DX^%>F%6(4]BJY;>DT?SVOTNO3+F,OWQ\]IK0CR_T"GQ MFD5[G>8!I'GXSXL,$?LX+@>C'Q^:3>/I=%D$?%-4ZWBXL6[6O%H&W[]K[!]I M^TFN^]WN67LP/&N3G]O=?GLI]@U!6\4A*+P9%%S0F&^*@YQ)+1FGX"F>S)*9 MBW]ID*Q>)+D*R]WRW_@X&>(MP3^!*-8%YO*]_H+24YAY)8!T0L$#TKOG?H;' M9>32[1T?W6+\/C!Y&:)F [DU<^W].V^O>O3]/G>NW*DV2,R5?.VNSNB*U7UK MI.?B1=94NFN\+??3U9BO7&V=!KU;"%PT2B @ #\L ; 97@M,S$R8V5L;'@R,#(S M,#,S,7@Q,'$N:'1M[5IKHNOA^QM4*Y8]-)0X5DPS$6->*G5Z.90+ MM4Z:I=)T.BU.JT4AQZ7AH&2:JI6X$(H6B2:Y\S/S!CXI)N?_.ONI4$"7PD\C M&FOD2XHU)2A5+!ZC#X2J!U0H9%9MDNF>;T?-[. M6'*NZKS8%US(YINR_7=J2@H!CAB?-=\.6405ZM$I M&H@(QV_S"N:@H*AD@3-4[+^TZ7G@GGV<.G^/H1W.8CKWWZL8ISL?K[L7W2&J M>L7*NL>K46,YAL"U2"!4:';%=Q]&FLKOY'R[,QAVK[KMUK#;[Z'^%;H=='OM M[FWK!EUU>RWX"M_Z5V#1&3P9W+X$=C^WK5N^7#FJUAVAP M?].Y0UX5%[S: 3Y$K=XE\NK$/>U]6*T[U+KLWPX[EV@UPKM.VTY:M5PQ$S>\ M[J"[UN"BU>O<%?H?;SJ_V]"AI%(N?Q$P_Y,JS8*9>\5B F-@E^Q7'X;:UF'H MYM%[&J8<_2I4R/+(I]*XAW2(]<]OZB>G.\>88$* & N M$/KMNU\?*J]6]$[,0'11B"<423IA= IY1H=,H=]2+&&1\!D:T$1(C42, MKH2,D%9Y8Y%R, !T"H"0[4Y9?WRL M0A1P,55SZ$HZ9DJ#K-<(FY=Y9 W!S?P*!-76%X1 0!@T<[BUV$);6 0"P$:=F7A$%E(XX UT"YL8L @XU/&J>"5,^%RJ% M>H9=I> ..8D4/B7P6J$# JA@#P'ALXG/\3QF*(6$-<@Y6!AQ6O]@![:JE:\ MFB?WR(PZC1UB3?O(L-L*D!VNC"\[=Q2L=11 1R;.Q_ &"Z,$7B"_3KP=$.LF MZOL@%N\-8NM%.PR75,% P?S91/@\N/(F1_LX5;M7,F)5!L&W$36&P,U0GY(7(WNT1\CVMD![9U;;0/CN?+@ST&%Q3!@Q M^,5*Q-@0/U: ?:-/#:BQ)'. >09'C'.],Q(@FW=FN5FL6AAYE;*FNF*OK7Y MY5,64)+*!&"NK(3Q?2&)=< JW3&-09EP0#N4T,0L(V,"*MXA&I8;2X#B7S.F M_3W"M!V&S@3SU%*:F6\:!* SV01F2FW1BR ^=B!G][A=.UKL0D4@5N4DZDBD M^NF^=TD?>&%-C?X.GM]'H=%J:#5PH_LD?PRRC53? F4,P& M/Q-_MN01#C^#0DWN%[Z?2@.$E42[UEXDE(8WYB 56E$^-/&G.S!"!QO& : 8 M".V17>8F;+BH/8DPAQ1QNO#ET'D28K50(H8*+>HIL3G"1I_Q]PQQ]D!Y=BSQ MR#[_@@%Y(<;W?@M7WQN,?_$6SIY>DOG*R"_IRK#G*E*7S&40]QF"9$/M@E,8 MM*X64BVROWT!C441TYK2K?E@)$!9F!+"P"=;_0"0#/2K#+W#7Z.UYTN._IDR M<-DNLC3V[2G%X3^[LV^8[UL,$ M^0&*['%X!K>\RXXLG@@^ MH29%QGBK+C"]IE' QHU Z#84C2;P&9@#?"]5"\>F??=8"RWYGU':CE1F, M (]4%F"<.4X4;7$!K58JU>,?<0M(3_9-YQ=D6A:*\HE#39+*LTBHWZT\7EHO=DV5\U>P+^ MU/[V5NLGQ4KC:*=F2W8@Y-P@PV'#S8U1_UPE.'Z7J^8>S6*SC#QK->_B*YAF MSCU7IY)\0H\8Q?V<_Q@0#@O?GE3LU9?W>(:\>M[>R5DLD><'9$MP9OWL56@7 MLW4%\D51;4L"M6VK6B3?/DRO#F'^_*9V?*KL)WK?N;Z_0;_V[ZZ[:V'O"-G/ M6!$_ @!Z.**[0B C>:L,$O#4G BCN8L_-#Y6+J_\@XGSH;E9^'_!"^V0T0!= M+;10WVU%OS(&_@:X/#>DWPL_3H3?NO-L&-"-H3W<'-N2%85;5.?J5=1$N(NX M3?>CU81N7$Y=LI15E>5E%3P"JDKU9I5G[K-FG^YJK;WD>_X_4$L#!!0 ( M +>!KU9-\?OB7 4 'T: ; 97@M,S(Q8V5L;'@R,#(S,#,S,7@Q,'$N M:'1M[5EM3]M($/Y^OV(:="U(\;L3\E:DD*0B*B5I8J[TTVFQUV0/V^O:&T+N MU]_LVN:E0 ]12J$J0E:\.S,[S\RSLV.[]VHX&7B?IR-8B#B"Z>'N_G@ -!E)4"!K ,F?)"7P*:'X* MFE9*#7BZSMC)0H!MV@Y\XMDI.R/%O& BHCN5G9Y1W/<,M4COF ?KG5[ SH % M;VO,=-N4NM:V;3I--R244-MUVW;3\8-C=[L=_FVADP:*%SJY6$?T;2UFB;:@ MHCI8$/1<: MB=A)TE'X:H6I2MSG$<\Z&Z;ZZ\H9+20QB]:=-QZ+:0X'= 4S'I/D33W'G&@Y MS5A8".;L7]JQ+%Q$W:Y*_]%.Q!):X;%L"6)TM#?>'7O@V+IU'<']?/>',#D'4QGXX/!>-K?A]'1:'#HC?\:X3!* MC&9P)]QG"V]Z.)L?]@\\\"9@M>!0G^L#'>:C@8)K.0VS_O) ]>?0'TZFWF@( M5_%5J-IF4R;2VQO!O#_;[1^,YMKD:'_T&?H#3\[8IFE_/^I;MO W-D!*@@"+ ME1;14'2$R/8)SX.FQ*L=<;+=LVNP,>IR19JSNKNP5HZ1W/8K!,[2.$/%,FOUR83-%5 M'@#%$ ;P@63^ ARK7I1GDD/((AR_<&5._66&!P9B)DD HW-_09(3BG4]CEF> M2[?Q7TH&> C @F84G;WJ7@&A\JX.8_!I)EB(GBRS?$DPZH)?W0YE--1VD!Z1 M@*?R?+DJ7@E)=N%ZRE.2'9.$YMKD/*)KZ/LJ;))==9PGHB[UXC6<)GR%$$_H MZXU&J_LPRC39 />3J)-:ZM"\?3+?Q47O8B#A_DHJ1LN(R2=CQR- M)(DNB)71+TN647GRYS)1EVG?),CA#*S&9K!UD=Q+&EY0L,RPU7;<@B>QXC2F MM=V59/T54FL_R]2R!,M*3%2^L'X)@IH!CJI457DG3%6;C.8RQ74Y3:((4 V= M(1$2($\QYWE=:84L(8DOQ]%@H#I457!0:AD5#.%8N=2:><6*LO+I#\OTHYX> M@AQ'M%(XYEE ,PW3%)$TIYWJ1S=@>1J1=8?(J-Q739P+8=W6W8LH<5Z+<(JH7+]E97[:TA@IMSCJ6WFM:=TZ9^]]RW MS+;0'_?1K3::NM-JW,NLH0)1! /#G2,OWM:<6J50IJQCI^=@7>^ 91:_CG@1 M[*??].JYY -98_$K3N0+3I;X7SBTW?7U0_=!J/Y9YK)]N%:DW=NV#4^?'J8E MZ?IZP]WNYNH*\_%PN->?>7M]>-\?COO7L-^3M:8,0>V78<$!GM3WY4%92E7M M3=%3'K$ *A=?-$GF+ @6V)0O"+PG 2-U;/'UH?Z;'SN>? _T"(7B-F!%OF]_ MPKR+,S^)((,%HR&VN]CZ"G9&81*&#!^=OGI/]6-H\GV,>OZ;;W.:,6PW4^PW M;P1XZ^86-%2G]NW6L/%RNTE7=]S&@[I)6W?;S1_033I-Y_&[R8;>U8;7/:.!#^ M?K]B2^;:9 :_8@@8R@PA9$(G 0K.I/UT(VP!NMJ6:XL0[M??2K9)TB1MKM-+ M7^X8QMC6[FJ?W4>K19T7Q^.^]WXR@)6(0IA<')T-^U#1#..RUC>,8^\83KWS M,W!TTP(O)7'&!.,Q"0UC,*I 925$XAK&9K/1-S6=ITO#FQK2E&.$G&=4#T10 MZ7;D&[Q2$G1_Z[S0-#CF_CJBL0 _I430 -89BY=P&=#L VA:(=7GR39ERY4 MV[1K<,G3#^R*Y.."B9!V2SL=(W_N&&J2SIP'VVXG8%? @M<5MK"LPY;M6"V[ M83L-TR)U9^X?-AV3TF:#UN9_6.BD@>*Y3B:V(7U=B5BLK:BL$"L M7,LT?Z\HN6YGP6.!DZ6HG-_F-NY;(ND2C0F>H#I:$O1::"1DR]A5^"JYJ5+< MYR%/W3U3?=IR1%N0B(5;]Y7'(IK!B&Y@RB,2OZIFF!,MHRE;Y((9^XNZEH63 MJ,=-X3_:"5E,2SR6+4$,WIT.CX8>U&S=OHO@:;[[&'F:YF]8'."3:S63[X6F M/YAZPY-AO^<-QR,8G\!D.ASUAY/>&9P,1SV\Q;OQ"4H,IH^B_6'132ZFLXO> MR -O#%83+O29WM=A-N@KM%:M;E9_/E"]&?2.QQ-O< RW\96H6F9#YM$['<"L M-SWJC08S;?SN;/ >>GU/CMBF^3AQGXSZ@17\&?XG) BP5FDA70BWUGB&V#D/ MQFX8@\_CF/JR(,.&B16(%86W:Y(BUG +4YKP5 !?P&1%8Q[1=S",?1WVI=C+ MO:9MF^T^CQ(2;]63U3X M'3"TP@L4WL+"YXJDQ]W)A-TE0= ,80!G)/47T'- MJN;5F62P8"&^W[DRH_XZQ?T",9,X@,&UOR+QDF)9CR*69=)M_$K) /< 6-&4 MHK.WW.AI)$.V*E]..:I51N M_)E,U$W:]PER. 6KOA\<[))[0\,=!8L,6ZV:D_,D4IS&M+;:DJR_0FKM'S*U M+,:R$A&5+ZQ?@J!F@&]5JLJ\$Z:J34HSF>*J'"9A"*B&SI 0"9 EF/.LJK06 M+":Q+]^CP4 UJ*K@H-0ZS!G"L7*I.;.2%47ETY^:Z6^V5P@R#VFI,.=I0%,- MDQ*2)*-N>=,.6):$9.NR6(56*;4+\W,N!(_<.DYP)+;K7E MZ#6G+AM6@7Z+H)RXZ&5UUW6J_K M3>=QU=MF#16(/!@8[@Q9\+I2JY0*1K/=2:;A3LEV7EHV?#D^6%:,.S%?N?$UU/GO'\)^I"?\7H DYVCC7S1H7,L3ZMQ7V5+QPG%M?\9%.=L7;_!E!+ 0(4 Q0 ( +>!KU82>Z-> MFR " A#%P 0 " 0 !B;&DM,C R,S S,S$N:'1M4$L! M A0#% @ MX&O5N0@WI1W% 6?( ! ( !R2 " &)L M:2TR,#(S,#,S,2YX 0 % @ &"7@( 8FQI+3(P,C,P M,S,Q7V1E9BYX;6Q02P$"% ,4 " "W@:]6%P+]O0PN !'/0 $P M @ &RQP( 8FQI+3(P,C,P,S,Q7V! MKU8T;Q!#"A_U @!B;&DM,C R,S S,S%? M;&%B+GAM;%!+ 0(4 Q0 ( +>!KU8)U4PH"JX *JV!P 4 M " 2L-! !B;&DM,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0 ( +>!KU:B M=,,SI@@ 'TL ; " 6>[! !E>"TS,3%C96QL>#(P,C,P M,S,Q>#$P<2YH=&U02P$"% ,4 " "W@:]6PA<-$H@( _+ &P M @ %&Q 0 97@M,S$R8V5L;'@R,#(S,#,S,7@Q,'$N:'1M4$L! A0# M% @ MX&O5DWQ^^)!KU9FL+NZ#04 M +X5 ; " 9S2! !E>"TS,C)C96QL>#(P,C,P,S,Q>#$P ;<2YH=&U02P4& L "P#I @ XM<$ end